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ABSTRACT 
Therapeutics such as proteins, DNA, or siRNA, can only exert their function in the 
cell cytosol or nucleus.  However, most of them are cell membrane impermeable 
molecules that can only be taken up by cells via endocytosis or phagocytosis.  Such 
drug molecules are thus confined in endolysosomes, where reduced pH and degradative 
enzymes may destroy them without therapeutic gain.  Efficient escape of drug 
molecules to the cytosol before destruction in endolysosomes is a major challenge for 
intracellular drug delivery.  To address this issue, we designed a pH-sensitive 
core-shell nanoparticle to segregate the functions of the particle into an 
endosome-disrupting pH-responsive core that would absorb protons at endolysosomal 
pH, and a shell whose composition could be tuned to facilitate particle targeting, cell 
binding, and drug binding. 
Two-stage surfactant-free emulsion polymerization of 2-diethylamino ethyl 
methacrylate (DEAEMA) (core) and 2-amino ethyl methacrylate (AEMA) (shell) in 
the presence of a crosslinker was used for the synthesis of monodisperse core-shell 
hydrogel nanoparticles of 200 nm in diameter.  The protonation of tertiary amine 
groups on the polyDEAEMA core on moving from extracellular to endolysosomal pH 
resulted in reversible swelling of the nanoparticles with a 2.8-fold diameter change.  
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With the aid of pH-sensitivity of these nanoparticles, efficient cytosolic delivery of 
calcein (with ~95% efficiency) was achieved by disrupting endolysosomes via proton 
sponge effect.  The primary amine rich shell was found to facilitate cell and drug 
binding, and provided negligible cytotoxicity by sequestering the proton sponge 
component from any direct interactions with cells.  These particles demonstrated a 
useful means to deliver therapeutic molecules to the cytosol of cells of interest 
efficiently.  The applications of nanoparticles showed significant improvement in 
delivering a model antigen vaccine protein ovalbumin (OVA) to primary dendritic 
cells for T cell activation, and promising knockdown of mRNA by delivering siRNA 
to epithelial cells for gene silencing. 
To extend this approach to a fully biodegradable system, nanoparticles with a 
cleavable crosslinker bis (acryloyl) cystamine (BAC) were synthesized.  Preliminary 
explorations of this approach showed that such particles can degrade in the presence 
of glutathione in vitro, a reducing peptide present at mM concentrations in the cytosol 
of mammalian cells.  This design could potentially serve as a drug releasing 
mechanism to further improve delivery efficiency.   
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1 Introduction and Thesis Scope 
1.1 Intracellular Drug Delivery 
In recent years, many potentially powerful therapeutic strategies for the treatment of 
disease require the delivery of drugs into the cytosolic or nuclear compartments of cells.  
Examples include gene therapy mediated by plasmid DNA,1-3 gene silencing or RNA 
interference via oligonucleotides,4 anti-tumor toxin delivery,5-7 and therapeutic protein 
delivery.8, 9  Each of these examples requires the delivery of membrane-impermeable 
molecules into the cytosol, which has pushed the field of drug delivery into a new era of 
investigation at the intracellular or molecular level.  
 
1.1.1 Typical Pathways for Intracellular Drug Delivery 
Cells may take up macromolecular drugs via endocytosis, macropinocytosis, or 
phagocytosis, but these processes confine the internalized compounds to closed vesicles 
(endosomes or phagosomes), where the pH is progressively lowered to 5.5-6.5.1  The 
fusion of these vesicles with lysosomes, intracellular compartments carrying the 
degradation machinery of the cell at a pH as low as 4.5,10, 11 often leads to rapid 
destruction of therapeutic molecules with little or no release into the cytosol.  For 
effective intracellular delivery, membrane-impermeable drug molecules are first 
introduced to the body through a specific route, such as intravenous, intramuscular or 
subcutaneous injection.  The therapeutic molecules together with their carrier should 
then locate the desired tissue, bind to the cell surface and enter the cell quickly.  The 
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drug molecules must then escape the endosome and enter the cytoplasm efficiently before 
being destroyed.  For DNA delivery, the gene must transfer to the nucleus to obtain 
protein expression.  Degradation of drug carriers in the cell can be a useful strategy to 
minimize the potential of cytotoxicity (Figure 1.1). 
 
Figure 1.1 Schematic of the typical pathway for intracellular drug delivery.  Drug 
molecules and delivery materials form a drug delivery system, which may be taken up by 
cells through endocytosis or phagocytosis.  The drug delivery system then has to escape 
from endolysosomes before being denatured, locating in the cell cytosol.   
 
1.1.2 Barriers and Current Strategies 
As discussed above, there are several barriers along the pathway for efficient 
delivery of drug molecules to the cell cytosol: 1) biodistribution and targeting of the drug 
pH 7.4 
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delivery system to a specific area or cell types upon administration, 2) cellular uptake, 3) 
endolysosomal escape, and 4) drug unpacking and degradation of the delivery system.  
Strategies to overcome these barriers are under investigation. 
A practical drug delivery system should be able to locate the disease area and target 
specific cell types.  This capability would decrease the biodistribution time of the drug 
delivery system in the body after administration, and avoid immune response or side 
effects of treating healthy cells with drugs.  Conjugation of targeting moieties would not 
only offer the advantage of enhancing specific binding to the cell membrane, but would 
also improve the cellular uptake via receptor-mediated endocytosis (RME).12  
Many studies have proven that particle size is a critical parameter for the interaction 
between particles and cells both in vitro and in vivo.  For instance, DNA is an extremely 
large molecule, and DNA-nanospheres in the size range of 200-750 nm can transfect 
some cell lines with limited efficiency.13  It is essential to condense DNA into a 
nanostructure around 50-200 nm.14  Cationic lipids, liposomes, and polymers have been 
used to condense DNA15-17 through electrostatic attraction between the cations and the 
negatively charged phosphate backbone of DNA.  Particle surface charge is another 
critical parameter for cellular uptake.  Advantages can be gained if the nanoparticle 
carries a positive charge, since the cell membrane possesses a slight negative charge.14 
Once endocytosis occurs, the extremely low pH (around 4-5) environment and the 
digestive enzymes present in maturing endolysosomes degrade the entrapped drug 
molecules and associated complexes.  There are two approaches to protect the drug 
delivery system.  One is to burst the endosome/lysosome membrane and release the 
drugs and their carriers to the cytosol before degradation.  Some endosomolytic and 
lysosomotropic agents, such as chloroquine,18, 19 glycerol,20 or fusogenic peptides21 have 
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been used in human cells for this purpose.  Polyethylenimine (PEI) and starburst 
dendrimers have been found to function as ‘proton sponges’ for promoting early release 
of DNA22-24.  Poly(ortho ester)25 and poly-L-histidine grafted polymers26, 27 were used 
for the same purpose.  The other approach is to use poly acids possessing pH-sensitive 
pendant groups that are protonated at reduced pH.  The resulting uncharged, 
hydrophobic polymer chain will interact with and disrupt the endosomal membrane, 
carrying drug molecules to the cytosol.28 
After endolysosomal escape, drugs are expected to be released into the cytosol or 
nucleus efficiently.  Failure to properly unpack these drug cargos from their carriers can 
lead to a low effective dosage of drugs in the cytosol.29, 30  In addition, the degradation 
of drug carriers is of interest for safe in vivo application.  Research focusing on the use 
of hydrolysis or enzymatic degradation to break down polymeric carriers and release drug 
molecules is ongoing.31-33 
In summary, an ideal intracellular drug delivery system would (i) selectively reach 
the desired tissue and cells, (ii) easily be taken up by cells; (iii) successfully escape from 
endolysosomes; and (iv) efficiently release drug molecules to the cell cytosol and break 
down delivery materials into non-toxic components.  Therefore, a biocompatible, 
biodegradable nanostructured delivery system of endolysosomal escaping capability, and 
of well-defined sizes and shapes with specific surface functionalities is needed.  
 
1.1.3 Delivery Systems and Challenges 
It is possible to obtain intracellular delivery through some physical methods, such as 
the microinjection/gene gun34, 35 and hydrodynamics,36 but there is concern that these 
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techniques cause tissue damage.37  Most efforts have focused on developing drug 
delivery vehicles that coat or encapsulate drugs and deliver them efficiently to the desired 
target.  Although viruses are relatively efficient gene transfer vehicles, repeated 
administration primes a potential anti-vector immune response that rapidly abolishes 
transgene expression.  Another major concern with viral vectors is fears of viral 
integration in the host genome, which can lead to transformation of cells (cancer), and 
pre-existing immunity to the vector, which may prevent even the first dose from 
working.14  Therefore a number of different non-viral systems have been investigated 
for intracellular drug delivery and gene therapy, which include calcium phosphate 
co-precipitates,38 DEAE-dextran,37 liposomes or lipids.16, 17  Polymeric materials are 
promising drug delivery systems because size, charge density, and chemistry can be 
uniquely tailored to achieve a desired functionality.  Furthermore, polymers are usually 
stable and can be engineered to have extended circulation time in the body.37 
Although in the past two decades gene therapy trials have been initiated worldwide, 
little has been achieved in terms of curing disease.  One of the major challenges of 
polymeric delivery systems is inefficiency in the escape of internalized DNA from 
intracellular compartments (e.g. endosomes) into the cytosol.  Polymer-based delivery 
systems such as poly(lactide-co-glycolide) (PLGA)39 have been able to encapsulate DNA 
and provide sustained release as the polymer degrades.  A major issue with PLGA and 
related encapsulation polymers is that the acidic microclimate within the delivery 
particles degrades DNA.33, 40  In addition, delivery systems made by these materials 
possess a very poor ability to escape from endolysosomes.  Most of the entrapped DNA 
or drugs is eventually degraded by low pH or digested by the enzymes of lysosomes 
before it can be successfully released to the cytosol.39  Therefore, endosomal escape, 
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which is a major bottleneck of the potency of current intracellular delivery systems, has 
been a focus for many researchers. 
PEI has provided promising delivery efficiency by endosome disruption via the 
‘proton sponge’ effect.  However, the efficient release of DNA29, 30 and trafficking to the 
nucleus is still a problem, due to the strong electrostatic binding between these 
polycationic materials and the negatively charged DNA.  More importantly, the toxicity 
of PEI has limited its use, particularly for in vivo application.41, 42   
Hoffman and coworkers have developed a series of poly acids (poly (2-ethylacrylic 
acid) (PEAA), poly (2-butylacrylic acid) (PBAA), and poly (2-propylacrylic acid) 
(PPAA)).28, 43  This family of polymers become hydrophobic and exhibits 
membrane-disrupting properties when the pH drops below their pKa.  Acid-labile bonds 
such as acetal have been used as linkages between the backbone of these polymeric 
carriers and drugs.  Its degradation in low pH facilitates drug release.  However, it 
could be used for drug delivery only if drug molecules could be attached to the polymer 
backbone with acid-degradable side-chains in a friendly environment without 
degradation. 
To enable delivery of membrane-impermeable molecules (such as antigen protein or 
siRNA) into the cytosol of cells, much research has been directed at the development of 
synthetic chaperones that can facilitate transport of hydrophilic molecules to the cytosol 
with minimal cytotoxicity.44  Approaches include the use of membrane-penetrating 
peptides,45, 46 pathogen-derived pore-forming proteins,47, 48 and ‘endosome escaping’ 
polymers or lipids that disrupt the endosomal membrane in response to the pH reduction 
which occurs in these compartments.17, 24, 43, 49-53  While many of these approaches show 
promise, strategies that can promote highly efficient delivery of molecules into the 
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cytosol while avoiding unacceptable cytotoxicity are still sought.  In addition, many of 
the chaperone molecules that efficiently aid transport of macromolecules into the cytosol 
are formulated with drug cargos by physical complexation of the chaperone and drug 
(e.g., polyplexes or lipoplexes of cationic polymers/lipids with DNA), forming 
nanoparticles whose size, stability, and properties are highly dependent on formulation 
parameters including the identity of the drug cargo, the drug-to-chaperone weight ratio, 
and the characteristics of the surrounding environment (pH, ionic strength, and 
presence/absence of serum proteins).24, 54, 55  Lack of control over chaperone/drug 
particle size and stability is of concern because particle size is a critical determinant of 
cellular uptake in vitro and biodistribution and toxicity in vivo.24  
It was therefore our aim to develop a drug delivery system which can protect drugs 
from degradation prior to release, while maintaining a hydrophilic environment.  When 
endocytosis occurs, the drug delivery system should be able to respond to the 
environmental pH change, and disrupt the endolysosomal membrane rapidly.  It should 
also possess the ability to facilitate the rapid release of drug molecules right after 
endosomal escape. 
 
1.2 Potential Applications 
Cytosolic delivery of membrane-impermeable molecules into dendritic cells (DCs), 
immune cells critically involved in the initiation of adaptive immune responses,56-59 is of 
particular interest.  DCs bind peptides derived from pathogens to their major 
histocompatibility complex (MHC) molecules, and present these peptide-MHC complexes 
at their surface for recognition by naïve T cells (Figure 1.2).  Importantly, presentation of 
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antigens to cytotoxic T cells is greatly amplified (up to 1000-fold) by delivery of antigens 
to the cytosol, where the DC intracellular machinery can load them efficiently onto class I 
MHC molecules for presentation to CD8+ T cells.60, 61  Likewise, certain 
immunostimulatory molecules, such as mimics of viral RNA that trigger potent anti-viral 
immune responses, operate by binding to proteins in the cytosol of DCs.62  Finally, 
efficient cytosolic drug delivery in DCs could be used to deliver plasmid DNA or gene 
silencing reagents in order to amplify or suppress adaptive immune responses for 
vaccines or immunotherapy.63  However, transfection of DCs is notoriously 
inefficient.64-66  As DCs would engulf particles easily through endocytosis or 
phagocytosis easily, it is suggested that efficient endosomal escape could help improve 
the intracellular delivery to DCs.  
 
Figure 1.2 Schematic of CD8+ T cell priming through cross presentation of Class I 
MHC.67 
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A second major application for intracellular drug delivery is in the area of gene 
silencing through RNA interference (RNAi).  RNAi is an evolutionarily-conserved 
process by which double-stranded small interfering RNA (siRNA) induces 
sequence-specific, post-transcriptional gene silencing.68  The RNAi pathway is initiated 
by the enzyme dicer, which cleaves long double-stranded RNA to short double-stranded 
fragments of 20 to 25 base pairs.  One of the two strands of each fragment, known as the 
guide strand, is then incorporated into the RNA-induced silencing complex (RISC) and 
base-pairs with complementary sequences.  When the guide-strand basepairs with a 
messenger RNA (mRNA) molecule and induces degradation of the mRNA, a 
post-transcriptional gene silencing happens (illustrated in Figure 1.3).  RNAi is thought 
to have enormous potential for the treatment of a great variety of diseases, by allowing 
selective knockdown of deleterious gene functions.  However, the promise of RNAi will 
only be a clinical reality when safe and efficient RNA delivery systems are established. 
 
Figure 1.3 Schematic of post transcriptional gene silencing via RNA interference.69 
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1.3 Thesis Scope 
1.3.1 Environmental-Responsive Hydrogels 
A hydrogel is a material capable of imbibing and retaining a large amount of water 
without dissolving because of its crosslinked network structure.  Polymers bearing 
hydrophilic groups such as –OH, -CONH, -COOH, -SO3H, and –NH2 can be crosslinked 
to form hydrogels.  The swelling properties of ionic hydrogels are unique due to the 
ionization of their pendant functional groups.  First, they exhibit the ability to respond to 
changes in environmental parameters, such as pH, temperature, pressure, and ionic 
strength of the external electrolyte.  Second, small changes in these parameters can 
cause sudden dramatic changes in the degree of swelling.70  In the case of a pH-sensitive 
hydrogel, the equilibrium degree of swelling can be changed suddenly by several orders 
of magnitude near the pKa or pKb of the hydrogels (Figure 1.4).  Examples of monomers 
used for pH sensitive gels include acrylic acid, p-styrene sulfonic acid, crotonic acid, 
vinyl pyridine, and aminoethyl methacrylate.  This behavior of the hydrogel can be 
explored in the development of drug delivery systems that respond to environmental pH 
change.  We thus took advantage of the swelling ability of cationic gels and applied it 
for endosomal disruption at low pH. 
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Figure 1.4 Schematic of equilibrium swelling versus pH for ionic hydrogel.70 
 
The candidate cationic monomers for drug delivery should be non-toxic, 
biocompatible, and ideally biodegradable.  In addition, they should have the potential of 
being modified for multiple functions such as cell/tissue targeting.  Siegel et al. have 
done extensive research on the swelling ability of the family of aminoethyl 
methacrylate.71  It has been reported that hydrogels made from diethyl aminoethyl 
methacrylate (DEAEMA) and poly (ethylene glycol) monomethacrylate (PEGMA) have 
a pKb around 6.7.72, 73  This is a desirable pKb to respond to endolysosomal pH.  We 
thus adopted DEAEMA as the basic monomer for the synthesis of a pH-sensitive gel.  
 
1.3.2 Design of pH-Sensitive Core-Shell Nanoparticles  
We first synthesized and studied poly(DEAEMA-co-PEGMA) bulk hydrogels.  The 
chemical compositions of the hydrogel system were extensively examined to obtain a 
detailed understanding of their effects on the pH-sensitivity and reversible swelling 
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behavior, and a desirable transition pH which could provide efficient response to 
endolysosomal environment. 
We then designed and tested an alternative strategy for cytosolic delivery, using 
monodisperse crosslinked pH-sensitive hydrogel nanoparticles as chaperones for delivery 
of molecules to the cytosol.  Compared to traditional polymeric delivery systems, which 
are usually formed by the electrostatic attraction between polymers and drugs, hydrogel 
nanoparticles provide predefined size, structure and stability.   
We pursued a core-shell particle structure, to physically and compositionally 
segregate the functions of the particle into an endosome-disrupting pH-responsive core 
that would absorb protons at endolysosomal pH, and a shell whose composition could be 
separately tuned to facilitate particle targeting, cell binding, and/or drug binding.  The 
shell also shielded any hydrophobic and insoluble components in the core, leading to 
minimum cytotoxicity. 
We further extended this concept of pH-sensitive core-shell nanoparticles to 
biodegradable nanoparticles crosslinked by a cleavable crosslinker by taking advantage 
of disulfide reduction happens in any mammalian cells by glutathione (GSH).  
Modifying DEAEMA with PEGMA improved the hydrophilicity and solubility of the 
breakdown components, and formed nontoxic micelles upon degradation in cytosol. 
We utilized emulsion polymerization for the synthesis of these nanoparticles, which 
enables (1) a broad palette of chemical groups to be easily incorporated and (2) controlled 
fabrication of monodisperse nanoparticles of a predefined size. 
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1.3.3 Endosomal Escape and Intracellular Drug Delivery 
The pH-sensitivity of nanoparticles was explored in biological systems, by 
considering the delivery of the small molecule calcein to dendritic cells.  Microscopy 
and flow cytometry were used to detect the endocytosis of nanoparticles and their 
localization in cells.  We have sought a detailed understanding on the mechanism of 
efficient cytosolic delivery of calcein through intracellular trafficking of nanoparticles 
with the aid of other molecular biology approaches.  
Nanoparticles were further applied as a drug delivery system to promote the delivery 
of a protein vaccine antigen ovalbumin (OVA) to primary dendritic cells.  The delivery 
efficiency and function were evaluated by the immune response of CD8+ T cells.  
siRNA delivery was also tested with the aid of nanoparticles.  The knockdown of target 
mRNA was examined and compared with a commercially available delivery agent.     
 
1.3.4 Thesis Outline 
The experimental work was carried out to fulfill the objectives discussed in sections 
1.3.1 to 1.3.3, and is presented in Chapters 2 to 6 of this thesis.  Chapter 2 describes the 
synthesis of poly(DEAEMA-co-PEGMA) hydrogels and their composition-dependent 
pH-sensitivity.  In Chapter 3, synthesis of pH-sensitive core-shell nanoparticles by 
emulsion polymerization is discussed.  The chemical characterization of the 
nanoparticles on their pH-sensitivity and proton buffering capacity is performed and 
presented.  Biological characterization of the nanoparticles on their capability to disrupt 
endolysosomes and deliver the small molecule calcein to the cell cytosol is described in 
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Chapter 4.  In this Chapter, the cytotoxicity of the core-shell nanoparticles is also 
examined by the metabolism and growth/proliferation of cells.  We then applied 
nanoparticles as an intracellular drug delivery system to several drug molecules such as 
antigen protein OVA, influenza A, and siRNA.  The delivery efficiency and potential 
utility in treating disease are investigated in Chapter 5.  The design of a biodegradable 
system based on the pH-sensitive core-shell nanoparticles with a cleavable crosslinker is 
discussed in Chapter 6.  The preliminary results to evaluate the degradation and calcein 
delivery are presented as well.  The thesis closes with a summary of conclusions 
gathered in this work and a discussion of important future directions. 
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2 Synthesis and Characterization of pH-Sensitive 
Hydrogels 
Environmental-responsive hydrogels could be potentially used as drug delivery 
system since they provide sudden dramatic changes in the degree of swelling upon the  
small changes in the environmental conditions.70  The natural pH changes in the 
intracellular pathway (as described in Section 1.1) make it possible to take advantage of a 
pH-sensitive hydrogel for disrupting endolysosomes efficiently at low pH (4-6) and 
release drug molecules into the cell cytosol.  In addition, acidic conditions (5-6.5) may 
exist naturally (e.g. in solid tumors74-76) or be induced artificially (e.g. acid byproducts by 
degradable polymers with enzymatic reaction72, 73).  Acid-sensitive hydrogels could be 
of interest for selective drug release in response to these environments other than 
intracellular endolysosomes.  Therefore, we will first discuss the synthesis and 
characterization of pH-sensitive bulk hydrogels to obtain a detailed understanding on 
their swelling behavior.  We aimed to identify a series of chemical compositions that 
could provide us sharp transition in hydrogel swelling ability around endolysosomal pH 
(4-6).  Fabricating the pH-sensitive core-shell nanoparticles through surfactant-free 
emulsion polymerization for intracellular drug delivery will then be introduced in the 
subsequent chapters. 
Diethyl aminoethyl methacrylate (DEAEMA) has been reported as a monomer to 
form an pH-responsive hydrogel system.71  However, hydrophobicity of the monomer 
limits its miscibility in an aqueous solvent.77  The possible conditions to form a 
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homogeneous hydrogel system are identified by a phase diagram.  Using PEGMA as a 
co-monomer, the formed hydrogels provide pKb value ~ 6.7.
72  This system could 
provide an idea sharp transition responding to endolysosomal pH.  PEGMA could 
increase the biocompatibility of the system by making a hydrophilic, steric ‘hairy’ layer 
at the gel surfaces to reduce electrostatic interactions of potential drug molecules with the 
gels.  Thus in our study, the compositions of poly(DEAEMA-co-PEGMA) are studied.     
 
2.1 Materials and Methods 
2.1.1 Materials 
All reagents were used as received without further purification.  2-diethylamino 
ethyl methacrylate (DEAEMA), tetraethylene glycol dimethacrylate (TEGDMA), 
2-aminoethyl methacrylate hydrochloride (AEMA, 90%), and ammonium peroxodisulfate 
(APS) were purchased from Sigma-Aldrich Chemical Co.  Poly (ethylene glycol) 
monomethacrylate (PEGMA, MWPEO=200, 400, or 1000 g/mol), and poly fluorTM 570 
methacryloxyethyl thiocarbamoyl rhodamine B were purchased from Polysciences Inc.  
Polydimethylsiloxane (PDMS) were made from Sylgard® 184 Silicone Elastomer Kit 
(Dow Corning Corporation).  
 
2.1.2 Mapping Ternary Phase Diagram of DEAEMA/Water/Ethanol 
System 
Clear, transparent formulations are indicative of a stable homogenous phase as the 
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sizes of the any microemulsion domains are much smaller than the wavelength of light.78  
To quantify the optical clarity of gel precursor solutions, varying amounts of DEAEMA 
and EtOH were micropipetted into a glass, flat-bottomed, 96-well microplate (500-µl well 
capacity, Alltech Associates, Inc.) and mixed thoroughly.  The appropriate amount of 
aqueous solution was then added with mixing to obtain a total volume of 350 µl.  Each 
ternary composition was run in triplicate.  Absorbance values were collected at a 
wavelength of 450 nm using a microplate spectrophotometer system (SPECTRAmaxTM 
250, Molecular Devices Corp.) to quantify turbidity.  Absorbance data were plotted on a 
contour diagram using JMP 3.0 software (JMP, SAS Institute Inc.). 
 
2.1.3 Polymerization of pH-sensitive Hydrogels 
Crosslinked poly(DEAEMA-co-PEGMA) hydrogels were prepared by premixing the 
comonomers DEAEMA, PEGMA, and the crosslinking reagent TEGDMA.  Using 
results from the ternary phase diagram measurements as the guidance, EtOH and water 
were added to reach the desired solvent concentration while maintaining a homogeneous 
system.  APS was used as a free radical initiator.  In a typical polymerization process, 
103µL DEAEMA (0.5mM), 155µL PEGMA 200 (0.5mM), and 1.5µL TEGDMA (0.5 % 
mol crosslinker/mol comonomers) were mixed in 269 µL 25 v% EtOH, giving a final 
solution containing 50 wt% comonomers.  For fluorescent labeling of gels, 10µL poly 
fluorTM 570 methacryloxyethyl thiocarbamoyl rhodamine B stock solution (50 mg/mL in 
25% EtOH) was added as needed.  The initiator APS (20 µL of 200mg/mL APS in 
water, freshly made) was added, and the mixture (~500µL) was transferred to a PDMS 
ring mold (H=5mm, R=2.5 mm, cut by a revolving punch, Small Parts Inc.) adhered to an 
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oxygen plasma-treated glass slide.  A disc-shaped poly(DEAEMA-co-PEGMA) 
hydrogel was polymerized by placing the gel precursor/initiator solution in an oven at 
60°C for 30 min under atmospheric pressure. 
The resulting gels were immersed in excess water for 3 days on a shaker to remove 
residual monomer/initiator.  The cleaned gels were stored in water at 4 °C until use.  
 
2.1.4 Swelling Study of pH-Sensitive Hydrogels 
Poly(DEAEMA-co-PEGMA) hydrogel discs were transferred to a 6-well plate, and 
equilibrated in phosphate buffer of varying pH (100 mM ionic strength, 3mL) with mild 
shaking in a Jitterbug shaker (Boekel Scientific, Model 130000).  The wet mass of each 
sample was measured at each condition to determine the mass swelling ratio (Q), defined 
as mass of gel at swelling status over the mass of deswollen gel at pH 9.  To assess 
equilibrium swelling, the gels were allowed to equilibrate for up to 24 hrs.  The mass of 
the gels was assessed at different time points (swelling over 2 hrs, 4hrs, 8hrs, and 24hrs) 
to confirm that swelling had reached equilibrium.  To assess the temperature sensitivity 
of gel swelling, the swelling ratio was measured at 25 °C and 37 °C.  To assess swelling 
kinetics, the hydrogel discs were first equilibrated in a pH 7.48 buffer.  For the swelling 
phase, gels were transferred to a pH 5.66 buffer, and the masses of gels was measured 
every 10 min for the first hour, every 20 min for the second hour, and every 30 min until 
it reached equilibrium.  For the deswelling phase, gels were then transferred back to a 
fresh pH 7.48 buffer, and the masses of gels were measured every 10 min for 1 hour, and 
then measured at 8 hours.  To assess reversibility of swelling, gels were equilibrated in 
pH7.48 buffer for 2 days, and then were equilibrated in pH 5.88 buffer and pH 7.48 
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buffer alternately.  For each condition, the swelling ratio was determined after the gels 
had reached equilibrium swelling. 
 
2.2 Synthesis and Characterization of pH-Sensitive 
Hydrogels 
In this chapter, we aimed to synthesize a pH-sensitive hydrogels with pKb ~ 7, which 
can thus respond to endolysosomal pH.  The pH responsiveness of the polymers were 
expected to provide enough swelling, which could be used to release drugs at a control 
rate, or be applied to disrupt endolysosomes at acidic environments.  As mentioned in 
Chapter 1, Peppas and coworkers have used DEAEMA and PEGMA as comonomer for 
pH-sensitive controlled release,72 we suggested similar monomers of the hydrogel (Figure 
2.1) which could provide pKb around 6.5.  
 
Figure 2.1 Chemical structures of monomers for poly(DEAEMA-co-PEGMA) 
hydrogels.  
 
2.2.1 Phase Diagram of DEAEMA/Water/Ethanol System 
The hydrophobicity of DEAEMA monomer severely limits its solubility in water.   
Prior studies by the group of Peppas have introduced ethanol (EtOH) as a useful 
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co-solvent for DEAEMA.79  To form homogeneous bulk hydrogels for characterization 
of the swelling properties of polyDEAEMA gels, we first mapped out a ternary phase 
diagram of DEAEMA in a water/ethanol co-solvent system, in order to identify 
monomer/solvent compositions that would allow homogeneous polymerization of 
hydrogels.  For this purpose, optical densities in the visible range were used to quantify 
turbidity in solutions reflecting phase separation.  A ternary diagram of OD vs. 
monomer/solvent composition (Figure 2.2) showed that DEAEMA had minimal 
solubility in water.  As increasing amounts of EtOH present, the ternary phase 
progresses from a turbid multi-phase region to a homogeneous single phase.  This 
ternary diagram provided a starting point for choosing suitable single-phase solution 
conditions.  Addition of the liquid comonomer PEGMA (e.g. MWPEO=200, 400 g/mol) 
increased the solubility of DEAEMA in water/ethanol solutions.  In the case of wax-like 
PEGMA (MWPEO=1000 g/mol, Tg = 40 °C), elevated temperature (~ 40 °C) was needed 
to dissolve the macromonomer and form homogeneous solutions. 
 
Figure 2.2 Pseudo-ternary phase diagram for the water, EtOH and DEAEMA system.  
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Absorbance (at 450 nm) was recorded for solutions of the indicated ternary compositions; 
values less than 0.25 indicated a clear, single-phase precursor solution; values above 0.25 
indicated phase separation.  Each data point was the average of duplicate samples, and 
the standard deviation between the duplicates was less than 0.05 for all the cases.  
 
2.2.2 Equilibrium Swelling of pH-Sensitive Poly(DEAEMA-co-PEGMA) 
Hydrogels 
All of the compositional variables and many aspects of synthesis conditions can 
impact the pH-sensitivity, equilibrium swelling, and swelling kinetics of polyelectrolyte 
hydrogels.70  Parameters such as the molecular weight of comonomer PEGMA, the ratio 
of each monomer in the comonomer mixture, the ratio of crosslinker to monomers, the 
solvent concentration, the starting pH of monomers mixture, and the ionic strength of 
buffer could potentially affect the transition point and swelling ability of hydrogels.  To 
determine how these compositional parameters of poly(DEAEMA-co-PEGMA) 
hydrogels control gel swelling behavior, we synthesized a series of different hydrogels as 
listed in Table 2.1, using the DEAEMA/water/EtOH conditions identified from the phase 
diagram described above.  Disk-shaped gel samples were polymerized at 60°C using 
APS as a free radical initiator and washed in water extensively.  
The mole ratio of DEAEMA to PEGMA was fixed at 1:1, but the total comonomer 
concentration was varied from 20-60 wt%.  In addition, gels were prepared using 
PEGMA with different molecular weights (MWPEO=200, 400, 1000) to determine the role 
of the PEG side chain length in gel swelling responses.  Finally, two crosslinker ratios 
(0.5 or 1 mol% of comonomer moles) were compared. 
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Table 2.1 Compositional Parameters of pH-Sensitive Hydrogels 
Sample DEAEMA (mg) 
PEGMA 
(mg) 
DEAEMA: PEGMA 
 (wt:wt) 
Solvent* 
 (mg) 
PEG200_50%** 95.4 154.6 3:5 250.0 
PEG400_20% 27.0 73.0 2:5 400.0 
PEG400_30% 40.5 109.5 2.5 350.0 
PEG400_40% 54.0 146.0 2:5 300.0 
PEG400_50% 67.5 182.5 2:5 250.0 
PEG400_60% 79.1 219.0 2:5 200.0 
PEG1000_50% 36.0 214.0 1:5 250.0 
*25 v% EtOH was used as solvent. 
** 50% represents the wt% of the comonomer in the precursor solution.  
 
Swelling of the gels was quantified using the mass swelling ratio, defined as: 
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We first examined the effect of comonomer concentration on the swelling ratio.  As 
shown in figure 2.3, the swelling ratio of hydrogels synthesized with DEAEMA and 
PEGMA400 (2:5 wt:wt) at different comonomer concentration (20-60 wt%) revealed that 
gels prepared with a higher comonomer concentration (from 40 to 60 wt%) during 
synthesis exhibited greater swelling.  We chose 50 wt% of comonomer, which proved a 
reasonable swelling ratio as well as great mechanical property of hydrogels, for our 
further study. 
 43
 
Figure 2.3 Mass swelling ratio (Q) of hydrogels with different comonomer 
concentrations at 37 °C.  DEAEMA and PEGMA400 were used at 2:5 (wt:wt) ratio with 
1 mol% of crosslinker TEGDMA.  The total mass was kept 500 mg.  Hydrogels were 
swelling in phosphate buffer of physiological ionic strength (100 mM) at pH 4.79.  
Shown are average ± standard deviation (S. D.) of triplicate samples.   
 
The equilibrium swelling as a function of pH was next characterized for gels where 
the molecular weight of the poly(ethylene glycol) chains of PEGMA was varied.  As 
shown in Figure 2.4, gels made with PEGMA200 or PEGMA400 could respond to 
reducing pH, and gave gel pKb around pH 7.4.  However, gels made with PEGMA1000 
did not show much transition in the given pH range.  In addition, lower molecular 
weight of PEGMA led to much larger swelling capacity as the highest swelling ratio at 
pH 4.79 were 3.2, 1.9 and 1.1 respectively for gels made with PEGMA200, 400, and 
1000.  These results showed that the higher molecular weight (MW) PEGMA provided 
more non-pH-sensitive hydrophilic chains into the system, which essentially affected the 
gel swelling capacity but not the gel transition point.  Comparison of the swelling data 
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in Figure 2.4 (Q ~ 2 at 25 °C for PEGMA400 gels at pH 4.79) with that of Figure 2.3 (Q 
~ 5 at 37 °C for PEGMA400 gels prepared with 50 wt% comonomers at pH 4.79) also 
reveals a substantial temperature dependence of poly(DEAEMA-co-PEGMA) gel 
swelling, which are discussed further below. 
The effect of the crosslink density in the hydrogels was also tested for two different 
crosslinker concentrations, 0.5 or 1 mol% relative to comonomers (Figure 2.5).  This 
two-fold change in crosslinker concentration had a minor effect on gel swelling and did 
not alter the pH where swelling onset was detected.  
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Figure 2.4 Mass swelling ratio (Q) of hydrogels with different PEGMA molecular weight 
at 25 °C.  Gels (500 mg total mass as-synthesized) were prepared with DEAEMA and 
PEGMA (MWPEO＝200 (), 400 (c), or 1000 (z) g/mol) at 1:1 (mole:mole) and 50 
wt% total comonomer concentration.  The average ± S.D. of triplicate samples are 
shown.  
Q
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Figure 2.5 Mass swelling ratio (Q) of hydrogels with different crosslinker ratio at 25 °C.  
Gels were made with DEAEMA and PEGMA200 with 0.5 (z) or 1 ({) mol% of 
comonomer (1:1 mole: mole between DEAEMA and PEGMA, 50 wt% of total weight of 
500 mg).  The average ± S.D. of triplicate samples are shown. 
 
In summary, DEAEMA was the major monomer to provide pH sensitivity.  The 
molecular weight of PEGMA would not affect the gel pKb, but the swelling ability was 
reduced by the long PEG chain.  The crosslinker ratio only affected the swelling 
capacity not the pKb as well.  Because gels composed of a 1:1 ratio of 
DEAEMA:PEGMA200 with 0.5 mol% crosslinker ratio and 50 wt% of comonomers 
concentration exhibited the most dramatic swelling changes in response to pH, this 
composition was used for the further studies.  In Figure 2.6, a picture showed gels made 
with this composition at freshly made, swelling, and deswelling status.   
Q
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Figure 2.6 Picture of hydrogels at freshly formed, swelling, and deswelling status.  Gels 
were made with DEAEMA and PEGMA200 comonomer (1:1 mole:mole between 
DEAEMA and PEGMA, 50 wt% of total weight of 500 mg) with 0.5 mol% TEGDMA.  
Gels were swelling at pH 4.79 buffer and collapsing at pH 9 phosphate buffer with 100 
mM ionic strength.  
 
2.2.3 Dynamic Swelling 
It is necessary to define and calculate the responsive characteristic time of gels as this 
will be a significant parameter controlling drug loading and release profiles from gels 
used for drug delivery.  To this end, changes in the swelling ratio as a function of time 
were measured following transfer of gels equilibrated at extracellular pH/ionic strength 
conditions to acidic pH conditions and vice versa.  As indicated in Figure 2.7, hydrogels 
were able to respond to the environmental pH change immediately.  Within 90 min, the 
gels could reach their equilibrium swelling when located in pH 5.66 buffer (Figure 2.7A).  
Swelling gel
Freshly made gel 
Deswelling gel
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The response curve was nonlinear, as gels swelled rapidly in the first 30 min, and the 
swelling speed decreased as it reached equilibrium.  Swelling of these polyelectrolyte 
gels was reversible, as hydrogels were able to shrink to the original size when put back in 
pH 7.48 buffer.  As in Figure 2.7B, deswelling of the gels reached 95% of equilibrium 
within 60 min.  The deswelling curve was in a linear pattern.  The difference between 
the swelling curve and deswelling curve might indicate that the two processes were 
controlled by a different mechanism.  This aspect would be potentially used for rapid 
first-order drug release as the gel’s deswelling process could eject the drug loaded to the 
environment in a controllable manner.  Note that swelling kinetics are typically 
dominated by diffusion times for the ions in the solution.80  Thus, we would expect very 
different swelling/deswelling kinetics for nanoparticles, where ions need only diffuse 
much shorter distances (nanoparticles vs. bulk gels).  These measurements provide a 
first-order idea of how fast the gels may respond, and we expect particles to respond 
much more quickly.  Here, we tested overall reversibility, which at least for one cycle, 
could be relevant in cells. 
 
Figure 2.7 Dynamic swelling of hydrogels at 37 °C.  Hydrogels (PEG200_50% with 
0.5mol% crosslinker) were equilibrated in pH 7.48.  (A) Swelling ratio in pH 5.66 buffer.  
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Hydrogels were transferred to pH 5.66 phosphate buffer with 100 mM ionic strength, and 
weighed every 10 min for an hour, every 20 min for another hour, and every 30 min 
before reaching equilibrium.  (B) Deswelling of the same gels from (A) when 
transferred back to a pH 7.48 buffer at 100 mM ionic strength.  Hydrogels were weighed 
every 10 min for the first hours, and then at 8 hours.  The average ± S.D. of triplicate 
samples are shown. 
 
For some applications, cyclic gel swelling/deswelling may be of interest for pulsatile 
drug delivery.72  To determine whether DEAEMA gels were able to repeat their swelling 
cycle, gels were equilibrated in buffers of alternative near-neutral and acidic pH (Figure 
2.8).  These experiments confirmed that the swelling/deswelling repsonsiveness of 
poly(DEAEMA-co-PEGMA) hydrogels was reversible.  Gels were able to cycle 
multiple times between a swollen or collapsed state with limited hysteresis in the 
endpoint responding to each of the two pHs tested. 
 
Figure 2.8 Reversible swelling of gels at endolysosomal and physiological pH at 37 °C.  
Hydrogels (PEG200_50% with 0.5mol% crosslinker) were equilibrated at pH 7.48 for 
8
9
10
11
12
13
14
0 2 4 6 8
Time (days)
pH 5.66 
pH 7.48 
Q
 49
two days.  On day 3, gels were transferred to a pH 5.66 buffer, and the swelling ratio 
was examined after 12 hrs when gels reached the equilibrium swelling.  On the 
subsequent days, gels were exposed to fresh physiological pH (pH 7.48) and 
endolysosomal pH (pH 5.66) alternately, and the swelling ratio was determined by the 
average of two individual samples.  Error bars are S.D. of duplicate samples. 
  
2.2.4 Temperature Sensitivity of Poly(DEAEMA-co-PEGMA) Hydrogel 
pH-Responsive Swelling 
As mentioned above, we noticed different swelling ratios for measurements made on 
the same gel compositions at different temperatures (Figure 2.3 and Figure 2.4).  To 
further analyze the temperature sensitivity of the gels, we did a swelling study at 25 °C 
and 37 °C with different gel compositions.  Interestingly, for all of the gel compositions 
studied (in Figure 2.9) higher temperature at 37 °C led to a larger swelling ratio and 
sharper swelling transition compared to room temperature (25 °C).  This comparison 
confirmed that poly(DEAEMA-co-PEGMA) responded to temperature change as well.  
We could potentially use this character to guide the design of a drug loading and 
releasing profile at both different temperature and pH.  
 
Figure 2.9 Mass swelling ratio (Q) at 25 °C and 37 °C with different hydrogel 
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compositions.  The swelling ratios of hydrogels synthesized with DEAEMA and 
PEGMA200 (A), PEGMA400 (B), or PEGMA1000 (C) were studied at 25 °C (open 
symbols) and 37 °C (filled symbols).   
 
In this chapter, we synthesized and characterized pH-sensitive 
poly(DEAEMA-co-PEGMA) hydrogel.  The ternary phase diagram suggested us 
compositions forming homogeneous hydrogel system.  The characterizations of 
equilibrium swelling, dynamic swelling, and reversible swelling of gels with different 
chemical compositions gained us knowledge of the effect of a variety of parameters on 
the transition pH and swelling capability of the bulk hydrogels.
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3 Synthesis and Characterization of pH-Sensitive 
Core-Shell Nanoparticles 
The study of p(DEAEMA-co-PEGMA) hydrogels confirmed that DEAEMA was 
potentially a good candidate as an acid-sensitive responsive drug delivery system.  Bulk 
gels could be utilized as injectable implants to release drugs in an environment-sensitive 
manner or to respond to artificially-induced mild local pH changes in a tissue (as 
mentioned in Chap 2).  However, we also hypothesized that translation of the bulk gel 
swelling properties to nanoparticles might allow the gel swelling in response to reducing 
pH to be used for endolysosomal disruption and efficient cytosolic drug delivery.  We 
now needed to design a process to fabricate hydrogel nanoparticles, whose size is in the 
cellular uptake range.  In general, particles less than ~5-10 µm can be engulfed by 
microphage through phagocytosis, while nanoparticles less than 250 nm can be 
internalized by many cell lines through endocytosis or macropinocytosis.24  We were 
therefore particularly interested in synthesis of pH-responsive particles smaller than 250 
nm. 
In this chapter, we fabricated pH-sensitive nanoparticles through surfactant-free 
emulsion polymerization by the hydrophobicity of DEAEMA.  Instead of using a 
comonomer system with PEGMA, we applied only DEAEMA to achieve better 
pH-sensitivity as the bulk gel studies from last chapter suggested that the presence of 
PEG chains reduced the pH responsiveness of the gels.  Unlike pursuing a homogenous 
single phase of precursor solution for the synthesis of bulk hydrogel, an emulsion 
suspension is favored for emulsion polymerization process.  PEGMA comonomer would 
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render the resulting polymer chains more hydrophilic, and could destabilize the emulsion 
polymerization.  Therefore, to introduce hydrophilicity to the nanoparticles, we 
proposed a core-shell structure with the hydrophilic components favored by the cells to 
the outside shell.  This structure could physically segregate the drug or cell binding 
function on the shell and the endolysosomal-disrupting capability in the core.  On the 
other hand, current intracellular drug delivery systems which could perform well for 
endolysosomal escape (e.g., PEI) often show noticeable cytotoxicity mainly due to the 
exposure of endosomal-disrupting components to the cells as well as inefficient 
unpacking of the drug molecules in cell cytosol.24, 42  This hydrophilic ‘protective’ shell 
could prevent the hydrophobic and endolysosomal-disrupting components from 
contacting the cells, resulting in minimum cytotoxicity.  The investigation of the 
core-shell nanoparticles for endolysosomal escaping and toxicity reducing in the 
biological system will be addressed in the subsequent chapters. 
 
3.1 Materials and Methods 
3.1.1 Materials 
All reagents were used as received without further purification. 2-diethylamino ethyl 
methacrylate (DEAEMA, 99%), methyl methacrylate (MMA, 99%), 2-aminoethyl 
methacrylate hydrochloride (AEMA, 90%), ammonium peroxodisulfate (APS) and 
glutathione (GSH, reduced form) were purchased from Sigma-Aldrich Chemical Co. 
Poly(ethylene glycol) dimethacrylate (PEGDMA, MWPEO=200 g/mol) was purchased 
from Polysciences Inc.  Cy5 mono-NHS ester was purchased from GE Healthcare UK 
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Limited.  The Limulus Amebocyte Lysate (LAL) QCL-1000® Kit and LAL water were 
purchased from Lonza Walkersville, Inc. 
 
3.1.2 Synthesis of pH-Sensitive Core-Shell Nanoparticles  
Emulsion polymerization  
DEAEMA (1 mL, 4.97 mmol) or MMA (528 µL, 4.97 mmol) premixed with 
PEGDMA 200 (10 µL, 0.03 mmol) were dispersed in water (9 mL) with stirring and 
equilibrated at 70 °C for 15 min before adding APS (50 µL of 200 mg/mL freshly made 
solution) as the initiator.  The emulsion polymerization was allowed to proceed at 70 °C 
for 3 hours to grow the particle core, followed by injection of AEMA (50 µL of 
800 mg/mL freshly made solution, 0.24 mmol) to grow the particle shells for an 
additional 1.5 hours.  The nanoparticles were purified by dialysis (10,000 MWCO 
Slide-A-Lyzer® Dialysis Cassettes, Pierce Chemical Co.) in deionized water for three 
days followed by ultrafiltration (10,000 MWCO PLGC Ultrafiltration Membrane, 
Millipore Co.) three times and centrifugation three times with PBS (pH 7.4) at 15,000 xg.  
Purified particles were stored in PBS at 4 °C.  
 
Morphology of pH-Sensitive Core-Shell Nanoparticles 
The primary amine-containing shells of nanoparticles were fluorescently labeled by 
incubating Cy5 mono-NHS ester (5 µL of 1 mg/mL solution in DMSO) with 
nanoparticles (~ 5 mg) in PBS (395 µL) overnight with moderate shaking at 4 °C.  
Unconjugated dye was removed by centrifugation (three times in 1mL PBS, at 15,000 xg 
for 10 min each).  The labeled particles were visualized using a Zeiss LSM 510 
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Confocal Laser Scanning Microscope (CLSM) using a 100X oil objective.  
Transmission electron microscopy (TEM) was used to characterize the morphology 
of the nanoparticles.  Condensed particles (10 µL, ~ 0.5 mg) were dehydrated through 
graded concentrations of ethanol (50%, 70%, 90%, 100%), and air-dried overnight on 
TEM grids.  Samples were examined using a JEOL JEM 1200 EX II at 60 KV or a 
Phillips EM410 at 80 KV. 
CryoEM was performed to measure the size of the nanoparticles in water.  A 
nanoparticle suspension in water (3 µL) was placed on a 2/4 Quantifoil holey carbon film 
after glow-discharging the grid.  Excess liquid was blotted by filter paper, and then the 
grid was plunged into liquid ethane using a Leica EM-CPC rapid freezing device, 
vitrifying the aqueous suspension.  The grid was directly loaded into a JEOL 2200FS 
TEM using a Gatan 626 cryo-specimen holder at liquid nitrogen temperature, and imaged 
at a low dose condition using 200kV accelerating voltage and 30 eV energy slit.  TEM 
images were recorded at a magnification of 50,000X on a slow-scan CCD camera (Gatan 
Inc.).  
 
3.1.3 pH Sensitivity and Buffering Capacity of Core-Shell Nanoparticles  
To characterize the pH sensitivity of the core-shell nanoparticles, the hydrodynamic 
diameters, determined by dynamic light scattering (DLS, Brookhaven 90Plus instrument), 
were measured for particles equilibrated in physiological ionic strength phosphate buffers 
(100 mM) with pH ranging from 4.9 to 9.5 at 25 °C or 37 °C.  Particles (~ 0.1 mg) were 
suspended in 1 mL buffer solution.  The particle size was detected at different time 
points (5 min, 10 min, and 30 min) repeatedly to examine the swelling/deswelling 
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equilibrium. 
The mass swelling ratio of polyDEAEMA core-shell nanoparticles was compared to 
that of PMMA core-shell nanoparticles to further validate the pH sensitivity and swelling 
behavior in this system.  The same amount of nanoparticles (~ 0.25 mg) was suspended 
in different pH buffer as described above overnight to reach equilibrium swelling.  
Centrifugation (15,000xg, 15 min) was then performed to pellet the particles in each 
buffer solution.  The weight of particles was determined after removing the supernatant.   
To determine the buffering capacity of nanoparticle suspensions, we examined the 
protonation of tertiary amine group on the nanoparticles by pH titration.  Nanoparticles 
(0.05 mmol repeat units of DEAEMA or MMA, 9.26 mg or 5.01 mg particles, 
respectively) were suspended in 0.1 M NaCl (20 mL) with 500 µL of 0.1 M NaOH.  The 
pH of the solution was recorded as HCl (0.1 M) was added stepwise to each suspension 
using a pH meter (Φ 350 pH/Temp/mV Meter, Beckman Coulter, Inc.). 
 
3.1.4 Endotoxin Evaluation by LAL Assay  
To evaluate potential LPS/endotoxin contamination of nanoparticles, the Limulus 
Amebocyte Lysate (LAL) QCL-1000® Kit was used to test the concentration of endotoxin 
in the nanoparticles according to the manufacturer’s instructions.  Nanoparticles 
(25 µg/mL) or endotoxin standard (at different concentration) were suspended in LAL 
water.  50 µL of the nanoparticles suspension or standard were dispensed in a 96-well 
plate, which was pre-warmed to 37 °C.  At time zero, 50 µL of the lysate solution (LAL) 
was added to each sample.  Ten minutes later, 100 µL of the substrate solution 
(prewarmed to 37 °C) was added to detect the endotoxin chromogenically.  Stop 
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solution (50 µL) made from sodium dodecylsulfate (SDS) was used at total time of 16 
minutes to stop the color reaction and to prevent the saturation of the color express.  The 
endotoxin concentration was then determined by the absorbance at 405 nm using a 
microplate spectrophotometer system (SPECTRAmaxTM 250, Molecular Devices Corp.) 
 
3.1.5 Zeta Potential 
50 µL of PDEAEMA nanoparticles (without or with AEMA shell) were suspended in 
different NaCl solutions (5 mM) with pH ranging from 4 to 10 adjusted by 0.1 M HCl or 
NaOH.  The value of the zeta potential was read from a Particle Size Analyzer 90Plus 
(Brookhaven Instruments Corporation). 
 
3.2 Synthesis and Characterization of pH-Sensitive 
Core-Shell Nanoparticles 
3.2.1 Emulsion Polymerization 
Emulsion polymerization is commonly used to form micro- or nano-sized polymer 
particles, and we adopted this method here to form our polyDEAEMA hydrogel 
nanoparticles.  A common type of emulsion polymerization is an oil-in-water emulsion, 
in which droplets of monomer (the oil) are emulsified (with surfactants) in a continuous 
phase of water.  Macroscopic monomer droplets are in equilibrium with monomer 
dissolved in micelles of surfactant dispersed throughout the aqueous phase.  
Polymerization takes place in these micelles, which become latex particles that form 
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spontaneously in the first few minutes of the process; these latex particles are comprised 
of many individual polymer chains.  Particle coagulation is prevented because each 
particle is surrounded by the surfactant; the charge on the surfactant repels other particles 
electrostatically.  When water-soluble polymers are used as stabilizers instead of 
surfactant (Figure 3.1), the repulsion between particles arises because these water-soluble 
polymers form a steric barrier, a “hairy layer” around a particle that repels the others.  
This repulsion helps to keep particles separate, thus ultimately providing a monodisperse 
particle suspension. 
As DEAEMA is basic and hydrophobic when unprotonated, it can form unstable 
micelles77 or phase separate from water solutions, as discussed in Chapter 2.  However, 
this character serves as an advantage and enables this monomer to be used for 
surfactant-free emulsion polymerization in water, as DEAEMA itself can form micelles 
in water, without further need for surfactants to form monomer-laden micelles in the 
initial stage. 
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Figure 3.1 Schematic of surfactant-free emulsion polymerization.  A small amount of 
hydrophobic monomer is dissolved in the aqueous phase, and in equilibrium with large 
droplets of monomer in the starting emulsion.  As initiators break down and create free 
radicals, they encounter the dissolved monomer and initiate chain growth.  As the chains 
grow, they precipitate, and form a nascent polymer particle, which is stabilized in the 
suspension due to electrostatic charge of the initiator fragments as well as the monomer 
units themselves.  To grow a ‘shell’ structure, a second monomer is injected after an 
initial ‘core’ polymerization stage is carried out. 
  
As shown in Figure 3.1, the particles were synthesized by a two-stage surfactant-free 
emulsion polymerization in water.  In the first stage, DEAEMA, which possesses a 
tertiary amine with a pKb of 7.0-7.3,72, 73, 77, 81 was polymerized for 3 hours with 
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poly(ethylene glycol) dimethacrylate (PEGDMA, MWPEO = 200 g/mol) as a crosslinker to 
form the pH-sensitive core of the particles (Figure 3.2).  Control particles lacking 
pH-sensitivity were synthesized by replacing DEAEMA with the non-ionizable monomer 
methyl methacrylate (MMA).  In the second stage, AEMA was injected to the stirring 
latex suspension to polymerize a pH-insensitive hydrophilic shell layer rich in primary 
amines (Figure 3.2).  The polymerization was stopped after another 1.5 hours and the 
particles were purified by extensive dialysis and centrifugation/washing.  To enable 
tracking of the nanoparticles by fluorescence microscopy, the fluorochrome Cy5 
succinimidyl ester was covalently conjugated to the primary amines available in the 
particle shells. 
 
Figure 3.2 Schematic structure and chemical composition of pH-responsive core-shell 
nanoparticles.  At extracellular/cytosolic pH, tertiary amines of DEAEMA repeat units 
in the particle cores are largely uncharged, and the particles are collapsed; at 
endolysosomal pH, the core tertiary amines ionize, and the particles swell.  
Surfactant-free polymerization of DEAEMA or MMA formed the core structure of 
hydrogel nanoparticles, crosslinked by PEGDMA; AEMA was polymerized in a second 
stage to form a thin shell structure rich in primary amines.   
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The surfactant-free emulsion polymerization is a very simple synthesis process.  As 
mentioned above, it enables control over the size of the nanoparticles, which should be 
highly monodisperse.  In addition, we did not have to use surfactant to stabilize the 
micelle, which made the formed nanoparticles very easy to be cleaned, as surfactant can 
remain in the polymer and can be difficult to remove.  Overall, this process is an 
excellent system to generate pure synthetic particles for biological applications.  
 
3.2.2 Morphology of Nanoparticles 
TEM and CryoEM were performed to verify the monodispersity, and to examine the 
size of the as-synthesized nanoparticles.  As expected, the emulsion polymerization 
yielded highly monodisperse particles as revealed by both TEM and CryoEM (Figure 3.3).  
During the preparation of TEM samples, the particles needed to be dehydrated.  This 
process could affect the particle size, so CryoEM was further used to analyze particle 
morphology and size in hydrated conditions.  The particles used in our cell culture 
studies were 205 ± 5 nm in diameter as observed in CryoEM (Figure 3.3B), which was in 
good agreement with the diameter of 208 ± 4 nm determined by DLS at 37 °C in aqueous 
phosphate buffer at pH 7.4 and physiological ionic strength (Figure 3.4A).  
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Figure 3.3 TEM and CryoEM images of nanoparticles.  Scale bars 500nm for TEM (A), 
200nm for CyroEM (B). 
 
3.2.3 pH Sensitivity and Buffering Capacity of Core-Shell Nanoparticles 
Compared to our bulk hydrogel system described in Chapter 2, we used only 
DEAEMA as the monomer, instead of a comonomer system with PEGMA, as the bulk 
gels studies suggested that the presence of long PEG chains reduces the pH-sensitivity of 
DEAEMA gels.  In addition, PEGMA comonomer would render the resulting polymer 
chains more hydrophilic, and could destabilize the emulsion polymerization.  However, 
DEAEMA is the major monomer to provide pH-sensitivity, and the group of Armes has 
shown that PDEAEMA-containing latex particles exhibit sharp swelling transitions near 
neutral pH,82, 83 analogous to bulk hydrogels composed of weak polybase network 
chains.84   
To characterize the pH sensitivity of our core-shell nanoparticles, the hydrodynamic 
diameters were measured by DLS for particles equilibrated in phosphate buffers at 
physiological ionic strength with pH ranging from 4.9 to 9.5 at 25 °C or 37 °C (Figure 
3.4).  Particle swelling/deswelling equilibrated within 10 min, and was reversible in 
BA 
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response to changes in buffer pH.  As shown in Figure 3.4 A, PDEAEMA core-shell 
nanoparticles were largely deswollen at elevated pH, but swelled abruptly between pH 
7.0 and 6.8 at 37°C.  The particles exhibited a 2.8-fold change in diameter (by DLS) on 
moving from the extracellular/cytosolic pH of 7.4 to an endolysosomal pH of 5, 
corresponding to a ~ 22-fold volume change.  Similar swelling trends were observed by 
measuring the swelling ratio (hydrated mass/dry mass, Figure 3.4B).  Note that the 
primary amines of the AEMA groups (pKb ~ 11) in the particle shells should remain 
highly ionized across this entire pH range; only the tertiary amines of the particle cores 
will respond to the changes in pH.  The swelling response of DEAEMA-containing 
nanoparticles showed modest temperature sensitivity: at 25 °C, the swelling transition 
was detected at pH ~ 7.4, while at 37 °C, the swelling transition moved to pH ~ 7.0.  
Control nanoparticles with pH-insensitive PMMA cores and PAEMA shells (diameter of 
284 ± 11 nm as determined by DLS at pH 7.4) exhibited no size/swelling change in 
aqueous phosphate buffers having pH 4.5 to 9.5 (Figure 3.4B). 
 
Figure 3.4 pH-responsive swelling of core-shell nanoparticles.  (A) Hydrodynamic 
diameters of the nanoparticles equilibrated in 100 mM phosphate buffers of different pHs, 
determined by DLS at ({) 25°C or (z) 37°C. (B) Mass swelling ratio of core-shell 
nanoparticles at 37°C.  () PMMA core-shell nanoparticles and (¡) PDEAEMA 
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core-shell nanoparticles.  Shown are average ± S. D. of triplicate samples. 
  
The morphology of PDEAEMA-core nanoparticles with fluorophore-labeled shells 
was also directly observed at extracellular/cytosolic and endolysosomal pH using 
confocal laser scanning microscopy (CLSM).  At pH 7.5 in the deswollen state (Figure 
3.5A), the shell-labeled particles appeared as punctuate spheres, while particles incubated 
in pH 4.8 phosphate buffer swelled, with the fluorescent shell of the swollen 
nanoparticles clearly resolved (Figure 3.5B).   
 
Figure 3.5 Morphology and pH-responsive swelling of core-shell nanoparticles.  CLSM 
fluorescence images of PDEAEMA core-shell nanoparticles with Cy5 fluorophore 
conjugated to the PAEMA shell of the nanoparticles at pH 7.5 (A) or pH 4.8 (B) in 100 
mM phosphate buffer at 25 °C.  Scale bars 5 µm.  
 
The swelling measurements indicated a sharp onset of particle core ionization at 
endosomal pH, but the proton sponge mechanism of endosomal escape relies on the 
buffering capacity of polymers undergoing ionization.85  Titration of initially basic 
aqueous particle suspensions with HCl revealed that the PDEAEMA-core particles had a 
substantial buffering capacity near neutral pH (Figure 3.6).  At 25 °C, the PDEAEMA 
BA 
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cores of nanoparticles bound up to 0.46 moles H+ per mole of DEAEMA units, buffering 
acidified solution near a pH ~7.1.  This buffering capacity was not affected by the 
PAEMA shell structure.  PMMA core nanoparticles, on the other hand, showed no pH 
buffering activity once the primary amines of the PAEMA shell were protonated.  This 
titration experiment further proved that the pH-responsiveness of the particles derives 
from the absorption of protons by tertiary amines of DEAEMA at the swelling transition 
pH.  The osmotic pressure, generated when water entering the gels to dilute the 
counterions which were associated with charged groups on the polymer chains, provided 
the hydrogel swelling ability.  This proton absorption character met our proposed 
requirements for endolysosomal disruption via the ‘proton sponge effect’.  
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Figure 3.6 Titration measurement of core-shell nanoparticle buffering capacity at 25 °C.  
(z) PDEAEMA-core/PAEMA-shell nanoparticles, ({) PDEAEMA-core/no-shell 
nanoparticles, and (S) PMMA-core/PAEMA-shell nanoparticles. 
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3.2.4 Analysis of Endotoxin Contamination  
Some cells such as dendritic cells (DCs) are highly sensitive to the presence of 
lipopolysaccharide (LPS, also known as endotoxin), which can trigger activation of these 
cells through Toll-like receptor-4.  Nanoparticles were thus prepared using 
endotoxin-free water or buffers.  We detected the LPS concentration was 0.0027 EU/µg 
nanoparticles, or 0.0685 ± 0.001 EU/mL (S.D. from triplicate samples) at the 
concentrations of 25 µg/mL nanoparticles used in our cell experiments.  This result 
confirmed that the endotoxin contamination in these particles was below levels reported 
to stimulate DCs or to trigger substantial changes in DC function.86-88   
 
3.2.5 Stability of Core-Shell Nanoparticles 
Stability in Intracellular Conditions 
As expected based on the incorporation of chemically stable PEGDMA crosslinks, 
we found that the particles were stable at least one week in neutral saline; the particles 
swelled slightly over a week but retained a narrow size distribution (Figure 3.7).  The 
dry weight of the particles was essentially unchanged after one week in PBS (1.5 ± 0.7% 
weight loss, based on triplicate samples).  In addition, the particles exhibited a nearly 
identical size distribution in pH 7.4 serum-free medium containing 10 mM glutathione 
(GSH) to mimic the reducing environment of the cytosol (Figure 3.7). 
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Figure 3.7 Size distributions of PDEAEMA core-shell nanoparticles assessed in different 
media over time.  Nanoparticles (270 µg/mL) were incubated in PBS (pH 7.4) or 10 mM 
GSH (in serum free medium, pH 7.4) at 37 °C.  The size distributions of the 
nanoparticles were measured after different incubation times: (z) 2 days in PBS, (S) 2 
days in GSH, and ({) 7 days in PBS.   
 
Zeta-Potential of Nanoparticles at Different pH 
We detected the zeta potential of the nanoparticles in different pH buffers to 
understand the stability and the surface charge of the nanoparticles.  The zeta potential is 
the electric potential in the interfacial double layer (DL) at the location of the slipping 
plane, versus a point in the bulk fluid away from the interface.  In other words, the zeta 
potential is the potential difference between the dispersion medium and the stationary 
layer of fluid attached to the dispersed particle.  Its value can be related to the stability 
of colloidal dispersions.  Colloids with high zeta potential are electrically stabilized, 
while colloids with low zeta potentials tend to coagulate or flocculate unless sterically 
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stabilized (e.g., by water-soluble surface-anchored polymer chains).  In Figure 3.8, the 
zeta potential of PDEAEMA nanoparticles with or without AEMA shells were examined 
in the NaCl solutions (5 mM) with different pHs.  The values of the zeta potential 
started decreasing at pH 7.0 for both core-shell and core-only nanoparticles.  In the case 
of core-only nanoparticles, it reached a much lower level (~ 27 mV) than that of 
core-shell nanoparticles (~ 44 mV) at pH 7.4.  This result confirms that the AEMA shell 
rich in primary amine provides a positive charge at near-neutral pH, facilitating drug 
binding and cell binding.  The non-shell particles would not bind negatively charged 
drugs (such as DNA or some proteins) very efficiently.  In addition, it was not favored 
by the slightly negatively charged cell membrane.  However, the IEP isoelectric points 
(IEPs) were around pH 9 for both core-shell and non-shell nanoparticles.  Ultimately, we 
were unable to explain the similarity of the IEPs despite the shell structure, and the 
difference between the IEPs and the polymer pKa of AEMA or pKb DEAEMA. 
The particles were prepared with APS as initiator.  Therefore the surface of the 
particles is rich in sulfate, which means they are zwitterionic instead of highly positively 
charged.  Armes reported similar findings in their APS-initiated latex particles.82  This 
hypothesis could be further evaluated by NMR on the particles in the collapsed state (e.g., 
pH 7.4 buffered D2O) to determine the ratio of amino to persulfate groups in the shell. 
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Figure 3.8 Zeta potential of PDEAEMA nanoparticles in the sodium chloride solutions at 
different pHs.  Particles with AEMA shells (filled circles) or without AEMA shells 
(open circles) were examined in the NaCl solutions (5 mM) with different pHs.  Shown 
are mean ± S.D. of three individual measurements.  
 
In this chapter, we fabricated hydrogel nanoparticles by surfactant-free emulsion 
polymerization.  The formed core-shell nanoparticles were highly monodisperse, with 
size of ~ 200 nm shown by EM.  We proved that those PDEAEMA-core/PAEMA-shell 
nanoparticles were able to swell to a 2.8-fold change in diameter (by DLS) on moving 
from the extracellular/cytosolic pH of 7.4 to an endolysosomal pH of 5, which was 
caused by the absorption of protons by the tertiary amine groups at reducing pH lower 
than DEAEMA’s pKb.  This ‘proton sponge’ effect could be applied for endolysosomal 
escape as we designed.  The characterization and application of these nanoparticles to 
the biological system will be discussed in the following chapter. 
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4 Endolysosomal Escape of pH-Sensitive Core-Shell 
Nanoparticles  
We successfully synthesized core-shell nanoparticles that can respond to 
endolysosomal pH and reversibly swell and buffer pH.  We hypothesized that the pH 
sensitivity of these core-shell nanoparticles would facilitate endosome/phagosome 
disruption, while preventing cytotoxicity via sequestration of the hydrophobic 
pH-sensitive component under the more hydrophilic shell of the particles.  Buffering 
polymers are thought to disrupt acidifying endolysosomes via an osmotic pressure 
buildup associated with chloride accumulation (the proton sponge effect).89, 90  In 
addition, membrane disruption might further be aided by swelling of the particles in situ. 
In this chapter, we tested this hypothesis first in an immortal cell line (DC2.4), using 
a small molecule calcein to examine the delivery efficiency, delivery mechanism, and 
cytotoxicity.  Application of this system to cytosolic delivery of macromolecules to 
primary dendritic cells will be discussed in the following chapter.   
 
4.1 Materials and Methods 
4.1.1 Materials 
All reagents were used as received without further purification.  RPMI 1640, 
DMEM (with 4.5 g/L glucose), and Trypsin/EDTA (0.25% trypsin/2.21 mM EDTA in 
HBSS without sodium bicarbonate, calcium, and magnesium) were purchased from 
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Mediatech Inc.  Fetal bovine serum (FBS) was purchased from Hyclone.  MTT Cell 
Proliferation Assay Kit was purchased from American Type Culture Collection (ATCC).  
LysoTracker® Red DND-99, Fura-2AM, and CyQUANT® NF Cell Proliferation Assay 
Kit were purchased from Invitrogen.  Bafilomycin A1 and Calcein were purchased from 
Sigma-Aldrich Chemical Co.  Trypan blue (0.04%) was purchased from VWR.  
 
4.1.2 Cell Culture and Calcein Delivery 
DC2.4 cells, a dendritic cell clone originally derived by Shen et al.,91 were a gift 
from Professor Kenneth Rock.  These cells were cultured and passaged in complete 
RPMI 1640 medium containing 10% FBS, 50 µM 2-mercaptoethanol, 5 mM L-glutamine, 
10 mM HEPES, and penicillin/streptomycin.  Murine embryonic fibroblasts (MEFs) 
were obtained from ATCC, and cultured and passaged in complete DMEM medium 
containing 10% FBS, 50 µM 2-mercaptoethanol, 4 mM L-glutamine, 10 mM HEPES, 
and penicillin/streptomycin. 
To test delivery efficiency of small molecules by the core-shell nanoparticles, DC2.4 
cells (1.2x105 cells/well) were plated in Lab-TekTM chambers and cultured overnight 
(~ 18 hours).  Calcein was added to the cells (150 µg/mL, 0.24 mM) with or without 
25 µg/mL PDEAEMA core-shell or PMMA core-shell nanoparticles in complete medium 
(RPMI 1640 with 10% fetal bovine serum (FBS)) for 1 hour at 37 °C.  After three 
washes with medium to remove extracellular calcein/particles, the cells were imaged live 
by CLSM at 37 °C.  The modified delivery process for LysoTracker®, bafilomycin A1, 
or Fura 2AM are described in the related sections.  
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4.1.3 TEM Imaging of Nanoparticles in Dendritic Cells 
DC2.4 cells were plated in Petri dishes (6-well plates, 1.2x106 cells/well) and 
cultured in complete medium for 18 hours.  Cells were treated with or without 25 µg/mL 
PDEAEMA or PMMA core-shell nanoparticles for 1 hour at 37 °C.  After washing three 
times with complete medium, the cells were fixed in 2.5% glutaraldehyde, 3% 
paraformaldehyde, 5% sucrose in 0.1 M sodium cacodylate buffer (pH 7.4), following by 
post fixation in 1% osmium tetroxide in veronal-acetate buffer (pH 7.0).  The cells were 
stained in block overnight with 0.5% uranyl acetate in veronal-acetate buffer.  After 
water rinsing, cells were then dehydrated through graded concentrations of ethanol (50%, 
70%, 90%, and 100%) and embedded in Spurrs resin.  Sections were cut on a Reichert 
Ultracut E microtome with a Diatome diamond knife at a thickness setting of 50 nm and 
stained with 2.0% uranyl acetate followed by 0.1% lead citrate.  Samples were 
examined using a JEOL JEM 1200 EX II at 60 KV or a Phillips EM410 at 80 KV. 
 
4.1.4 Cytotoxicity 
MTT Assay for Cell Metabolic Rate 
DC2.4 cells were plated in 96-well plates at a density of 5x104 cells/well.  After 
incubation at 37 °C for 18 hours in complete medium, cells were incubated with 
25 µg/mL (or different concentration) PMMA core-shell, PDEAEMA core-shell, 
PDEAEMA-core/no-shell nanoparticles, or blank medium for 1 hour at 37 °C.  After 
washing three times with complete medium, cells were treated with MTT reagent 
immediately or after an additional 24 hours culture in complete medium post-particle 
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treatment, followed by adding MTT detergent after an additional 4 hours.  The cell 
density was then determined by the absorbance at 570 nm wavelength using a microplate 
spectrophotometer system (SPECTRAmaxTM 250, Molecular Devices Corp.)  
 
Cell-Growth Assays of Cell Viability 
For cell-growth assays, cells were harvested after nanoparticle treatment as above, 
washed, and replated in 96-well plates at a density of 2.5x104 cells/well.  The replated 
cells were then cultured for an additional 3 days, and the number of cells grown out in 
these cultures was determined by the CyQUANT® NF Cell Proliferation Assay Kit at 
488 nm/530 nm using a fluorescence microplate reader (SPECTRAmaxTM GEMINI, 
Molecular Devices Corp.) 
 
4.2 Calcein Delivery 
4.2.1 Cytosolic Calcein Delivery with Nanoparticles 
Because of our interest in delivering membrane-impermeable molecules into 
dendritic cells for vaccines and antiviral drug delivery, we investigated the uptake of the 
nanoparticles by a dendritic cell clone,91 DC2.4.  Calcein, a membrane-impermeable 
fluorophore, was used as a model drug molecule and tracer to monitor the stability of 
endosomes/phagosomes following particle uptake.43  Calcein delivery with PDEAEMA 
(pH-sensitive) and PMMA (pH-insensitive) core-shell nanoparticles was carried out as 
described in Section 4.1.2.  Briefly, DC2.4 cells (1.2x105 cells/well) were plated in 
Lab-TekTM chambers for 18 hours, and then calcein (150 µg/mL, 0.24 mM) was added to 
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the cells with or without nanoparticles (25 µg/mL) in complete medium for 1 hour at 
37 °C.  After three washes with medium to remove extracellular calcein and particles, 
the cells were imaged live by confocal laser scanning microscopy (CLSM) at 37 °C.  As 
shown in Figures 4.1 A/D/G, cells treated with calcein alone showed a punctuate 
distribution of fluorescence indicative of endolysosomal compartmentalization of the dye.  
In contrast, cells co-incubated with calcein and PDEAEMA-core/PAEMA-shell 
nanoparticles exhibited calcein fluorescence throughout the cytosol and nucleus (Figures 
4.1 B/E/H).  Calcein entry into the cytosol triggered by the presence of nanoparticles 
required the pH-sensitive core, as calcein remained in an endosomal distribution in cells 
co-incubated with calcein and PMMA-core/PAEMA-shell nanoparticles (Figures 4.1 
C/F/I). 
Figure 4.2 summarizes the frequency of cells observed by CLSM exhibiting 
endosomal vs. cytosolic/nuclear calcein distributions after 1 hour incubation under the 
three experimental conditions.  Fewer than 5% of cells incubated with calcein alone or 
calcein together with PMMA core-shell nanoparticles exhibited a cytosolic/nuclear 
calcein distribution, while ~ 90% of cells incubated with PDEAEMA core-shell 
nanoparticles had calcein distributed throughout the cytosol.  Particles prepared with 
PDEAEMA cores but lacking the PAEMA shell also triggered cytosolic entry of calcein 
(Figure 4.3) suggesting that the non-pH-responsive cationic amine groups in the shells are 
not required for the calcein distribution seen in Figures 4E and H. 
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Figure 4.1 pH-responsive core-shell nanoparticles chaperone the delivery of the 
membrane-impermeable dye molecule calcein into the cytosol of dendritic cells.  (A-I) 
CLSM images at 40X.  (A-C) Brightfield images.  (D-I) Fluorescence overlays (red, 
nanoparticles; green, calcein).  (A, D, G) Cells were treated with calcein alone.  (B, E, 
H) Cells were co-incubated with calcein and PDEAEMA-core/PAEMA-shell 
G 
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nanoparticles. (C, F, I) Cells were co-incubated with calcein and 
PMMA-core/PAEMA-shell nanoparticles.  Scale bars (A-F) 20 µm; (G-I) 10 µm.  
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Figure 4.2 Cytosolic delivery efficiency of calcein in DC2.4.  Average percentage of 
cells observed by CLSM exhibiting cytosolic/nuclear calcein distributions after 1 hour 
incubation from three independent experiments: calcein alone (no particles), calcein with 
PDEAEMA core-shell particles, or calcein with PMMA core-shell particles (n=350-700 
cells scored per condition in each experiment; shown are means ± S.D.).  
  
Figure 4.3 Crosslinked PDEAEMA nanoparticles lacking a PAEMA shell also trigger 
calcein delivery to the cytosol.  Confocal images of live DC2.4 cells following 1 hour 
A B
C
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incubation with 25 µg/mL PDEAEMA-core/no-shell nanoparticles and 0.24 mM calcein 
were collected at 100X.  (A) Brightfield image.  (B) Overlay of nanoparticle (red) and 
calcein (green) fluorescence.  Scale bars 10 µm. 
 
Experiments performed with different incubation times showed that the cytosolic 
delivery of calcein occurred within 45 min, and was observed for more than 95% cells 
incubated with calcein and PDEAEMA core-shell nanoparticles by 90 min.  DCs treated 
with nanoparticles for 1 hour, washed, and then cultured for an additional 24 hours 
showed that most or all of the nanoparticles remain within the cells for at least 1 day 
(Figure 4.4).  Note that DC2.4 proliferation occurred over this time period, which led to 
some dilution of the density of nanoparticles in any given cell after prolonged incubation.  
Cytosolic delivery of calcein triggered by core-shell nanoparticles was not limited to 
dendritic cells, as we observed similar results in murine embryonic fibroblasts (Figure 
4.5). 
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Figure 4.4 PDEAEMA core-shell nanoparticles stably retained in cells for at least 24 
hours.  DC2.4 cells were incubated with 25 µg/mL PDEAEMA core-shell nanoparticles 
for 1 hour, washed, and then imaged live by confocal microscopy at 40X (A).  The cells 
were then cultured an additional 24 hours and imaged again to determine whether 
nanoparticles remain associated with the cells (B).  Shown are overlays of nanoparticle 
fluorescence (red) and cells (brightfield).  Scale bars 20 µm. 
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Figure 4.5 Core-shell nanoparticles deliver calcein to the cytosol of fibroblasts.  Murine embryonic 
fibroblasts were incubated for 1 hour with 0.24 mM calcein (A, B) or calcein and 25 µg/mL pH 
sensitive PDEAEMA-core/PAEMA-shell nanoparticles (C, D), and then imaged live at 37 °C by 
CLSM at 40X.  Shown are brightfield (A, C) and fluorescence overlays (red, nanoparticles; green, 
calcein fluorescence; B, D).  Scale bars 20 µm.  
 
4.2.2 Tracking Endosomal Disruption Triggered by Core-Shell 
Nanoparticles in Live Cells  
 As shown above, DEAEMA-core pH-sensitive nanoparticles were able to delivery 
calcein to the cell cytosol of DC2.4 efficiently.  We next designed experiments to further 
A 
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B
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understand the mechanism underlying this process.  The cellular uptake, localization of 
nanoparticles, necessity for co-internalization of drug molecules with the nanoparticles, 
and requirement for acidification of the endolysosomal environment were examined, and 
are discussed in detail below.  
 
Cellular Uptake of Calcein and Nanoparticles 
Particle size24 usually plays an important role for endocytosis; substantial uptake of 
nanoparticles by cells in a short time period may be desirable to ensure adequate drug 
delivery to individual cells.  To quantify relative uptake of core-shell nanoparticles of 
different compositions, we performed flow cytometry.  As described in Chapter 3, 
particles were labeled with Cy5 dye on the shell, enabling fluorescence analysis.   
Although CLSM images had proved the fluorescent label was on the particles (Figure 
3.5), we used flow cytometry to further test the fluorescent labeling efficiency of the 
nanoparticles.  Only particle samples were run through flow cytometer, and 99% of 
labeled particles showed a strong fluorescent marker (in Figure 4.6A).  Similar results 
were obtained for PMMA core-shell nanoparticles (data not shown).  We then analyzed 
the relative cellular uptake of these particles following the same incubation conditions 
used for calcein delivery studies as described in Figure 4.1.  Cells were incubated with 
fluorescence-labeled nanoparticles for 1 hour at 37 °C and washed three times, and flow 
cytometry was then performed to identify the Cy5 positive cells.  As shown in Figure 
4.6 B, the majority of cells internalized nanoparticles irrespective of the core composition 
following this incubation treatment; 80% of cells were Cy5 positive for PDEAEMA 
core-shell nanoparticles, while 60% of cells were Cy5 positive for PMMA core-shell 
nanoparticles.  Thus, cells are capable of internalizing the particles efficiently after 1 
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hour of incubation with nanoparticle suspensions.  
 
Figure 4.6 Quantification of relative uptake of nanoparticles by DC2.4 cells.  (A) 
Fluorescent labeling efficiency of nanoparticles.  Flow cytometric analysis of (cell-free) 
nanoparticle suspensions showed 99% labeled (red) PDEAEMA core-shell nanoparticles 
were Cy5 positive compared to non-labeled control (green) nanoparticles.  (B) 
Percentage of cells that showed Cy5 positive without (red) or with treatment of calcein 
alone (green), PDEAEMA core-shell nanoparticles (blue), and PMMA nanoparticles 
(brown).    
 
Particle Localization 
The data shown in Figures 4.1-4.5 do not clarify the precise sub-cellular localization 
of the nanoparticles following binding/internalization by cells.  As shown in the 
confocal images (Figures 4.1 E, F, H, and I), both PDEAEMA and PMMA core-shell 
nanoparticles were taken up by the phagocytic DC2.4 cells, and treatment of cells with 
0.04% (wt/vol) trypan blue to quench extracellular fluorescence91, 92 following particle 
incubation confirmed that particles associated with cells were in fact internalized (data 
BA 
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not shown).  Optical sectioning of cells treated with PDEAEMA-core/PAEMA-shell 
nanoparticles also provided further evidence that particles in cells exhibiting cytosolic 
calcein fluorescence were localized within the cells, rather than being simply bound to 
the plasma membrane (Figure 4.7). 
 
 
Figure 4.7 Optical sectioning of calcein- and nanoparticle-loaded dendritic cells.  Serial 
confocal optical z-sections at 100X of nanoparticle (red) and calcein (green) fluorescence, 
illustrating the intracellular localization of nanoparticles in a calcein-flooded DC.  Scale 
bars 5 µm.  The number under each image gives the z-distance/interval of each image 
relative to the approximate vertical center of the cell.   
 
The internalized nanoparticles could be localized in endolysosomes following 
endocytosis/macropinocytosis.  To obtain more direct evidence for escape of the 
core-shell nanoparticles from endolysosomes into the cytosol, we performed confocal 
fluorescence imaging of cells incubated with nanoparticles in the presence of a 
1.79 µm -0.9 µm -1.79 µm 0 µm 0.89 µm 2.68 µm 
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fluorescent marker of endolysosomal compartments, as well as transmission electron 
microscopy (TEM) on fixed thin sections of cells incubated with nanoparticles.  The 
pH-sensitive fluorescent indicator LysoTracker® Red DND-99 (1 µM, Invitrogen) was 
added together with 0.24 mM calcein and 25 µg/mL core-shell nanoparticles to DC2.4 
cells for 1 hour at 37 °C in order to label endolysosomal compartments during calcein 
uptake.  After washing, cells were imaged by CLSM at 37 °C.  The CLSM images 
(Figure 4.8 A, B, and C) revealed that a significant fraction of the internalized 
PDEAEMA core-shell nanoparticles (blue) failed to co-localize with endolysosomal 
vesicles (red) while delivering calcein (green) to the cytosol.  In contrast, cells 
co-incubated with calcein and PMMA core-shell nanoparticles exhibited strong 
co-localization of nanoparticles (blue), endolysosomal vesicles (red), and calcein (green), 
which had a punctuate vesicular distribution (Figure 4.8 D, E and F).  To more directly 
interrogate the location of internalized nanoparticles, TEM images were taken of thin 
sections (50 nm) from fixed and stained cells following 1 hour incubation of DC2.4 cells 
with nanoparticles.  Core-shell nanoparticles with a pH-insensitive PMMA core were 
localized within membrane-bounded endosomes/phagosomes (Figure 4.8 G).  However, 
PDEAEMA core-shell nanoparticles were observed both within membrane-bounded 
vesicles (Figure 4.8 H) and within the cytosol (Figure 4.8 I).  These trends were 
consistently observed in imaging 55 particles from three individual experiments (8 
PMMA particles, and 47 PDEAEMA particles, of which 10 were in endosomes and 37 
were in the cytosol).  Together, these data support the conclusion that the pH-sensitive 
PDEAEMA core-shell nanoparticles do not remain trapped in acidic intracellular 
compartments, but instead escape to the cytosol following internalization. 
 83
 
 
Figure 4.8 Endosomal escape of pH-responsive core-shell nanoparticles.  (A-F) DC2.4 
cells were co-incubated with LysoTracker® Red DND-99 (to label endolysosomes), 
calcein, and either PDEAEMA-core/PAEMA-shell (A-C) or PMMA-core/PAEMA-shell 
nanoparticles (D-F).  Confocal images were taken at 100X, collecting brightfield images 
(A, D) as well as fluorescence (B, C, E, F) from calcein (green), LysoTracker® Red (red), 
and Cy5-labeled nanoparticles (blue).  Scale bars 10µm (A, B, D, E) and 5 µm (C, F, 
zoomed views of boxed areas in B, E showing overlaid LysoTracker® Red and 
nanoparticles fluorescence).  (G-I) TEM images of nanoparticle localization within 
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DC2.4 cells: (G) Cell sections with PMMA-core/PAEMA-shell particles revealed the 
particles internalized in membrane-bound compartments.  (H-I) Cell sections with 
PDEAEMA-core/PAEMA-shell particles showed particles internalized either in 
membrane-bound compartments (H) or in the cell cytosol without a clear binding 
membrane structure (I).  Scale bars 500 nm.   
 
Endocytosis and Acidification Requirement for Efficient Cytosolic Calcein Delivery 
The intracellular distribution of calcein observed in the presence of 
PDEAEMA-core/PAEMA-shell nanoparticles could arise either due to the particles 
causing disruption of endosomes that contain calcein, or via nanoparticles permeating the 
cell surface plasma membrane (note that calcein that reaches the cytosol is also able to 
freely enter the nucleus by diffusion93).  Though proton-absorbing polymers and lipids 
have been proposed to cause escape of molecules into the cytosol following endocytosis 
and endosome acidification via the proton sponge effect,89 it has also been shown that 
polycations such as polyethylenimine (PEI) and poly-L-lysine (PLL) have the ability to 
directly interact with the plasma membrane (the exterior cell surface), generating 
nanoscale transient pores that allow leakage of molecules into and out of the cytoplasm.94  
To examine the mechanism of cytosolic delivery of calcein by the core-shell 
nanoparticles, we tested calcein uptake by DC2.4 cells under additional conditions.   
First, to confirm that active internalization of the nanoparticles/calcein was required 
for calcein delivery to the cytosol, DCs were equilibrated at 4 °C for 30 min to block 
endocytosis/macropinocytosis, and then calcein alone, or calcein and PDEAEMA 
core-shell nanoparticles, were added to the cells (using the same calcein and nanoparticle 
concentrations as described in Figure 4.1).  Neither calcein nor nanoparticles were 
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internalized by cells following incubations up to 3 hours at 4 °C, although some particles 
bound to the plasma membrane of cells (Figure 4.9), suggesting that calcein/nanoparticle 
uptake and calcein entry into the cytosol of DCs required an active internalization process 
such as endocytosis or macropinocytosis. 
   
Figure 4.9 Calcein and nanoparticle internalization require active internalization in 
DC2.4 cells.  CLSM images (40X) of live DC2.4 cells following incubation with calcein 
(green) and 25 µg/mL PDEAEMA core-shell nanoparticles (red) at 4 °C for 3 hours.  (A, 
B) Cells with calcein and PDEAEMA core-shell nanoparticles: (A) Brightfield image and 
(B) overlay of fluorescent images.  Scale bars 20 µm.  (C) Overlay of boxed area from 
A and B.  Scale bar 10 µm.   
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If the core-shell nanoparticle promoted calcein escape to the cytosol via a transient 
osmotic pressure which was generated only under the acidic conditions in endolysosomes,    
calcein and nanoparticles were requested to localize in the same endolysosomal 
compartment.  Nanoparticles internalized into discrete vesicles from calcein should be 
unable to promote calcein access to the cytosol.  To test this hypothesis, we designed a 
simple experiment to deliver calcein and nanoparticles separately.  Calcein alone was 
incubated with DC2.4 for 1 hour at 37 °C (same calcein concentration as described in 
Figure 4.1).  After washing off the extra calcein carefully, samples were treated with 
PDEAEMA core-shell nanoparticles (25 µg/mL) only, or with nanoparticles and calcein 
for one more hour at 37 °C.  As shown in Figure 4.10 A, cells treated first with calcein 
only showed endolysosomal compartmentalization of the calcein dye.  As we expected, 
samples treated with calcein first then with nanoparticles showed the similar distribution 
of calcein dye inside the cells (Figure 4.10B).  Note that although the cellular uptake of 
nanoparticles was obvious, they were hardly co-localized with the calcein.  However, 
control cells where co-internalization of calcein and nanoparticles was shown efficient 
cytosolic delivery of calcein (Figure 4.10C).  These results confirmed that to facilitate 
the cytosolic delivery of calcein, nanoparticles had to be co-internalized by cells and 
present in the same endolysosomes with calcein.  This conclusion directed us later in the 
design of drug loading/binding for the intracellular delivery system for macromolecules. 
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Figure 4.10 Calcein internalized in separate endosomal compartments from nanoparticles 
not delivered to the cytosol.  DC2.4 cells were incubated with calcein for 1 hour at 
37 °C.  After 3 washes with warm medium, cells were incubated with complete medium 
(A), PDEAEMA core-shell nanoparticles only (B), or calcein and PDEAEMA core-shell 
nanoparticles (C).  Confocal images were taken at 63X, collecting fluorescence from 
calcein (green), Cy5-labeled nanoparticles (red).  Scale bars 10µm. 
 
To test whether acidification of endolysosomes is necessary for the pH-sensitive 
nanoparticles to facilitate calcein delivery to the cytosol, we incubated DCs with the 
H+-ATPase inhibitor bafilomycin A1 (80 nM)89, 95 for an hour at 37 °C before calcein and 
pH-sensitive nanoparticles treatment (one more hour at 37 °C).  Consistent with the 
proton sponge mechanism, bafilomycin A1 inhibition of endolysosomal acidification 
blocked nanoparticle-mediated calcein delivery to the cytosol (data not shown).   
Next, as a test of plasma membrane integrity during the incubation of DCs with 
core-shell nanoparticles at 37 °C,96 we loaded DCs with the fluorescent dye fura-2AM 
(Invitrogen) according to the manufacturer’s instructions.  Fura-2AM enters cells as a 
membrane-permeable acetomethoxy ester, but is cleaved by intracellular esterases 
following loading into the cell, to form a membrane-impermeable product that is trapped 
A B C
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in the cytosol.  We incubated fura-loaded DCs with core-shell nanoparticles, and imaged 
the fluorescence from fura over 3 hours at 37 °C by videomicroscopy in 1-min intervals 
to determine if fura escaped to the surrounding medium.  Fura fluorescence 
photobleached uniformly in cells over time, equally in the fura-only control (Figure 4.11 
A and C, red line in E) and fura/nanoparticle co-incubation experiments (Figure 4.11 B 
and D, black line in E), no sign of fura loss driven by the nanoparticles was detected.  
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Figure 4.11 Fura fluorescence in cells incubated with or without PDEAEMA core-shell 
nanoparticles.  (A-D) Images shown were the fura fluorescence at time 0 before adding 
nanoparticles (A, B) and after 3 hours without (C) or with (D) treatment of PDEAEMA 
core-shell nanoparticles.  Scale bars 10 µm.  (E) Integrated intensity changes over the 
C D 
B A 
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time for fura-loaded cells treated without (red line) or with (black line) PDEAEMA 
core-shell nanoparticles.  
 
Based on these experiments, we conclude that the nanoparticles deliver calcein to the 
cytosol of cells by co-endocytosis of calcein and particles, followed by particle disruption 
of endolysosomes and escape of the dye into the cytosol/nucleus.  This process appears 
to occur without disruption of plasma membrane integrity. 
    
4.3 Cytotoxicity 
4.3.1 Core-Shell Structure of Nanoparticles 
A concern for the design of any intracellular delivery system is the cytotoxicity of the 
delivery material.  As discussed in Chapter 1, some polymeric materials such as PEI, 
which have promising intracellular delivery efficiency for plasmid DNA, show noticeable 
toxicity and side effects on the metabolic activity of cells.41, 97  Achieving efficient 
cytosolic delivery without concomitant cytotoxicity remains an ongoing challenge for 
synthetic delivery materials.  Although poly dimethyl aminoethyl methacrylate 
(PDMAEMA, a water-soluble polymer)90, 98-100 and PDEAEMA based co polymers (such 
as poly (DEAEMA-co-PLL)101 have been used to bind and condense DNA for gene 
delivery, however, its hydrophobicity and potential toxicity is of concern.90, 102, 103  To 
overcome potential toxicity due to interactions of the hydrophobic, polycationic 
PDEAEMA core of our nanoparticles, we enveloped this pH-sensitive component with a 
hydrophilic amino ethyl methacrylate (AEMA) shell: effectively sequestering the proton 
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sponge component of the system from any direct interactions with the external or internal 
cell membranes.  In addition, the core-shell structure can be used to segregate the 
drug/cell binding and pH sensitivity functions of the particle carrier.  We have tested the 
pH-sensitivity and endolysosomal disruption by the core in the previous section; now we 
turn to a discussion of the function of the shell structure in preventing toxicity of this 
nanoparticle carrier. 
 
4.3.2 Effects of Nanoparticle Treatment on Cell Metabolism and 
Growth/Proliferation 
To assess the cytotoxicity of the core-shell nanoparticles, a dimethylthiazolyl 
diphenyltetrazolium bromide (MTT) assay was used to determine the metabolic rate of 
cells exposed to nanoparticles vs. untreated controls.  Here, 5x104 DC2.4 cells were 
plated in triplicate in 96-well plates, and incubated with or without 25 µg/mL 
nanoparticles for 1 hour at 37 °C.  The cells were then washed three times with warm 
complete medium.  The metabolic rate (expressed as a percentage relative to controls 
that were not exposed to nanoparticles) was measured either immediately by the standard 
MTT assay (details in Section 4.1.4) to detect the acute effects of nanoparticles on the 
cells, or after an additional 24 hours of culture to measure the latent effects of 
nanoparticle treatment on cell metabolism (Figure 4.12).  Core-shell particles with a 
pH-insensitive PMMA core had negligible cytotoxicity up to 24 hours post particle 
incubation.  Likewise, core-shell nanoparticles with the pH-responsive PDEAEMA core 
also had very low toxicity: at nanoparticle concentration of 25 µg/mL that provided 
efficient intracellular delivery of calcein shown in Figure 4.1, cells had ~ 95% of the 
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metabolic activity of controls at either tested time point.  Notably, nanoparticles lacking 
a PAEMA-rich shell (PDEAEMA core only) exhibited much greater cytotoxicity than 
core-shell particles.  This may reflect the combined impact of cationic charge and 
hydrophobicity in crosslinked PDEAEMA, which is exposed in the ‘core-only’ particles 
but sequestered in the core-shell structures under the more hydrophilic PAEMA surface 
layer; the combination of cationic charge and hydrophobicity is a common feature of 
highly membrane-interactive polymers.99, 100  Similar cell viability trends were obtained 
from a cell-growth assay, in which cells were treated with nanoparticles (or left 
untreated), and then replated and allowed to grow for three days, followed by 
measurement of total cell numbers (Figure 4.13).   
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Figure 4.12 Metabolic rates of nanoparticle-treated cells relative to untreated controls.  
DC2.4 were incubated with PMMA-core/PAEMA-shell nanoparticles (stripe), 
PDEAEMA-core/PAEMA-shell particles (white), or PDEAEMA-core/no-shell 
nanoparticles (black) for 1 hour at 37 °C, washed, and then acute (0 hr) and latent (24 hrs) 
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effects on cell metabolism were measured by MTT assay.  Error bars represent S.D. of 
triplicate samples. 
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Figure 4.13 Cell-growth assay for cell viability.  DC2.4 cells were incubated with 
25 µg/mL nanoparticles or untreated for 1 hour, washed three times, then replated at 
2.5x104 cells/well and allowed to grow 3 days; the number of cells grown out for each 
condition was then quantified. 
  
4.3.3 Dose Dependence of Nanoparticles on Cell Metabolism  
The cytotoxicity assays performed above analyzed a single dose of particles 
(25 µg/mL) that provided near-100% calcein delivery in endosome-disruption studies.  
We also assessed the dose dependence of nanoparticle treatment on cell metabolism via 
the MTT assay, summarized in Figure 4.14.  For the PDEAEMA core-shell 
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nanoparticles, cells did not show much metabolic rate change with up to 100 µg/mL of 
the particle treatment.  This compares well to polyethyleneimine (PEI) polymers, which 
have often been reported to reduce metabolic rates to 50% of untreated cells at doses of 
20-35 µg/mL.42  However, as shown above for the single-dose studies, 
PDEAEMA-core/no-shell particles, even at a 25 µg/mL particle concentration, killed 
more than 40% of the cells.  Thus, the core-shell structure provides a substantial 
protection from cytotoxic effects of the insoluble components of PDEAEMA chains 
exposing to the cell.  (Note however that we cannot rule out access of soluble cellular 
proteins to the core of the core-shell particles, given that the shell is itself a hydrogel with 
nanoscale pores that may permit protein diffusion.) 
 
Figure 4.14 Effect of particle dosage on the metabolic rate.  DC2.4 were incubated with 
PMMA core-shell nanoparticles (z), PDEAEMA core-shell nanoparticles (), 
PDEAEMA-core/no-shell nanoparticles () for 1 hour at 37 °C, washed, and then acute 
(0 hr) effects on cell metabolism were measured by MTT assay.  Error bars represent 
S.D. of triplicate samples.  
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In this chapter, we evaluated the pH-sensitivity of core-shell nanoparticles in a 
biological system, DC2.4 cells.  The efficient cytosolic delivery of calcein by 
co-incubation with the nanoparticles suggested their capability of endolysosomal 
disrupting by the nanoparticles’ pH-sensitive core via proton sponge effect.  This 
process was carried out after the cellular uptake of calcein and nanoparticles via 
co-endocytosis without any cell membrane integrity.  We further tested the effect of the 
presence of the ‘protective’ shell on cytotoxicity of the particles.  This chemical 
modification of the nanoparticles highly reduced the cytotoxicity as expected, due to 
minimum exposure of the cells to PDEAEMA.  In a broader view, this core-shell 
structure could be of significant use in designing any drug delivery systems with reduced 
cytotoxicity by preventing the cells from contacting the hydrophobic and insoluble 
components.  Further application of core-shell nanoparticles for intracellular drug 
delivery will be discussed in next chapter. 
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5 Applications of pH-Sensitive Core-Shell 
Nanoparticles for Intracellular Drug Delivery 
We have characterized our pH-sensitive core-shell nanoparticles in a biological 
system, DC2.4, and shown that: 1) these nanoparticles deliver calcein efficiently to 
the cell cytosol in a manner mechanistically consistent with the ‘proton sponge effect’; 
and 2) cytotoxicity of these particles is minimized by encapsulating the 
endosome-disrupting polymer core within a hydrophilic shell.  In this chapter, we 
consider several further applications of our nanoparticles for the intracellular delivery 
of macromolecules.  After discussing the function of the shell structure for drug 
binding, we test the delivery of a model protein antigen, ovalbumin (OVA) to murine 
primary dendritic cells, the delivery of Influenza A virus to human monocyte-derived 
dendritic cells (MDDCs), and the delivery of siRNA into epithelial cells. 
The promising cytosolic delivery efficiency of macromolecules motivated us to 
convert our nanoparticles into a biodegradable system.  Strategies for biodegradable 
nanoparticles that could potentially provide a drug releasing mechanism and lead us to 
in vivo studies will be discussed in the next chapter.    
 
5.1 Materials and Methods 
5.1.1 Materials 
All reagents were used as received without further purification.  RPMI 1640, 
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DMEM (with 4.5 g/L glucose), and Trypsin/EDTA (0.25% trypsin/2.21 mM EDTA in 
HBSS without sodium bicarbonate, calcium and magnesium) were purchased from 
Mediatech Inc.  Fetal bovine serum (FBS) was purchased from Hyclone.  
Ovalbumin (OVA) Alexa Fluor® 488 conjugate was purchased from Invitrogen.  
Recombinant murine granulocyte macrophage colony stimulating factor (GM-CSF) 
was from Peprotech, Inc.  Influenza A Antigen Strain Texas from embryonated 
chicken eggs (strain: Texas 1/77 (H3N2)) was purchased from Meridian Life Science, 
Inc.  Sodium bicarbonate (pH 9.0, 1.0 M), Alexa Fluor-488 succinimidyl ester, and 
dimethyl sulfoxide (DMSO) were purchased from Molecular Probes.  Ficoll-Paque® 
was purchased from GE Healthcare Ltd.  Recombinant human Interleukin 4 (rhIL-4), 
and recombinant human granulocyte macrophage colony stimulating factor 
(rhGM-CSF) were purchased from R&D Systems, Inc.  siGLO Cyclophilin B 
Control siRNA (Human/Mouse/Rat), fluorescence labeled antiGFP siRNA, DNA 
primers, and DharmaFECT® transfection reagent were purchased from Dharmacon 
(Thermo Fisher Scientific, Inc.), and provided by Dr. James J. Liu.  TaqMan® 
Universal PCR Master Mix, TagMan® probes, and primers were from Applied 
Biosystems.   
 
5.1.2 Binding Efficiency of Core-Shell Nanoparticles 
Binding Efficiency of OVA to Core-Shell Nanoparticles 
 Alexa Fluor® 488 conjugated OVA (0.1, 1, 10, 100, 250 µg/mL) was premixed 
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with 25 µg/mL PMMA or PDEAEMA core-shell nanoparticles for 5 minutes in 
200 µL of serum free RPMI medium to allow electrostatic binding of OVA to 
nanoparticles.  Free OVA was removed by centrifugation at 15,000xg for 15 min and 
the supernatant (~ 190 µL) was transferred to a 96-well plates.  The OVA-decorated 
particles were resuspended in complete medium by sonicating for 15 min.  The 
wash-off OVA was removed again by centrifugation at the same condition described 
above, and the supernatant (~ 190 µL) was saved in 96-well plates. The concentration 
of the free OVA in the supernatant was then determined by the fluorescence intensity 
of the solution at 488 nm/530 nm using a fluorescence microplate reader 
(SPECTRAmaxTM GEMINI, Molecular Devices Corp.).  The OVA bound to the 
nanoparticles was determined by subtracting OVA in the supernatant from the OVA 
added.  
  
Binding Efficiency of Influenza A to Core-Shell Nanoparticles 
To label Influenza A with fluorescent dye,104 50 µL of 1.0 M sodium bicarbonate 
(pH 9.0) was added to 500 µL (~ 2 x104 HA units) virus.  Alexa Fluor-488 
succinimidyl (0.005 µg/HA unit) was dissolved in 2 µL of DMSO, and added to the 
virus solution.  After stirring for 1 hour at room temperature in the dark, the labeled 
Influenza A was dialyzed (Slide-A-Lyzer® Mini Dialysis Units 3500 MWCO, Pierce) 
in PBS (1.0 M, pH7.4) at 4 °C overnight in the dark.  The volume change was 
recorded to calculate the final HA units of the labeled virus.  
Alexa Fluor® 488 conjugated Influenza A (1000, 2000, 5000 HA unit/mL) was 
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premixed with 25 µg/mL PDEAEMA core-shell nanoparticles for 5 min in 200 µL of 
serum-free RPMI medium to allow electrostatic binding of the virus to the 
nanoparticles.  Free Influenza A was removed by centrifugation at 15,000xg for 
15 min and the supernatant (~ 190 µL) was transferred to a 96-well plates.  The 
Influenza A-decorated particles were resuspended in complete medium by sonicating 
for 15 min.  The concentration of the Influenza A in the supernatant was then 
determined by the fluorescence intensity of the solution at 488 nm/530 nm using a 
fluorescence microplate reader (SPECTRAmaxTM GEMINI, Molecular Devices 
Corp.).  The Influenza A bound to the nanoparticles was determined by subtracting 
flu in the supernatant from the flu added 
 
5.1.3 OVA Delivery and OT I Assay  
Bone Marrow-Derived Dendritic Cells and Naïve T Cells Isolation and Cell 
Culture 
Animals were cared for following institute, state, and federal guidelines under an 
IUCAC-approved protocol.  Bone marrow-derived dendritic cells (BMDCs) were 
prepared following a procedure modified from Inaba et al.105  Bone marrow 
progenitors were harvested from the femur and tibia of C57BL/6J female mice (The 
Jackson Laboratory).  These cells were cultured (1x106 cells/mL/well in 24-well 
plate) in complete RPMI 1640 medium (10% FBS, 50 µM 2-mercaptoethanol, 5 mM 
L-glutamine, 10 mM HEPES, and penicillin/streptomycin) containing GM-CSF 
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(10 ng/mL).  80% of the medium was replaced with fresh complete medium 
containing GM-CSF (10 ng/mL) on day 2, 4, and 6 to obtain BMDCs.  BMDCs were 
used on day 6-7. 
Naïve CD8+ OVA-specific T cells were harvested from the spleens of OT-I TCR 
transgenic mice92, 106 (The Jackson Laboratory) using magnetic assistant cell sorting 
(MACS) beads (CD8+ T cell negative selection kit, Miltenyi Biotec, Inc.) according to 
the manufacturer’s instructions, and used immediately in OT-1 T cell priming assays.  
 
Cytosolic Delivery of OVA by Fluorescence Microscopy 
DC2.4 cells or day 6 BMDCs were plated in Lab-TekTM chambers (Nunc 8-well 
chambered coverglasses, 1.2x105 cells/well) and cultured in complete RPMI 1640 
medium for 18 hours.  OVA (200 µg/mL for DC2.4, or 100 µg/mL for BMDCs) was 
premixed with 25 µg/mL PMMA or PDEAEMA core-shell nanoparticles for 5 min to 
allow electrostatic binding of OVA to nanoparticles.  Free OVA was removed by 
centrifugation at 15,000xg for 15 min.  The OVA-decorated particles were 
resuspended in complete medium by sonicating for 15 min and added to cells for 1 
hour at 37 °C.  After three washes with complete medium to remove extracellular 
OVA and nanoparticles, the cells were imaged live by CLSM at 37°C. 
 
OT-I T Cell Priming Assay 
BMDCs were counted and plated in 24-well plates (1x106 cells/well) on day 6 
and cultured in complete medium for 2 hours to allow the cells settle to the bottom.  
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Freshly dissolved OVA (0.1, 10, or 100 µg/mL) was premixed with 25 µg/mL PMMA 
or PDEAEMA core-shell nanoparticles for 5 min to allow electrostatic binding of 
OVA to nanoparticles.  Residual free OVA was removed by centrifugation at 
15,000xg for 15 min followed by aspiration of the supernatant.  The OVA-decorated 
particles were then resuspended in complete medium by sonicating for 15 min.  
Soluble OVA (0.1, 10 or 100 µg/mL) or OVA-coated nanoparticles were added to 
cells for 1 hour at 37 °C.  The cells were collected and washed with complete 
medium by centrifugation.  After the resuspension, OVA-pulsed BMDCs were 
replated in 96-well plates in triplicate (1x105 cells/well/100 µL) for 3 hrs.  OT-I 
CD8+ T cells were added to each well (5x105 cells/well/100 µL), and co-incubated 
with BMDCs for 3 days.  Interferon gamma (IFN-γ) in the supernatants of these 
cultures was then quantified using an ELISA kit (murine Interferon gamma (IFN-γ) 
Duoset ELISA Development Kit, R&D Systems) according to the manufacturer’s 
instructions.  The DCs stimulation and T cells co-culture were carried out in 
complete medium.  A round-bottom 96-well plate was used to promote cell crawling 
and contacting. 
 
5.1.4 Cytosolic Delivery of Influenza A 
Isolation of Monocytes from Human Blood and Differentiation of Human 
Monocytes-Derived Dendritic Cells  
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Buffy coat (not older than 8 hours) was ordered and delivered at room 
temperature.  The blood was diluted with PBMC wash buffer (PBS with 0.1% BSA 
and 0.6% Sodium Citrate) with 1:2 ratio (30-35 mL buffy coat to 66 mL PBMC 
buffer).  15 mL of Ficoll-Paque® was added to a 50 mL conical centrifuge tube, and 
35 mL of cell suspension was layered on top carefully without disturbing the interface.  
After centrifugation at 400xg for 25 min at room temperature in a swinging bucket 
rotor without brake, the blood sample was separated into four portions from top to 
bottom: plasma (thick layer), buffy coat (very thin layer), Ficoll-Paque® (thick layer), 
and blood cells (red pellet at the bottom).  The buffy coat was taken out carefully 
using a pipette with a long sharp tip to avoid any disturbance to the interfaces, and 
transferred to a new 50 mL conical tube.  The tube was filled with PBMC buffer, and 
centrifuged at 300xg for 10 min with brake.  The supernatant was removed carefully 
without disturbing the cell pellet, which was then washed twice with 15 mL of cold 
PBMC buffer and centrifuged at 200xg for 8 min at 4 ºC.  The supernatant was clear 
after removing all the platelets.  The monocytes were isolated using magnetic 
assistant cell sorting (MACS) beads (CD14 monocytes-positive selection kit, Miltenyi 
Biotec, Inc.) according to the manufacturer’s instructions. 
The monocytes were suspended in the RPMI 1640 complete medium (10% FBS, 
50 µM 2-mercaptoethanol, 5 mM L-glutamine, 10 mM HEPES, and penicillin/ 
streptomycin) containing rhIL-4 (1,000 U/ml, 2.9x 04 U/ug) and rhGM-CSF (1,000 
U/ml, 1.5x104 U/ug).  Cells were then plated in 24-well plates at the density of 
1x106 cells/well/mL.  On day 2 and day 4, 80% of the medium was replaced by fresh 
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medium containing rhIL-4 and rhGM-CSF to derive MDDCs.  MDDCs were used 
on day 6-7. 
 
Cytosolic Delivery of Influenza A by CLSM 
On Day 6, MDDCs were plated in Lab-TekTM chambers (Nunc 8-well chambered 
coverglasses, 1.2x105 cells/well) and cultured in complete medium for 18 hours.  
Influenza A (1657 HA unit/mL) was premixed with 25 µg/mL PDEAEMA core-shell 
nanoparticles for 5 min to allow electrostatic binding of Influenza A to nanoparticles.  
Free Influenza A was removed by centrifugation at 15,000xg for 15 min.  The 
Influenza A-decorated particles were resuspended in complete medium by sonicating 
for 15 min and added to cells for 1 hour at 37 °C.  After three washes with complete 
medium to remove extracellular Influenza A and nanoparticles, the cells were imaged 
live by CLSM at 37 °C. 
 
5.1.5 Intracellular Delivery of siRNA 
Cytosolic Delivery of siRNA by Fluorescence Microscopy 
DC2.4 cells or BSC-40 cells, a type of epithelial cells from monkey kidney 
(ATCC), were plated in Lab-TekTM chambers (Nunc 8-well chambered coverglasses, 
1.2x105 cells/well) and cultured in DMEM medium containing 10% FBS, 50 µM 
2-mercaptoethanol, 4 mM L-glutamine, 10 mM HEPES, and penicillin/streptomycin.  
Fluorescence-labeled siRNA (2.6 µg/mL) was premixed with 25 µg/mL PDEAEMA 
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core-shell nanoparticles for 5 min to allow electrostatic binding of siRNA to 
nanoparticles.  The siRNA-decorated particles were resuspended in complete 
medium by sonicating for 15 min and added to the cells for 1 hour at 37 °C.  After 
three washes with complete medium to remove extracellular siRNA and nanoparticles, 
the cells were imaged live by CLSM at 37 °C. 
 
Transfection of Epithelial Cells by siRNA 
BSC-40 cells were plated in 6-well plate (2x105 cells/well/mL) and cultured in 
DMEM complete medium for 18 hours.  siGLO Cyclophilin B Control siRNA  
(2.6 µg/well, 100 nM) was premixed with 25 µg/mL PDEAEMA core-shell 
nanoparticles for 5 min to allow electrostatic binding of siRNA to nanoparticles.  
The siRNA-decorated particles were resuspended in complete medium (2 mL/well) by 
sonicating for 15 min.  A positive control was prepared using DharmaFECT® 
transfection reagent (Dharmacon, Thermo Fisher Scientific, Inc.) as the delivery 
system for the same amount of siRNA.  According to the manufacturer’s instructions, 
siRNA (2.6 µg/well, 100 nM) and DharmaFECT® transfection reagent (5 µL/well) 
were diluted in 200 µL serum-free medium separately, and incubated for 5 min at 
room temperature.  The two solutions were mixed gently by pipetting carefully up 
and down, and incubated for 20 min at room temperature.  1600 µL of antibiotic-free 
complete medium was added to the solution for the final desired volume of 
transfection medium (2 mL/well).    
siRNA-coated nanoparticles or siRNA-mixed lipid were added to cells for 1 hour 
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(for siRNA/nanoparticles) or 4 hours (for siRNA/lipid) at 37 °C.  The cells were 
washed with warm PBS three times, and cultured in DMEM complete medium for 
24 hours (recorded from the start of the incubation).  Cells were collected by 
trypsinization and centrifugation at 400xg for 5 min.  Cellular RNA was isolated by 
a RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions.   
 
Detection of mRNA Level by RT-PCR 
To prepare a reverse transcription-polymerase chain reaction (RT-PCR) for testing 
the remaining targeted mRNA, the concentration of total RNA of each sample was 
measured and diluted to make sure there was sufficient and similar amount RNA for 
each sample.  Cyclophilin B was the house keeping gene here and actin was chosen 
as the control or calibrator gene.  5 µL of each sample (~ 400 ng of RNA, to provide 
~ 10-20 ng cDNA for amplification) was mixed with 10 µL of TaqMan® Universal 
PCR Master Mix (combines AmpliTaq Gold® DNA Polymerase, AmpErase® UNG, 
dNTPs with dUTP, Passive Reference I for signal normalization, and optimized buffer 
components in an easy-to-use premix; Applied Biosystems), TagMan® probes, and 
primers of Cyclophilin B and actin genes in RNase-free water to make a final volume 
of 20 µL.  The one-step real time RCR was carried out in a MicroAmpTM optical 
96-well reaction plate (with Barcode, Applied Biosystems) with the following thermal 
cycle conditions: 1 cycle of three sequential incubations (50 °C for 2 min, 60 °C for 
30 min, and 95 °C for 5 min), followed by 50 cycles of amplification (95 °C for 5 s 
and 62 °C for 30 s) in a 7700 prism sequence detection system (Perkin-Elmer Applied 
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Biosystems).  The target mRNA concentration was evaluated by the comparative Ct 
method.  
 
5.2 Drug Binding Efficiency  
It is necessary for a drug delivery system to have an efficient mechanism to load 
and release it’s drug molecules.  As we mentioned in Chapter 1, many of the 
polycationic systems that could efficiently aid transport of macromolecules into the 
cytosol are formulated by physical complexation of the polycationic molecules and 
drug (e.g., polyplexes or lipoplexes of cationic polymers/lipids with DNA or RNA).  
These strategies usually result in complexes lack of control over carriers/drug particle 
size and stability,24, 54, 55 which is a critical determinant of cellular uptake in vitro and 
biodistribution and toxicity in vivo.24  In addition, the loading efficiency directly 
determines the dose of drug that can be delivered, which is a significant parameter for 
the design of a drug delivery system. 
In this project, we designed a core-shell structure to segregate the function of 
cell/drug binding from the function of endolysosomal disruption by pH-sensitivity.  
This approach allows independent tuning of the chemistry used to bind the drug 
molecules and the pH-sensitive component, which we proved to enable highly 
efficient endolysosomal disruption in Chapter 4.  In this study (shown in Figure 5.1), 
we incorporated 2-aminoethyl methacrylate (AEMA) groups into the shell, providing 
primary amines capable of electrostatically binding negatively charged drugs (e.g. 
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proteins, siRNA, or DNA).  The binding efficiency of the core-shell nanoparticles to 
some model drug cargos tested for intracellular delivery, such as OVA and influenza A, 
are discussed in this section. 
 
Figure 5.1 Schematic of drug delivery system formation.  Negative charged drug 
molecules, such as proteins, siRNA, or DNA, adsorbed to the positively charged 
AEMA shell of nanoparticles electrostatically.  
 
5.2.1 Binding Efficiency of OVA to Core-Shell Nanoparticles 
OVA Binding at Different Concentration 
To test the ability of core-shell nanoparticles to deliver a model protein vaccine 
antigen (OVA) into dendritic cells, we first assessed electrostatic binding of OVA to 
the nanoparticles as a function of OVA concentration.  The loading efficiency of 
OVA to the AEMA shell of the nanoparticles is shown in Figure 5.2.  In this 
experiment, OVA at different concentrations were mixed with 25 µg/mL PDEAEMA 
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or PMMA core-shell nanoparticles.  After a 5 min incubation period, the unbound 
OVA was removed by centrifugation and measured.  The OVA loading efficiency 
(solid symbols with solid lines) was 100% for both types of nanoparticles at low 
concentration of OVA (0.1, or 1 µg/mL).  When the OVA concentration was 
increased, the binding was more efficient for PDEAEMA nanoparticles than for 
PMMA nanoparticles: at OVA concentrations of 10, 100, and 250 µg/mL, the binding 
efficiency for PDEAEMA nanoparticles was 100%, 58%, and 52% respectively, while 
the binding efficiency for PMMA nanoparticles was 70%, 35%, and 28% respectively.  
The bound OVA amount increased proportionally as the OVA in the solution increased 
(e.g. 10, 58, 130 µg/mL of OVA bound to PDEAEMA nanoparticles when the OVA 
concentration was 10, 100, 250 µg/mL respectively).  
As expected, after OVA-coated nanoparticles were washed with complete 
medium, which was rich in serum and promoted competitive binding between the 
serum protein and the OVA to the nanoparticles, we saw a dramatic decrease of the 
binding efficiency for both types of nanoparticles (empty symbols with dashed lines), 
while the difference of binding efficiency between two types of nanoparticles still 
remained.  These binding curves allowed drug delivery systems to be prepared with 
known quantities of OVA to the amount of core-shell nanoparticles used (25 µg/mL). 
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Figure 5.2 OVA binding to core-shell nanoparticles at pH 7.4.  Soluble OVA (0.1, 1, 
10, 100 or 250 µg/mL) was premixed with 25 µg/mL PDEAEMA core-shell 
nanoparticles (square) or PMMA core-shell nanoparticles (circle) for 5 min in 200 µL 
of serum-free RPMI medium to allow electrostatic binding of OVA to nanoparticles.  
The OVA-decorated particles were resuspended in complete medium by sonicating for 
15 min and washed by centrifugation.  The OVA bound (solid symbols with solid 
lines) to the nanoparticles and the remaining OVA after washing (open symbols with 
dashed lines) were determined.  Shown are the mean ± S.D. from triplicates.  
 
Effect of pH on OVA Loading Efficiency 
The primary amine group on AEMA shell has a pKb of appximately 11.  Thus, 
the pH range from endolysosomal to physiological pH should not have an effect on 
the charge density of the AEMA shell.  However, the DEAEMA would be affected 
dramatically, as the tertiary amine group would be highly charged when the pH is 
lowered below pH 7.  As we hypothesized that not only the shell but the core would 
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PDEAEMA nanoparticles at reduced pH.  As shown in Figure 5.3, OVA binding 
efficiency (100%) was similar at a range of pHs when the OVA concentration was low 
(10 µg/mL).  However, the binding efficiency was much higher at endolysosomal pH 
(~5-6) than that of physiological pH at higher OVA solution concentrations (100, and 
250 µg/mL).  This result explained that more positive charge was present as the 
tertiary amine groups in the core were protonated and the PDEAEMA nanoparticles 
were swelling.  In addition, the size change of the nanoparticles (swelling to much 
larger size) could potentially provide more surface area and binding sites on the shell, 
and thus cause the higher binding efficiency.   
After we washed OVA-bound nanoparticles in complete medium (pH 7.4), the 
binding efficiency was reduced to the level similar as that shown in Figure 5.2 (empty 
square with dashed line).  This result further tested our hypothesis above, and 
provided us information that in the endolysosomal disrupting process when 
nanoparticles were swelling, the drug should be stably bound to the nanoparticles.  
However, we could lose OVA (drug molecules) if the delivery system could not be 
endocytosed efficiently, as binding competition between other proteins or positively 
charged molecules in the cell culture could decrease the bound OVA on the 
nanoparticles.  A method to encapsulate the drug in the nanoparticles could be a 
future direction for drug loading and protection.   
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Figure 5.3 OVA Binding efficiency at different pH overnight.  Soluble OVA (10, 100, 
and 250 µg/mL) was premixed with 25 µg/mL PDEAEMA core-shell nanoparticles 
overnight with moderate shaking in 200 µL phosphate buffer (100 mM) with pH 4.98 
(z), 6.03 (), and 7.48 (c) to allow electrostatic binding of OVA to nanoparticles.  
The OVA conjugated to the nanoparticles was determined.  Shown are the mean ± 
S.D. from triplicate samples.  
  
In addition, we found that long incubation times of nanoparticles with OVA (~ 18 
hours in Figure 5.3) did not improve the protein binding efficiency compared to the 
very brief incubations (5 min, in Figure 5.2), as the binding efficiency at pH7.4 was 
similar in these two cases.  This comparison suggested that the electrostatic binding 
process reached equilibrium quickly when the drug molecules met the nanoparticles 
in the solution. 
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5.2.2 Binding Efficiency of Influenza A to Core-Shell Nanoparticles 
Similar to the OVA delivery experiments, we adsorbed fluorescently-labeled 
Influenza A to the shell of nanoparticles through electrostatic interactions.  The 
particle binding efficiency for different concentrations of virus protein is shown in 
Figure 5.4.  The pH-sensitive nanoparticles (25 µg/mL) had ~ 55-65% binding 
efficiency at the given virus protein concentration.  Typically, a concentration of 
1000 HA unit/mL107 is used to elicit and recall T cell responses from human 
peripheral blood T cells stimulated with DCs in vitro.  We thus mix 1657 HA 
unit/mL of virus protein with our nanoparticles to provide a 1000 HA unit/mL final 
overall concentration bound to nanoparticles.  
 
Figure 5.4 Binding efficiency of Influenza A to pH-sensitive nanoparticles at pH 7.4.  
Influenza A (1000, 2000, and 5000 HA unit/mL) was premixed with 25 µg/mL 
PDEAEMA core-shell nanoparticles for 5 min in 200 µL of serum-free RPMI medium 
to allow electrostatic binding of Influenza A to the nanoparticles.  Influenza A bound 
to the nanoparticles was determined.  Shown are the mean ± S.D. from triplicate 
samples. 
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For the case of siRNA, another model drug we used, fluorescent-labeled siRNA 
(2.6 µg/mL, 100 nM) showed 100% binding to the nanoparticles at the concentration 
(25 µg/mL) we examined for the cytosolic delivery.  Binding efficiency at other 
siRNA concentrations was not evaluated due to the cost and the availability of siRNA 
sample. 
 
5.3 Delivery of Protein Vaccine Antigens to Promote 
Class I MHC Presentation to CD8+ T Cells  
Having observed efficient cytosolic delivery of calcein and low cytotoxicity of 
DCs following treatment with the pH-sensitive core-shell nanoparticles, we now 
tested the ability of these particles to chaperone the cytosolic delivery of a protein and 
promote a functional response.  As we discussed in Chapter 1, dendritic cells could 
bind peptides derived from pathogens to their MHC complexes at the cell surface for 
recognition by naïve T cells.  This presentation of antigens to cytotoxic T cells is 
greatly amplified (up to 1000-fold) by delivery of antigens to the cytosol, where the DC 
intracellular machinery can load them efficiently onto class I MHC molecules for 
presentation to CD8+ T cells.60, 61  However, the cytosolic delivery to DCs were very 
inefficient.64-66  Here, we applied ovalbumin (OVA) as the model antigen protein, 
and investigated the cytosolic delivery efficiency as well as the immune response 
from naïve T cells. 
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5.3.1 OVA Delivery in Dendritic Cells  
For these experiments, we employed bone marrow-derived dendritic cells 
(BMDCs), to determine whether delivery in primary cells differed from results 
obtained using the DC2.4 cell line.  We first tested delivery of the model protein 
antigen OVA (45 KDa).  OVA is known to be internalized by cells into endosomal 
compartments and has also been commonly used as an endocytic tracer.108, 109  
Fluorescent OVA (200 µg/mL for DC2.4, and 100 µg/mL for BMDCs) was premixed 
with core-shell nanoparticles (25 µg/mL) for 5 min to allow electrostatic adsorption of 
the protein to the cationic surfaces of the core-shell particles.  The majority of free 
OVA was removed by centrifugation and aspiration of supernatant.  The 
OVA-adsorbed particles were then resuspended in complete medium and added to 
DC2.4 (Figure 5.5) or BMDCs (Figure 5.6) for 1 hour at 37 °C, followed by washing 
and confocal imaging.  Similar to the prior results obtained for calcein, OVA 
fluorescence was observed throughout the cytosol and nucleus in DC2.4 (Figure 5.5 A, 
B) and BMDCs (Figure 5.6 A, B) co-incubated with OVA-coated PDEAEMA 
core-shell nanoparticles.  The frequency of cells with cytosolic OVA was ~ 36% 
(n=150) for DC2.4 and ~ 43% for BMDCs (n=150).  When DC2.4 or BMDCs were 
incubated with OVA-coated PMMA core-shell nanoparticles, the fluorescence was 
instead observed with a punctuate distribution in the endosomal compartments (Figure 
5.5 C, D for DC2.4, and Figure 5.6 C, D for BMDCs).  Notably, since OVA was 
tightly absorbed on the surface of the core-shell nanoparticles due to the positively 
charged amine groups in the AEMA shell, a mechanism for releasing OVA from the 
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nanoparticles may be necessary to further enhance the frequency of cells exhibiting 
cytosolically-distributed protein.  Studies addressing this issue will be discussed in 
next chapter. 
 
Figure 5.5 Cytosolic delivery of OVA by core-shell nanoparticles to DC2.4 cells.  
CLSM images at 100X: (A, C) Brightfield images; (B, D) Fluorescence overlays of 
OVA (green) and nanoparticles (red).  (A, B) Cells incubated with OVA adsorbed to 
PDEAEMA core-shell nanoparticles.  (C, D) Cells incubated with OVA adsorbed to 
PMMA core-shell nanoparticles.  Scale bars 10µm.  
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Figure 5.6 pH-sensitive core-shell nanoparticles deliver OVA to the cytosol of 
primary dendritic cells.  (A-D) CLSM images at 100X: (A, C) Brightfield images; (B, 
D) Fluorescence overlays of OVA (green) and nanoparticles (red).  (A, B) BMDCs 
incubated with OVA adsorbed to PDEAEMA core-shell nanoparticles.  (C, D) Cells 
incubated with OVA adsorbed to PMMA core-shell nanoparticles.  Scale bars 10µm. 
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5.3.2 Functional Test of Cytosolic OVA Delivery: Priming of 
OVA-Specific CD8+ T Cells by Nanoparticle-treated DCs  
OT I T Cell Priming  
DCs can internalize protein antigens by endocytosis and break them down into 
peptides.  When incubated with high concentrations of soluble antigens, dendritic 
cells have the ability to load peptides derived from a small fraction of such 
exogenously-derived antigen onto class I MHC molecules, a process known as cross 
presentation.67  DCs displaying antigen bound to MHC I molecules on their surfaces 
can then activate CD8+ T cells.  However, direct delivery of protein antigens to the 
cytosol of DCs can substantially enhance the presentation of antigen on MHC I 
molecules.  To determine whether nanoparticle-mediated transport of OVA to the 
cytosol could enhance priming of CD8+ T cells by DCs, we treated BMDCs with 
different concentrations of soluble OVA or OVA (the same quantity) adsorbed to 
either PDEAEMA or PMMA core-shell nanoparticles for 1hour.  
Antigen/nanoparticle-loaded DCs were then mixed with naïve OT-1 CD8+ T cells that 
specifically respond to a peptide derived from OVA.106  Interferon gamma (IFN-γ) 
secreted by the T cells in response to antigen presentation by the DCs was measured 
by ELISA after 3 days.  As shown in Figure 5.7, some IFN-γ secretion was triggered 
by DCs incubated with soluble OVA (10 or 100 g/mL), consistent with prior data 
from our laboratory and others, showing that a small amount of spontaneous cross 
presentation can occur when DCs are incubated with high concentration of soluble 
antigen.92  However, DCs loaded with OVA via pH-responsive nanoparticles elicited 
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much higher IFN-γ level (~ 4−5 fold) from T cells at the given concentrations (0.1, 10, 
and 100 g/mL).  In contrast, DCs pulsed with OVA via pH-non-responsive 
nanoparticles elicited the similar level of IFN-γ as the soluble OVA control.  Notably, 
to reach the same level of IFN-γ secretion (e.g. 2000 pg/mL as indicated by the blue 
dot line), a larger amount of OVA (100 µg/mL) was needed if it was delivered as a 
soluble protein or with pH-non-sensitive PMMA nanoparticles.  However, only less 
than 1 µg/mL of OVA was needed if it was delivered with pH-sensitive PDEAEMA 
nanoparticles.  This comparison indicated a more than 100-fold increase in 
functional antigen delivery by using our pH-sensitive nanoparticles.  This result also 
indicated that our nanoparticles could not only be used as a type of drug delivery 
system, but might also be useful as a signal amplifier to enable ex vivo screening of T 
cell responses to immunization; studies related to this aspect will be addressed in 
Section 5.4. 
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Figure 5.7 Cytosolic delivery of OVA for OT-I T cell priming.  BMDCs were 
incubated with different concentrations of soluble OVA ({), OVA-coated PDEAEMA 
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core-shell nanoparticles (c), or OVA-coated PMMA core-shell nanoparticles (), 
before being washed and mixed with naïve OT-1 OVA-specific CD8+ T cells.  IFN-γ 
secreted by the T cells in response to antigen presentation by the DCs was measured 
by ELISA after 3 days.  Shown are mean ± S.D. of triplicate samples. 
 
Effect of OVA Loading Methods 
As we discussed in Section 5.2.1, the binding efficiency of OVA to the 
nanoparticles varied when the binding conditions were changed.  The actual OVA 
concentration that was bound to the nanoparticles and added to BMDCs is important, 
as it determines the eventual dosage and efficiency of the T cell priming.  In this 
experiment, we tested different ways to deliver soluble or bound OVA to BMDCs 
(Figure 5.8).  We used 10 µg/mL of OVA, which provided us 100% binding 
efficiency in pH 7.4 serum-free (SF) medium, and 2x105 cells/well/100µL of BMDCs 
with 1x106 cells/well/100µL of T cells.  As we always washed off nanoparticles after 
one hour of incubation, we washed the cell samples with soluble OVA as well.  This 
led to the possibility that the differences seen in OVA delivery to DCs in soluble vs. 
particle-bound form could be partially due to differences in the kinetics of OVA 
uptake for soluble vs. particle-bound protein.  For instance, rapid particle 
internalization could lead to faster protein uptake when bound to particles.  To 
determine if soluble OVA could be as effective as particle-delivered OVA given 
enough time, we carried out control stimulation condition where OVA protein was left 
in the medium with the DCs throughout the 3-day T cell stimulation period, to allow 
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additional antigen uptake.  As shown in Figure 5.8, we observed slightly higher 
secretion of IFN-γ from the samples where we left soluble OVA in the medium for 
three days, when compared to the samples that we washed off OVA after one hour 
incubation.  However, the degree of cross-presentation/T cell stimulation measured 
was still much lower than that of detected for particle-delivered OVA, demonstrating 
that the enhanced response to particle-bound OVA was not simply due to a kinetic 
difference in antigen uptake/processing. 
In the studies of calcein delivery discussed in Chap 4, we demonstrated that 
co-endocytosis of calcein and nanoparticles in the same endolysosomal compartment 
could lead to efficient cytosolic delivery of calcein via endolysosomal escape of the 
nanoparticles co-localized.  We tested here whether co-delivery of nanoparticles and 
OVA by simple mixing could achieve same effect as calcein delivery.  BMDCs was 
incubated with OVA-mix nanoparticles (briefly mixing for 5 min without 
centrifugation) or OVA-bound nanoparticles (briefly mixing for min with 
centrifugation).  Interestingly, we found that activation of the T cells (determined by 
the IFN-γ secretion level) in the samples of OVA-mix DEAEMA nanoparticles 
(~ 9000 pg/mL) was much less than that of the samples of OVA-bound DEAEMA 
nanoparticles (~ 15000 pg/mL), while the difference between the sample of OVA-mix 
PMMA nanoparticles and OVA-bound PMMA nanoparticles was negligible.  These 
comparisons confirmed that the presence of pH-sensitive nanoparticles was the key to 
improve the cytosolic delivery efficiency of OVA, as the T cells response and 
cytokine secretion were low in the case of pH-insensitive nanoparticles.  Since 
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PMMA core-shell nanoparticles possessed similar binding efficiency as PDEAEMA 
core-shell nanoparticles by the similar AEMA shells (data not shown), the low 
efficiency of OVA delivery proved that both OVA bound- or OVA-mix PMMA 
nanoparticles could only cause a small amount of spontaneous cross presentation as 
soluble OVA.  We suspected that the cellular uptake of OVA was highly improved 
when OVA was bound to the nanoparticles using centrifugation, which suggested by 
the difference between OVA-mix and OVA-bound DEAEMA nanoparticles.   
We know that serum free medium was used in a lot of protocols for drug delivery, 
as the presence of serum protein could lead to the instability of the drug delivery 
system that formed by the complexation of polymers and drug molecules.24, 54, 55  
However, incubation with serum free medium may not provide enough nutrients that 
are needed by cells.  In addition, it limits the applications for in vivo studies, as 
proteins are always present in the physiological environment.  Therefore, the 
stability and function of drug delivery systems in complete medium containing serum 
protein is important.  As emphasized, the core-shell structured hydrogel 
nanoparticles were expected to provide predefined size, and stability in biological 
system which were suggested by the efficiently delivery of OVA and high level of 
IFN-γ secretion in the serum containing medium.   
 123
0
3000
6000
9000
12000
15000
Control Soluble OVA Soluble OVA
with wash
OVA-mix
DEAEMA
NPs
OVA-mix
PMMA NPs
OVA-bound
DEAEMA
NPs
OVA-bound
PMMA NPs
IF
N
-γ
 S
ec
re
te
d 
(p
g/
m
L)
 
Figure 5.8 Cytosolic delivery of OVA for OT I T cell priming with different OVA 
loading methods.  BMDCs were incubated with the same concentration of soluble 
OVA (10 µg/mL) (with or without wash-off after 1 hour of incubation), OVA mixed 
with PDEAEMA or PMMA core-shell nanoparticles (without centrifugation), 
OVA-bound PDEAEMA or PMMA core-shell nanoparticles (with centrifugation).  
IFN-γ secreted by the T cells in response to antigen presentation by the DCs was 
measured by ELISA after 3 days.  Shown are mean ± S.D. of triplicate samples. 
  
In conclusion, we demonstrated that pH-sensitive PDEAEMA core-shell 
nanoparticles were able to efficiently deliver the antigen protein OVA to the cytosol of 
dendritic cells.  The delivered OVA could further promote the cross presentation of 
OVA-derived peptides on MHC I molecules and thus led to enhanced CD8+ T cell 
priming compared to soluble protein delivery, as evidenced by high levels of IFN-γ 
secretion by OVA-specific T cells.  Nanoparticle-mediated OVA delivery enhanced 
the efficiency of cross-presentation by a factor of ~100-fold based on the dose 
response of T cell priming by DCs treated with antigen-loaded core-shell particles.  
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This enhancement could be further explored for ex vivo human vaccine screening, 
which is discussed in next section.  
 
5.4 Cytosolic Delivery of Influenza A  
Vaccination studies in humans are hampered by the limited assays that can be 
used to measure the strength, breadth, and quality of immune responses elicited in 
human patients.  For assessment of T cell responses, clinical trials are limited to 
analyzing the phenotype/function of T cells recovered from peripheral blood samples.  
In cases where the immune response involves a known peptide antigen and HLA 
combination, it is possible to directly identify antigen-specific T cells from blood 
samples using recombinant peptide-MHC tetramer technology.110-112  However, for 
novel vaccines where the immunodominant antigens are poorly defined or unknown, 
the only recourse for ex vivo analysis of the immune response lies in restimulation of 
effector or memory T cells in vitro using patient-derived dendritic cells pulsed with 
the vaccine antigen.107, 113, 114  For vaccines employing complex antigens (e.g., whole 
tumor lysate vaccines), there is no guarantee that incubation of vaccine antigen with 
DCs in vitro will lead to sufficient cross-presentation of any given epitope to properly 
mimic the potential antigen display elicited in vivo.  Thus, a hurdle facing analysis of 
vaccine trials is the possibility that the restimulation assays used to detect CD8+ T cell 
responses ex vivo may be inadequate to detect immune responses even if they were 
actually elicited by the vaccine. 
 125
The ability of the core-shell nanoparticles developed here to promote 
cross-presentation by DCs for CD8 T cell priming opens the possibility that these 
particles could be used to facilitate in vitro restimulation assays on detection of 
effector or memory T cell responses during human vaccine clinical trials.  As a first 
step in this direction, we explored the possibility of delivering a complex antigen 
(whole inactivated virus) for restimulation of memory T cells readily obtainable from 
human populations (influenza memory T cells).107 
Influenza is an infectious disease of birds and mammals caused by viruses.  Flu 
spreads around the world in seasonal epidemics, killing millions of people in 
pandemic years and hundreds of thousands in non-pandemic years.  For instance, a 
deadly avian strain named H5N1 (‘bird flu’) has posed the greatest risk for a new 
influenza pandemic since it first killed humans in Asia in the 1990s.  Vaccinations 
against influenza are usually given to people to prevent the virus infection.  However, 
a vaccine formulated for one year may be ineffective in the following year, since the 
influenza virus changes rapidly over time and different strains become dominant.  In 
this section, we investigated the possibility of our nanoparticles to deliver a type of flu 
virus into human dendritic cells and to promote an immune response.  We used 
whole inactivated Influenza A (H3N2) as our test strain.   
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5.4.1 Influenza A Delivery by Fluorescence Microscopy  
We employed human monocyte-derived dendritic cells (MDDCs), to determine 
whether the pH-sensitive nanoparticles could deliver Influenza A virus protein to the 
human dendritic cells efficiently.  Fluorescent Influenza A (1000 HA unit/mL) was 
premixed with PDEAEMA core-shell nanoparticles (25 µg/mL) for 5 min to allow 
electrostatic adsorption of the protein to the cationic surfaces of the core-shell 
particles.  The majority of free Influenza A was removed by centrifugation and 
aspiration of supernatant.  The Inlfuenza A-adsorbed particles were then 
resuspended in complete medium and added to MDDCs for 1hour at 37 °C, followed 
by washing and confocal imaging.  Similar to the prior results obtained for calcein 
and OVA delivery, Influenza A fluorescence was observed throughout the cytosol and 
nucleus in MDDCs (Figure 5.9 B, pointed by white arrows) co-incubated with 
Influenza A-coated PDEAEMA core-shell nanoparticles.  Incubation of MDDCs 
with Influenza A also showed high amounts of virus uptake, likely through normal 
antigen capture/uptake mechanisms specifically evolved for efficient recognition of 
pathogens by DCs (Figure 5.9 D).  Notably however, even for the high levels of free 
virus internalized by the cells, signatures of free cytosolic fluorescence extending into 
dendrites of the cells was lacking, suggesting that nanoparticles may be favoring 
cytosolic entry over the response to the free virus.  A potential complication for this 
particular choice of antigen is the possibility that the inactivated whole virus 
preparation may have some residual intrinsic endosome-disruption activity from the 
native cellular entry proteins of the virus.  Following on these preliminary 
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investigations, analyses of T cell responses to the delivery of Influenza A using 
flu-specific human T cells is ongoing with collaborators at the Dana Farber Cancer 
Institute/Harvard Medical School.   
 
Figure 5.9 Cytosolic delivery of Influenza A to MDDCs.  CLSM images at 100X: 
(A, C) Brightfield images; (B, D) Fluorescence overlays of Influenza A (green) and 
nanoparticles (red).  (A, B) Cells incubated with Influenza A adsorbed to 
PDEAEMA core-shell nanoparticles.  (C, D) Cells incubated with Influenza A alone.  
Scale bars 10µm.  White arrows pointed the cells with cytosolic delivery of 
Influenza A protein.  
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5.5 Intracellular Delivery of siRNA 
In addition to protein delivery, a final area of therapeutic delivery we have briefly 
examined with the core-shell nanoparticle system is the delivery of double-stranded 
RNA oligonucleotides for RNA interference (RNAi).  RNAi is originally considered 
as a self-defense mechanism of cells to the infection by RNA.  As mentioned in 
Chapter 1, in recent years, the potential use of siRNA as therapeutic agents has 
attracted great attention.  For instance, treating severe and chronic diseases (e.g. 
cancer) could be done by silencing RNA and regulating protein levels with siRNA.  
However, the extremely low efficiency of intracellular delivery of siRNA and the 
relatively high dose of siRNA required for gene silencing limit its therapeutic 
applications.  An ideal delivery system that would (1) be able to bind siRNA in a 
reversible manner to ensure subsequent release of the siRNA; (2) escape from 
endosomal compartment; and (3) be biocompatible.  Our pH-sensitive core-shell 
nanoparticles could be a good candidate as a siRNA delivery system.  
 
5.5.1 siRNA Delivery by Fluorescence Microscopy 
We employed DC2.4 and an epithelial cell line from monkey kidneys, BSC-40, to 
determine whether the pH-sensitive nanoparticles could deliver siRNA to the cell 
cytosol efficiently.  Cy5-labeled siRNA (100 nM) was premixed with PDEAEMA or 
PMMA core-shell nanoparticles (25 µg/mL) for 5 min to allow electrostatic 
adsorption of the siRNA to the cationic surfaces of the core-shell particles.  The 
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siRNA-adsorbed particles were then resuspended in complete medium and added to 
DC2.4 cells for 1 hour at 37 °C, followed by washing and confocal imaging.  Similar 
to the prior results obtained for calcein and OVA delivery, Cy5 fluorescence of 
siRNA was observed throughout the cytosol and nucleus in DC2.4 (Figure 5.10 B) 
co-incubated with siRNA-coated PDEAEMA core-shell nanoparticles.  The 
cytosolic/nuclear delivery efficiency was 43.0 ± 2.3% (S.D. of three individual 
samples, n=150 cells were scored).  When DC2.4 were incubated with 
siRNA-coated PMMA core-shell nanoparticles, the fluorescence was instead observed 
with a punctuate distribution in the endosomal compartments (Figure 5.10 D).   
 
Figure 5.10 pH-sensitive core-shell nanoparticles deliver siRNA to the cytosol of 
DC2.4 cells.  (A-D) CLSM images at 100X: (A, C) Brightfield images; (B, D) 
Fluorescence overlays of siRNA (blue) and nanoparticles (red). (A, B) DC2.4 
incubated with siRNA adsorbed to PDEAEMA core-shell nanoparticles. (C, D) Cells 
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incubated with siRNA adsorbed to PMMA core-shell nanoparticles.  Scale bars 
10µm. 
 
We tested the intracellular delivery of fluorescent siRNA to BSC-40 cells in a 
similar protocol.  In this study, we tested an antiGFP siRNA, which has the sequence 
as listed in Table 5.1. 
Table 5.1 Sequence of antiGFP siRNA 
working strand  U.G.C.G.C.U.C.C.U.G.G.A.C.G.U.A.G.C.C.dT.dT.3'-Cy5 
complementary strand Cy3-G.G.C.U.A.C.G.U.C.C.A.G.G.A.G.C.G.C.A.dT.dT 
Non-labeled core-shell nanoparticles were used in this study, as both of the 
strands for siRNA were labeled.  In Figure 5.11 B, the Cy5 and Cy3 dye were 
co-localized and displayed a punctuate distribution in the cells.  This result showed 
that with PMMA core-shell nanoparticles, siRNA was confined in endolysosomes.  
When BSC-40 cells were incubated with siRNA-coated PDEAEMA core-shell 
nanoparticles (Figure 5.11 D), the Cy3 and Cy5 fluorescence was observed 
throughout the whole cytosol, indicating the efficient intracellular delivery of siRNA.  
At the same time, the Cy5 fluorescence was shown as punctuate dots in certain 
locations inside the cells, besides flooding the cell cytosol together with Cy3 label.  
It could be the evidence that the working strands with Cy5 label were targeting 
specific mRNA sequences, after being released from the endolysosomes.  This 
hypothesis needed to be further investigated by examining the mRNA level of the 
cells.  
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Figure 5.11 Intracellular delivery of siRNA to epithelial cells, BSC-40.  (A-D) 
CLSM images at 40X: (A, C) Brightfield images; (B, D) Fluorescence overlays of 
different siRNA strands (blue, Cy5-labeled working strand; and red, Cy3-labled 
complementary strand).  (A, B) DC2.4 incubated with siRNA adsorbed to PMMA 
core-shell nanoparticles.  (C, D) Cells incubated with siRNA adsorbed to 
PDEAEMA core-shell nanoparticles.  Scale bars 20 µm. 
 
5.5.2 Gene Silencing Following Particle-Mediated siRNA Delivery 
To evaluate the efficiency of siRNA delivery, we used reverse transcription RCR 
(PT-PCR) to detect the mRNA level of siRNA-transfected cells.  RT-RCR is a 
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process in which single-stranded RNA is reverse transcribed into complementary 
DNA (cDNA) by using total cellular RNA together with a reverse transcriptase 
enzyme, a primer, dNTPs and an RNase inhibitor.  The resulting cDNA can be used 
in a real time PCR reaction, which can make a large number of copies of the specific 
gene ex vivo in short periods.  With the amplification of PCR, we can screen for the 
genetic information expected in cells by applying proper primers.  
As described in section 5.1.5, we transfected BSC-40 cells with siGLO 
Cyclophilin B control siRNA (100 nM) coated PDEAEMA nanoparticles (25 µg/mL) 
for 1 hour or siRNA/Lipid (DharmaFECT® transfection reagent, 2.5 µL/mL) for 4 
hours.  After a 24 hour incubation period, the cellular RNA was isolated, measured, 
and diluted for RT PCR in a 7700 prism sequence detection system (Perkin-Elmer 
Applied Biosystems). 
 After real time PCR, Ct, the number of PCR cycles at which a significant 
exponential increase in TaqMan® fluorescence is detected.  This threshold cycle is 
directly correlated with the number of copies of DNA template present in the reaction.  
A quantitative approach, the comparative Ct method, was used to determine the 
mRNA amount in the cytosol.  In this method, the Ct values of the samples of 
interest were compared to a control or calibrator, such as a non-treated sample or 
RNA from normal tissue (actin gene in our case).  The Ct values of both the 
calibrator and the samples of interest were normalized to an appropriate endogenous 
housekeeping gene (cyclophilinB).  
 133
( ) CalibratortSampletSamplet CCC ,,, δδδ −=∆  
nghousekeepitSampletSamplet CCC ,,, −=δ  
nghousekeepitCalibratortCalibratort CCC ,,, −=δ  
The mRNA amount was determined as  
SampletCmRNA ,2δ=  
In figure 5.12, the knockdown rate of mRNA, which is the remaining amount of target 
mRNA in the transfected cells compared to that of untreated control, was plotted for 
different samples.  For the positive control, siRNA delivered by commercial lipid 
(DharmaFECT® transfection reagent) for longer time (4 hours), 6.3±1.2% (S.D of 
three individual samples) of targeted mRNA remained in the cells.  When cells were 
transfected with siRNA-coated PDEAEMA core-shell nanoparticles for only 1 hour, 
the target mRNA was calculated as 23.3 ± 14.0 % (S.D of three individual samples) of 
untreated cells.  This result demonstrated the efficiency of the cytosolic delivery of 
siRNA by our nanoparticles.  Note that the mRNA level was measured with total 
cellular RNA of all the cells in the sample, as it was assumed that the transfection of 
siRNA was homogenous.  The result shown in Figure 5.12 was the average of the 
whole cell population.  However, from the CLSM, we knew that the cytosolic 
delivery efficiency was ~ 43%, and not all the cells were affected in the same way for 
the siRNA delivery.  This result indicated that some of the cells were affected by the 
siRNA delivered to the cytosol, and the targeted mRNA level could be close to zero.  
However, there were some cells that might not be affected at all, and the targeted 
mRNA level was still high.  The flow cytometry technique could be further applied 
to detect remaining level of protein translated from the targeted mRNA with certain 
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fluorescent indicators through the cell population.   
This inefficiency in different cells could be caused by the lack of drug unpacking 
mechanism.  This limitation of the present system will be further discussed in the 
next chapter examining future directions for this research. 
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Figure 5.12 mRNA level of BSC-40 cells with the cytosolic delivery of siRNA.  
Cells were treated with no siRNA (control), siRNA with DharmaFECT® transfection 
reagent (siRNA/Lipid), or siRNA with pH-sensitive core-shell nanoparticles 
(siRNA/DEAEMA NPs), and cultured for 24 hours.  For each condition, total 
cellular RNA of the whole cell population was isolated and detected by RT-PCR.   
 
In this chapter, we applied the pH-sensitive PDEAEMA core-shell nanoparticles 
as an intracellular drug delivery system, and demonstrated that these particles are 
capable of efficient cytosolic delivery of membrane-impermeable macromolecules 
such as OVA protein, Influenza A, or siRNA to different cell types.  By sequestering 
the hydrophobic, pH-buffering component of the polymer particles within the core by 
a more hydrophilic shell composition, these particles effectively disrupted endosomes 
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and delivered molecules to the cytosol of cells without overt cytotoxicity.  These 
materials may be of utility for delivery of membrane-impermeable drug compounds 
or oligonucleotides to the cytosol of dendritic cells for immunotherapy, and other cell 
types for cytosolic drug therapy.  In the next chapter, we will explore the extension 
of this concept to core-shell nanoparticles that quickly dissolve to non-toxic soluble 
components upon reaching the cytosol, to promote efficient unpacking of drugs 
carried to the cytosolic compartments.
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6 Design of Biodegradable Nanoparticles 
We have synthesized pH-sensitive core-shell nanoparticles and demonstrated their 
capability of delivering small molecules or macromolecules to the cell cytosol 
efficiently by endosome disruption.  We would like to further test and apply our 
nanoparticles as a drug delivery system in vivo.  However, lack of degradability is of 
great concern, as the biodistribution of nanoparticles in the blood stream and the 
accumulation of nanoparticles in the spleen and kidney might cause toxicity in long 
term.115  Design of a biodegradable system that can dissolve and be excreted out of 
the body is necessary.  
In addition, our studies with protein or siRNA delivery described in the last 
chapter suggested that the release of macromolecular drugs electrostatically bound to 
the particles is inefficient.  This inefficient release is a barrier to an optimal function 
of the particles as a delivery system.  A degradable particle could potentially 
facilitate drug ‘unpacking’ and address this issue.   
 
6.1 Materials and Methods 
6.1.1 Materials 
Most reagents were obtained as described in Chapter 3.  N, N-bis (acryloyl) 
cystamine (BAC), and glutathione (GSH, reduced form) were purchased from 
Sigma-Aldrich Chemical Co.  Cy3 mono-NHS ester was purchased from GE 
 138
Healthcare UK Limited.  Poly fluorTM 570 methacryloxyethyl thiocarbamoyl 
rhodamine B was purchased from Polysciences Inc.  
 
6.1.2 Synthesis of Nanoparticles by Emulsion Polymerization  
Similarly as described in Section 3.1.2, nanoparticles were synthesized with the 
biodegradable crosslinker BAC.  Typically, BAC (16 mg, 0.5 mol%) was weighed 
and dissolved in EtOH (300 µL) at 70 °C.  PEGMA1000 (220 mg, 20 wt%) was 
prewarmed at 70 °C, and added to the BAC solution.  DEAEMA (960 µL, 80 wt%) 
was then mixed with PEGMA1000 and BAC solution, and dispersed in prewarmed 
water (9 mL) with stirring, and equilibrated at 70 °C for 20 min, before adding APS 
(50 µL of 200 mg/mL freshly made solution) as the initiator.  The emulsion 
polymerization was allowed to proceed at 70 °C for 3 hours to grow the particle core, 
followed by injection of AEMA (50 µL of 800 mg/mL freshly made solution, 
0.24 mmol) to grow the particle shells for an additional 1.5 hours.  The nanoparticles 
were purified by dialysis (10,000 MWCO Slide-A-Lyzer® Dialysis Cassettes, Pierce 
Chemical Co.) in deionized water for three days followed by ultrafiltration (10,000 
MWCO PLGC Ultrafiltration Membrane, Millipore Co.) three times and 
centrifugation three times with PBS (pH 7.4) at 15,000xg.  Purified particles were 
stored in PBS at 4 °C.  Fluorescent labeling the AEMA shell structure with Cy-3 
mono-NHS ester was carried out as described in Section 3.1.2.  The labeled particles 
could be visualized by Confocal Laser Scanning Microscope (CLSM).  CryoEM was 
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performed to measure the size of the nanoparticles, as described in Section 3.1.2. 
 
6.1.3 Degradation Study of BAC Crosslinked Nanoparticles 
To mimic different physiological and cellular environments, GSH (10 mM) was 
dissolved in deionized water (pH 3), serum free PRMI 160 medium (pH 7.4), and 
complete PRMI 160 medium (pH 7.4).  In addition, phosphate buffer at 
physiological ionic strength (100 mM) with different pH was used for certain 
conditions.  
100 µL of purified nanoparticles (~ 0.5 mg) were suspended in 1 mL PBS 
(pH 7.4), GSH in water (pH 3), or GSH in SF medium (pH 7.4) with mild shaking in 
the Jitterbug at 37 °C.  The degradation of the BAC nanoparticles was examined by 
quantifying the optical clarity of the suspension using UV/VIS Spectrum (Helios 
Gamma, Thermo Fisher Scientific Inc.) to collect absorbance values at a wavelength 
of 450 nm; or by evaluating the size distribution of the nanoparticles by DLS (Particle 
Size Analyzer 90Plus, Brookhaven Instruments Corporation). 
 
6.1.4 Biological Characterization of BAC Crosslinked Nanoparticles 
Calcein Delivery in DC2.4 Cells 
The cytosolic delivery efficiency of BAC crosslinked nanoparticles was tested in 
DC2.4 cells with the small molecule calcein.  DC2.4 cells were cultured according to 
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the conditions described in Section 4.1.2.  DC2.4 cells (1.2x105 cells/well) were 
plated in Lab-TekTM chambers and cultured overnight (~ 18 hours).  Calcein was 
added to the cells (150 µg/mL, 0.24 mM) with or without 25 µg/mL BAC 
nanoparticles in complete medium (RPMI 1640 with 10% fetal bovine serum (FBS)) 
for 1 hour at 37 °C.  After three washes with medium to remove extracellular calcein 
and particles, the cells were imaged live by CLSM at 37 °C.   
 
Cell-Growth Assays of Cell Viability 
BMDCs were harvested and derived as described in Sec 4.1.4.  Day 6 BMDCs 
(1x106 cells/well/mL) were plated in a 6-well plate for 2-4 hours to allow the cells to 
attach to the bottom of the plates.  Cells were then incubated with 25 µg/mL of 
BAC-crosslinked or PEGDMA-crosslinked nanoparticles for 1 hour at 37 °C.  After 
washing three times with complete medium to discard the extracellular nanoparticles, 
cells were collected, counted, and replated in 96-well plates at a density of 5x104 
cells/well.  The replated cells were then cultured for an additional three days, and the 
number of cells grown out in these cultures was determined by the CyQUANT® NF 
Cell Proliferation Assay Kit at 488 nm/530 nm using a fluorescence microplate reader 
(SPECTRAmaxTM GEMINI, Molecular Devices Corp.)  
 
Degradation In Vitro 
To enable tracking of dissolution of the particle cores in live cells, nanoparticles 
were labeled by poly fluorTM 570 methacryloxyethyl thiocarbamoyl rhodamine B in 
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the core.  This fluorescence dye was dissolved in EtOH (50 mg/mL) and added to 
comonomer and BAC mixture (10 µL in 1 mL) before the synthesis. 
Day 6 BMDCs (1.2x105 cells/well) were plated in Lab-TekTM chambers and 
cultured overnight (~ 18 hours).  Cells were treated with or without 25 µg/mL of 
BAC nanoparticles in complete medium for 1 hour at 37 °C.  After three washes 
with medium to remove extracellular particles, the cells were imaged live by CLSM at 
37 °C.  The cells were then cultured and imaged live by CLSM at 37 °C over 24 and 
48 hours.  
 
6.2 Design of Biodegradability  
An important consideration for clinical application of this polymeric drug 
delivery systems is the ultimate fate of the polymeric materials, which will be 
determined by its method of synthesis, its subsequent degree of purity, its behavior on 
administration into the individual biological system, and its biodistribution.115  The 
biodegradability of nanoparticles used for drug delivery is of great concern, as the 
blood circulation and final accumulation of the polymeric materials and the 
by-products could potentially cause serious toxicity or immune response.115 
Biodegradability can be defined as the capability of the material to be broken 
down in vivo into excretable or metabolized products.  An efficient process inside 
the body to disassociate the nanoparticles from the drugs, and then break them down 
into inert or harmless chemicals that can exit the body quickly is needed for a 
 142
biodegradable drug delivery system.   
Hydrolysis is used as a major mechanism to degrade polymeric systems, for 
example, polymers with ester linkages such as the poly(lactide-co-glycolide) (PLGA) 
family.39  In general, an ester link can be slowly broken down in water into a 
hydroxyl functional group and a carboxylic acid functional group.  With the aid of 
dilute acid to protonate the carbonyl group, the acid-catalysed hydrolysis can be much 
more efficient.  However, it has been reported that PLGA has poor stability in 
endolysosomes,33, 116  as drugs cargoes are often degraded in acidic microclimate 
before it can be successfully released to the cytosol.39, 40  Hydrolysis process is not 
suitable to design the biodegradability of our nanoparticles.  If the nanoparticles 
were degradable in acidic environment under hydrolysis, their pH-responsive function 
could be compromised.   
Enzymatic degradation31, 32, 72, 73 is another commonly used mechanism for 
biodegradation.  Almost all processes in a biological cell need enzymes.  In an 
enzymatic reaction, the substrate could be converted into different molecules 
selectively by specific enzyme(s) at a significant rate.  However, enzymes are rich in 
endosomes, and especially lysosomes.  As the kinetics of endolysosomal escape is 
not clear, the cytosolic delivery could happen by the disruption of the endosomes or 
lysosomes.  If the nanoparticles could be located in the lysosomes for certain period 
of time, the enzymes could digest the nanoparticles and drug cargos there efficiently, 
unless we could make use of a specific enzymatic reaction in the cytosol.  Instead of 
locating a specific enzyme that only present in cytosol of certain cell types, we 
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explored a specific chemical reaction as an alternative mechanism for nanoparticles 
degradation.  
 
Cytosolic Environment and Degradable Crosslinker 
Glutathione is a small molecule made up of three amino acids, which exists in 
almost every cell of the body (Figure 6.1).  Thiol groups (~ 5 mM) are usually kept 
in a reduced state.  In effect, glutathione reduces any disulfide bonds formed within 
cytoplasmic proteins to cysteines by acting as an electron donor.  The presence of 
glutathione is required to maintain the normal function of the immune system, as it is 
known to play a critical role in the multiplication of lymphocytes which occurs in the 
development of an effective immune response.117  Furthermore, glutathione is used 
to detoxify various chemicals from the body.  Glutathione is found almost 
exclusively in its reduced form in the cytosol since the enzyme glutathione reductase 
is constitutively active and inducible upon oxidative stress.  This enzyme converts 
oxidized form glutathione disulphide (GSSG) to the sulfhydryl form GSH.  In fact, 
the ratio of reduced glutathione to oxidized glutathione within cells is a measure of 
cellular toxicity.   
Based on these facts, we sought to take advantage of the constant concentration 
of GSH present in the cell cytosol, and apply disulfide reduction as a mechanism of 
biodegradability of our nanoparticles.118-122  With the thiol groups of GSH in 
cytoplasm, the nanoparticles rich in disulfide links would be broken down to polymer 
chains by the reducing environment.  In addition, since the intracellular GSH 
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concentration (1-10 mM) is 1000-fold greater than the extracellular level (2 µM),120, 
123-126 the particles could potentially be stable until degradation is carried out in the 
cytoplasm after endolysosome escape.  Thus, a crosslinker BAC127-129 (Figure 6.1) 
with a disulfide bond was chosen to synthesize the nanoparticles.   
 
 
Figure 6.1 Chemical structures of GSH and BAC. 
 
Non-toxic Micelle Formation 
Given the hypothesis that nanoparticles crosslinked by disulfides could be 
degraded by GSH in the cell cytosol, the final components and their cytotoxicity are 
still of concern.  By simply replacing the PEGDMA crosslinker of the ‘stable’ 
core-shell nanoparticles with the disulfide-linked BAC, disulfide cleavage would be 
proposed to produce insoluble polymer chains of PDEAEMA in the cytosol.  These 
PDEAEMA breakdown products could be toxic to cells, as was reported by Zuidam et 
al. in a study of structurally-similar poly(dimethylaminoethyl methacrylate) 
polymers.90  We have investigated core-only nanoparticles in Chapter 4, and proved 
their potential cytotoxicity as well.  Although we shield the hydrophobic and slightly 
cytotoxic core by the hydrophilic AEMA shell, breakdown of the nanoparticles would 
expose the PDEAEMA polymer to internal membranes of the cell.  Similar to 
core-shell structure used to sequester PDEAEMA in the intact particles, we need a 
design to ‘hide’ the PDEAEMA polymer chains in the breakdown products as well.   
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To achieve this goal, we pursued the approach schematically outlined in Figure 
6.2.  We hypothesized that copolymerization of DEAEMA with a hydrophilic PEG 
methacrylate in the core, crosslinked by the disulfide BAC crosslinker, would provide 
a degradable particle with a nontoxic breakdown structure:  each chain of the 
crosslinked core would have a ‘comb’ copolymer architecture, with a DEAEMA 
backbone and short PEG side chains.  Cleavage of the crosslinks holding the core 
together would result in release of individual comb chains.  The hydrophobic nature 
of the DEAEMA backbone units at neutral pH would favor collapse of the backbone 
units, while the hydrophilic PEG chains would extend into solution, forming a 
unimolecular micelle.  We hypothesized that such a unimolecular micellar 
breakdown product could be safely eliminated from cells and eliminated from the 
body, e.g., through the kidneys.   
In summary (Figure 6.2), we would crosslink DEAEMA and PEGMA by BAC, 
which possesses a disulfide bond and can be reduced by GSH in the cytoplasm, to 
form the degradable nanoparticles.  The nanoparticles should still have the capability 
to disrupt the endolysosomes and release drugs via their pH-sensitivity.  After the 
nanoparticles carrying the drug molecules are released to the cytosol, they would be 
digested by GSH in the cytoplasm.  The breakdown poly(DEAEMA-co-PEGMA) 
comb polymer chain could form non-toxic micelles by hiding the slightly toxic 
PDEAEMA to the core while facing the hydrophilic PEG toward cell environment.  
At the same time, drug molecules would be unpacked from the nanoparticles, and 
released to the cytosol upon the degradation of drug cargos.   
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Figure 6.2 Schematic of biodegradable nanoparticles.  (A) Chemical architecture of 
biodegradable nanoparticles.  (B) Behavior of biodegradable nanoparticles in cells.  
At extracellular pH, nanoparticles remain in their deswelled state and bind drug 
molecules on the shells electrostatically. At endolysosomal pH, the core tertiary 
amines ionize, and the particles swell and disrupt the endolysosomes, while the drugs 
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remain bound.  In the cytoplasm environment, GSH reduces the disulfide bonds of 
the crosslinker BAC, and the nanoparticles are digested into non-toxic micelles, 
which have the hydrophilic PEGMA as outside layer and hydrophobic PDEAEMA as 
inside core, and the drug molecules are released.  
   
6.3 Degradation of BAC Crosslinked Nanoparticles 
As designed above, the degradation of the nanoparticles mainly depends on the 
concentration of the crosslinker BAC, as the amount of the disulfide bonds in the 
nanoparticles decides the efficiency of the reduction by GSH.  However, parameters 
such as the molecular weight of comonomer PEGMA, and the ratio of PEGMA to 
DEAEMA in the comonomer mixture, can impact the solubility and cytotoxicity as 
we discussed above.  To determine how these physical parameters of 
DEAEMA-PEGMA-BAC hydrogel nanoparticles affect the degradation, we 
synthesized a range of different nanoparticles as listed in Table 6.1.  Note that in this 
Chapter, all the nanoparticles discussed were core-shell structured unless specified.
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Table 6.1 Composition of Degradable Hydrogel Nanoparticles 
Sample 
DEAEMA 
(mg) 
PEGMA 
(mg) 
BAC 
(mg) 
DB1* 922.0 0 16 
DB1.5 922.0 0 25 
DB2.5 922.0 0 40 
DB3.75 922.0 0 60 
DB5 922.0 0 80 
DPEG200_10%*** 862.1 95.8 16 
DPEG400_10% 885.1 98.3 16 
DPEG1000_10% 903.6 100.4 16 
DPEG1000_20% 885.1 221.3 16 
DPEG400_10%_Stable 885.1 98.3 (21.6)** 
* D: DEAEMA; B: BAC; 1, the molar ratio of BAC compared to monomer(s)  
** PEGDMA200 (mg) used to reach same molar ratio as using 16 mg BAC.  
*** 10%: weight ratio of PEGMA 
 
The total monomer concentration for each synthesis was kept constant (~ 5 mmol) 
as our original nanoparticles, while the weight ratio of PEGMA to DEAEMA was 
varied from 0:10 to 2:8.  Nanoparticles were prepared using PEGMA with different 
molecular weights (MWPEO = 200, 400, 1000) to determine the role of the PEG side 
chain length in degradation and cytotoxicity.  The crosslinker ratio of BAC was from 
0 to 5 mol%.  Because BAC was poorly soluble in water or DEAEMA, 300 µL of 
EtOH was used to dissolve BAC at 70 °C before mixing with the other comonomers 
(see 6.1.2 for details). 
 
6.3.1 Effect of BAC Concentration on Degradation 
As the concentration of GSH in the cytoplasm is constant for most of the cell 
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types, and maintained ~ 1-10 mM according to different cell types,94, 126 we first 
sought to determine whether BAC-crosslinked nanoparticles were sensitive to 
degradation by such GSH concentrations and assess the impact of crosslink density on 
particle breakdown.  For these initial experiments, we tested the response of 
core-shell BAC-crosslinked polyDEAEMA nanoparticles (no PEGMA co-monomer) 
to GSH treatment.  This experiment is also to determine whether the presence of 
sulfate groups on the chain ends of emulsion-polymerized polyDEAEMA chains 
and/or pendant sulfhydryls groups would impart solubility to the breakdown products 
at neutral pH.  Nanoparticles were synthesized with varying concentrations of BAC 
(1-5 mol% relative to DEAEMA).  The particles (~ 0.5 mg) were then suspended in 
different buffers (1 mL) at 37 °C for 24 hrs with mild shaking.  Absorbance of the 
suspensions at 450 nm was measured to evaluate turbidity as a first-order readout for 
the presence of intact particles.  PBS (pH 7.4) was used as a control sample, since 
the nanoparticles were stable without any size change when incubated in PBS for 
24 hours (data not shown).  As shown in Figure 6.3, particles suspended in 
GSH-containing serum-free medium (GSHM, 10 mM GSH) gave a similar 
transparency to those in PBS.  This result was not completely unexpected since 
polyDEAEMA homopolymers is not normally soluble at pH 7.4 in aqueous solutions.  
To confirm that the lack of transparency of the particles suspensions was a result of 
polymer chain insolubility but not failure of GSH to cleave the disulfide crosslinks, 
we tested the particle suspension in GSH-supplemented deionized water (GSHW, 
10 mM GSH).  Besides reducing capability, this solution provided an acidic 
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environment (pH ~ 3) that could protonate and thus dissolve PDEAEMA chains 
completely following crosslink degradation.  In this case, the BAC-crosslinked 
samples were totally transparent (Figure 6.3).  This result suggested the BAC 
concentrations used were sufficient to respond to the GSH, while improvement of the 
solubility of break-down components was needed.  Unless specified otherwise, 
1 mol% of BAC (16 mg) was used in the further studies testing the effect of other 
parameters on the degradability. 
As we mentioned, due to the solubility of BAC, EtOH was used to achieve a 
homogenous monomer/crosslinker mixture before adding to the water bath.  The 
addition of EtOH could reduce the hydrophobicity of the monomer, and thus affect the 
emulsion polymerization.  The inefficient crosslinking between BAC and the 
monomer could result in homopolymer nanoparticles, which would consist of only 
PDEAEMA chains instead of crosslinked hydrogels.  In this case, the PDEAEMA 
chains would dissolve in acidic conditions irreversibly.  To test this hypothesis, we 
simply suspended the particles into phosphate buffer at pH 4.86, and detected their 
turbidity.  We then added NaOH to bring the pH back to 7.4, and checked the 
turbidity of the solution again.  In all the cases (data not shown), the nanoparticle 
suspension looked transparent (absorbance at 450 nm < 0.25) when incubated in 
phosphate buffer at pH 4.86 while the absorbance was restored when the pH was 
adjusted to 7.4 by NaOH.  This result indicated that the nanoparticles were formed 
with BAC crosslinker.  Otherwise, the solution would have remained transparent 
(absorbance < 0.25) when the pH was changed back to pH 7.4 as the non-crosslinked 
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polymer chains were dissolved in acid irreversibly.  
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Figure 6.3 Effect of crosslinker ratio on degradability.  BAC-crosslinked 
polyDEAEMA nanoparticles were synthesized with different concentration of 
crosslinker: 1 (white), 1.5 (dot), 2.5 (black), 3.75 (stripe), 5 (grey) mol% BAC (~ 5 
mmol total monomer DEAEMA).  Nanoparticles were suspended in PBS, GSH in 
serum free medium (GSHM, pH 7.4), or GSH in water (GSHW, pH 3.0).  The UV 
absorbance of the particle suspensions were measured after 24 hours of shaking at 
37 °C.  Shown are mean ± S.D. of triplicate samples.  
 
6.3.2 Effect of PEGMA on Degradability 
 The initial degradation measurements described in 6.3.1 suggested that pure 
polyDEAEMA nanoparticles do not have sufficient solubility for dissolution 
following crosslink degradation.  To impart solubility to the nanoparticle polymer, 
we synthesized copolymer particles using DEAEMA and PEGMA as comonomers.  
PEGMA with different molecular weights could provide different chain lengths with 
 152
different hydrophilicity, thus affecting the degradability of the nanoparticles and their 
cytotoxicity.  We synthesized nanoparticles of DEAEMA with no PEGMA, and 
compared to copolymer particles prepared with DEAEMA and PEGMA200, 
PEGMA400, or PEGMA1000 at a fixed weight ratio of 90:10 of DEAEMA:PEGMA 
(as summarized in Table 6.1).  The same amount of BAC (1 mol% relative to 
monomers) was used in each condition.  The particles (~ 0.5 mg) then suspended in 
PBS or GSHM (1 mL) at 37 °C with mild shaking before absorbance measurements.  
Particles with PEGMA400 and PEGMA1000 showed obvious degradation after one 
day of incubation, as the absorbance of these samples was decreased in GSHM when 
compared to those in PBS (Figure 6.4); the absorbance of PEGMA1000 copolymer 
particles was only 26.3% of the initial suspension.  This result suggested that longer 
PEG side chains provided enhanced solubility relative to shorter PEG in these 
DEAEMA-PEGMA copolymers.  For PEGMA200 sample, the absorbance in GSHM 
was much higher than that in PBS.  The reasons for this discrepancy are unclear but 
could reflect improved access of GSH to the core of the particles due to PEG enabling 
water/GSH penetration to the particles.  Without substantially enhancing the 
solubility of freed polymer chains, this process favored particle aggregation rather 
than dissolution, thus resulting in the larger value of absorbance as indicated in Figure 
6.4. 
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Figure 6.4 Effect of PEGMA molecular weight on degradability.  Nanoparticles 
were synthesized by DEAEMA alone (white) or DEAEMA and PEGMA (MWPEO＝
200 g/mol (black), 400 g/mol (stripe), or 1000 g/mol (grey)) at the weight ratio of 
90:10.  1 mol% of BAC was used as crosslinker.  Nanoparticles were suspended in 
PBS or GSH in serum free medium (GSHM, pH 7.4).  The UV absorbance of the 
particle suspensions was detected after 24 hours shaking at 37 °C.  Shown are mean 
± S.D. of triplicate samples. 
 
In the discussion above, we used the turbidity of the solution to monitor the 
degradation of the nanoparticles, as it was a simple method to infer changes in the 
particles under different conditions.  However, such measurements are only useful as 
first-order analyses as particle swelling may reduce absorbance without reflecting 
actual permanent particle dissolution.  We thus employed dynamic light scattering 
(DLS) measurements to provide further insight into the effect of GSH treatment on 
BAC-crosslinked nanoparticle breakdown.  Stable nanoparticles crosslinked by 
PEGDMA200 (as used in the studies of Chapters 3-5) at the same 
monomer:crosslinker ratio (1 mol% crosslinker) were prepared for comparison with 
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copolymer nanoparticles (DEAEMA and PEGMA400 at a weight ratio of 90:10).  
As shown in Figure 6.5, the mean hydrodynamic diameter of degradable nanoparticles 
decreased dramatically after incubation in GSHM (from ~ 500 nm to ~ 100 nm), 
while the size of stable nanoparticles remained constant (~ 350 nm).  To further 
favor particle breakdown/polymer solubility, we tested nanoparticles synthesized with 
an 80:20 mass ratio of DEAEMA:PEGMA1000.  As shown in the CryoEM 
examination of these particles shown in Figure 6.6A, we confirmed that inclusion of 
this increased quantity of hydrophilic PEGMA1000 units in the particles did not 
interfere with particle formation/particle monodispersity.  DLS measurements 
following incubation of these particles in PBS for 48 hours (solid circles Figure 6.6B) 
showed the particles were slightly swollen, and the size distribution had a sharp peak 
at ~ 230 nm.  In contrast, incubation of the particles in GSHM (empty circles Figure 
6.6B) led to the development of two populations according to the size distribution.  
One was at ~ 100 nm, at which particles had a relatively broad distribution, with a 
half width of the peak being ~ 40 nm.  A second smaller peak in the size distribution 
was found at ~ 20 nm, a size consistent with individual solubilized polymer chains in 
a unimolecular micelle configuration.  This distribution curve confirmed our design 
that particles could degrade in GSHM with the disulfide reduction, and confirmed the 
possibility of forming solubilized (presumably micellar) breakdown products when 
PEGMA was used to increase hydrophilicity and solubility.  
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Figure 6.5 Degradability of nanoparticles by DLS.  Nanoparticles synthesized with 
DEAEMA and PEGMA 400 at a weight ratio of 90:10.  PEGDMA200 (black) and 
BAC (white) were used as crosslinker (1 mol%).  Nanoparticle size was measured by 
DLS after suspending in PBS, or GSH in serum free medium (GSHM, pH 7.4) for 
24 hours at 37 °C with mild shaking.  Shown are mean ± S.D. of triplicate samples. 
 
Figure 6.6 Size studies of biodegradable nanoparticles by CryoEM and DLS.  
Particles were synthesized with DEAEMA and PEGMA1000 at a weight ratio of 
80:20, and the BAC was kept 1 mol%. (A) CryoEM of BAC-crosslinked 
nanoparticles.  Scale bar 200 nm; (B) Size distributions of BAC-crosslinked 
nanoparticles by DLS.  Particles were suspended in PBS (filled circles) or GSHM 
(open circles) for 48 hours at 37 °C. 
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 In conclusion, we proved that using BAC as crosslinker could provide 
degradability to the nanoparticles, and including PEGMA with high molecular weight 
could increase the solubility of the break-down components.  At the specific 
conditions we tested above (DPEG1000_20%, with BAC 1 mol%), the size 
distribution of nanoparticles degrading in GSHM for two days indicated the micelle’s 
formation as we expected. 
   
6.4 Biological Characterization of Biodegradable 
Nanoparticles 
We were able to synthesize biodegradable nanoparticles using BAC crosslinker 
and PEGMA1000 as comonomer.  As discussed above, the nanoparticles 
(DPEG1000_20%) showed promising degradation in two days in GSHM at 37 °C.  
Further investigation of the pH-sensitivity and degradation in vitro in live cells were 
performed.  
 
6.4.1 Endolysosomal Disruption by pH-Sensitivity  
 We first sought to confirm that the significant changes in nanoparticle structure 
described above (change in crosslinker and inclusion of PEGMA for solubility) did 
not affect the endosome disruption activity of the particles.  Here, we used calcein 
delivery to examine the capability of endolysosomal disruption by the biodegradable 
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nanoparticles (DPEG1000_20%, BAC 1 mol%). 
Calcein delivery with biodegradable BAC nanoparticles was carried out as 
described in Section 6.1.4.  DC2.4 cells (1.2x105 cells/well) were plated in 
Lab-TekTM chambers for 18 hours, and then calcein (150 µg/mL, 0.24 mM) was added 
to the cells with or without BAC nanoparticles (25 µg/mL) in complete medium for 
1 hour at 37 °C.  After three washes with medium to remove extracellular calcein 
and particles, the cells were imaged live by CLSM at 37 °C.  As shown in Figures 
6.7 A/C, cells treated with calcein alone showed a punctuate distribution of 
fluorescence, indicative of endolysosomal compartmentalization of the dye.  Cells 
co-incubated with calcein and BAC nanoparticles exhibited calcein fluorescence 
throughout the cytosol and nucleus (Figure 6.7 B/D).  This result was similar as that 
observed in Figures 4.1 B/E/H, which showed efficient calcein delivery by stable 
crosslinked nanoparticles.  It confirmed that although changes had been made in the 
chemical composition, BAC nanoparticles still possessed substantial pH-sensitivity, 
providing efficient endolysosomal disruption and calcein delivery to the cell cytosol.  
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Figure 6.7 Calcein delivery to DC2.4 cells with biodegradable BAC nanoparticles.  
Calcein alone (A, C) or calcein with 25 µg/mL of BAC nanoparticles (B, D) were 
incubated with DC2.4 for 1 hour, and then imaged live at 37 °C by CLSM at 40X.  
Shown are brightfield (A, B) and fluorescence overlays (red, nanoparticles; green, 
calcein fluorescence) (C, D).  Scale bars 20 µm.  
 
6.4.2 Cytotoxicity in Primary Dendritic Cells 
 Another concern of using the BAC nanoparticles for the biological system was 
their cytotoxicity.  As we discussed in Section 6.2, the design for biodegradability 
was to facilitate safe elimination of the nanoparticles (for eventual in vivo application) 
A B
C D
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and decrease any toxicity or side effects that accumulation of stable nanoparticles 
might cause in cells/tissues.  To assess the cytotoxicity of the BAC-crosslinked 
degradable particles, the viability of bone marrow-derived dendritic cells (BMDCs) 
treated with BAC nanoparticles was assessed.   
Using the cell-growth assay described in section 6.1.4, day 6 BMDCs were 
incubated with 25 µg/mL of BAC-crosslinked or PEGDMA-crosslinked nanoparticles 
for 1 hour at 37 °C.  After washing three times with complete medium to remove 
extracellular nanoparticles, cells were collected, counted, and replated in 96-well 
plates at a density of 5x104 cells/well.  The replated cells were then cultured for three 
days, and the number of cells grown out in these cultures was determined.  Stable 
nanoparticles crosslinked with PEGDMA had very low cytotoxicity, 
nanoparticle-treated cells expanded to a level of 85% of untreated control cells 
following three days’ growth (Figure 6.8).  Likewise, biodegradable nanoparticles 
crosslinked with BAC also had low toxicity: at nanoparticle concentrations of 
25 µg/mL that provided efficient intracellular delivery of calcein as shown in Figure 
6.7, cells expanded to a level of 95% of controls (Figure 6.8).  
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Figure 6.8 Cell viability post biodegradable nanoparticles treatment.  Day 6 BMDCs 
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were incubated with 25 µg/mL stable nanoparticles (PEGDMA as crosslinker), 
biodegradable nanoparticles (BAC as crosslinker), or no particles (control) for 1 hour, 
washed three times, then replated at 5x104  cells/well and allowed to grow for three 
days. The number of cells grown out for each condition was then quantified.  Shown 
are mean ± S.D. of triplicate samples. 
 
We further investigated another two conditions in the similar study: the 
nanoparticles synthesized with DEAEMA and BAC without any PEGMA (DB1), and 
nanoparticles of DPEG1000_20% without AEMA shell.  Here, for the DB1 
core-shell nanoparticles, we observed very strong toxicity (~ 50% cells were dead; 
Figure 6.9).  Although the shell could decrease cytotoxicity by shielding the 
DEAEMA core inside, the degradable nanoparticles with BAC crosslinker were 
broken down to PDEAEMA polymer chain in the cell cytosol by GSH.  The shell 
was also expected to dissolve in this process, and could not provide a shield to the 
PDEAEMA anymore.  Including PEGMA as the comonomer to provide 
hydrophilicity and solubility to the PDEAEMA after degradation was necessary.  
This contrasts with the lack of toxicity from BAC-crosslinked 
poly(DEAEMA-co-PEGMA) core-shell particles (DPEG1000_20%), where 
DEAEMA units from the core are still shielded from interactions with intracellular 
components following breakdown/dissolution of the shell by the presence of the 
PEGMA units on each core copolymer chain (shown in Figure 6.2).  As shown in 
Figure 6.9, the low toxicity of the poly(DEAEMA-co-PEGMA) particle core in fact 
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makes the shell layer unnecessary to avoid toxicity.  Thus, tuning of the particle core 
composition to facilitate biodegradation also allows the option of simplifying the 
overall design of the particles (from core-shell to core-only), as long as a suitable drug 
binding/loading method could be designed.  
0
20
40
60
80
100
120
140
Control DB1 core-shell
NPs
DPEG1000_20%
core-only NPs
%
 C
el
ls
 
Figure 6.9 Effect of shell or PEGMA of biodegradable nanoparticles on cell viability.  
Day 6 BMDCs were incubated with 25 µg/mL DB1 core-shell nanoparticles, 
DPEG1000_20% core-only nanoparticles, or no particles for 1 hour, washed three 
times, then replated at 5x104 cells/well and allowed to grow for three days.  The 
number of cells grown out for each condition was then quantified.  Shown are mean 
± S.D. of triplicate samples. 
 
6.4.3 Degradation In Vitro 
Finally, we examined the degradability of BAC-crosslinked nanoparticles in 
dendritic cells.  Instead of labeling the shell with Cy3 mono-NHS ester, 
nanoparticles were labeled by poly fluorTM 570 methacryloxyethyl thiocarbamoyl 
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rhodamine B in the core, to enable tracking of dissolution of the particle cores in live 
cells.  By labeling the core, we expected that particle fluorescence would only take 
on a diffuse cytosolic distribution (or be eliminated from the cells altogether) when 
the core was totally dissolved in the cytosol, since as shown in Chapter 4, the intact 
particles remain within DCs for several days without exocytosis. 
Day 6 BMDCs (1.2x105 cells/well) were plated in Lab-TekTM chambers and 
cultured overnight (~ 18 hours).  Cells were incubated with or without 25 µg/mL 
BAC nanoparticles (DPEG1000_20% core-shell) in complete medium for 1 hour at 
37 °C.  After three washes with medium to remove extracellular calcein/particles, 
the cells were imaged live by CLSM at 37 °C.  The BAC particles were observed in 
the cells after 1 hour of incubation (Figure 6.10 B/F), which indicated the endocytosis 
and/or endolysosomal escape of the nanoparticles compared to the control (Figure 
6.10 A/E).  However, after 24 hours and 48 hours of incubation, punctuate 
fluorescence of the nanoparticles still remained in the cytosol (Figure 6.10 C/G and 
D/H), in a manner that was qualitatively indistinguishable from the observations after 
only 1 hour incubation.  
This result indicated that the nanoparticles do not appear to be degraded 
efficiently in BMDCs.  We observed the nanoparticles’ degradation in GSHM in two 
days with forming micelles; however, there were still remaining particles around 
100 nm as the size distribution curve showed.  Thus the BAC particles we used in 
the cell study could still be around 100 nm in size after two days of degradation.  
Second, the study discussed in Section 6.2 was carried out in 10 mM GSH medium, 
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while the concentration of GSH in cell cytosol varied in different cell types from 
1-10 mM.  The nanoparticles might encounter GSH concentration lower than 10 mM 
in BMDCs, thus the degradation would be less efficient.  Furthermore, there are a lot 
of proteins present in cell cytosol, which could agglomerate with our nanoparticles 
and prevent the GSH diffusion into the nanoparticles.  Alternatively the aggregation 
of break-down polymer chains with protein could prevent their ultimate solubility.  
We observed large size (>500 nm, data not shown) of breakdown components when 
incubating the BAC-crosslinked nanoparticles in GSH in complete medium 
containing serum protein (10% FCS, 10 mM GSH).  Optimization of the chemical 
composition of these particles to obtain faster/more complete degradation is still 
ongoing, and represents an important goal for future work.  
 
Figure 6.10 BAC nanoparticles in BMDCs.  BMDCs were incubated without (A, E) 
or with BAC nanoparticles for 1 hour, and then imaged live at 37 °C by CLSM at 
100X (B, F).  The cells were then cultured an additional 24 hours (C, G), and 
48 hours (D, H) and imaged again to determine whether nanoparticles degraded.  
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Shown are fluorescent images (A-D) and overlays (E-H) of nanoparticle fluorescence 
(red) and cells (brightfield).  Scale bars 10 µm.  
 
In conclusion, we designed and synthesized biodegradable nanoparticles using 
BAC, a crosslinker with a disulfide bond, which could be digested by GSH in cell 
cytosol.  PEGMA was included as comonomer to provide the system with more 
hydrophilicity and solubility after degradation.  The preliminary study showed 
promising degradation results in GSHM, and DLS data indicated that the 
DEAEMA-co-PEGMA polymer chains formed micelle-sized components, which was 
proved non-toxic in BMDCs by a 3-day cell growth assay.  These BAC nanoparticles 
possessed pH-sensitivity and were able to delivery calcein efficiently to cell cytosol.  
However, via CLSM we did not observe BAC-crosslinked nanoparticle breakdown in 
BMDCs after two days.  Further studies on the compositions which could provide 
more efficient and faster degradation are ongoing.  The development of fully 
biodegradable nanoparticles could potentially lead to in vivo testing in animal models 
for immunotherapy.
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7 Conclusions and Future Directions 
7.1 Novel Designs for Intracellular Drug Delivery 
In this thesis, we systemically studied the swelling behavior of a hydrogel system 
formed by diethyl amino ethyl methacrylate (DEAEMA), and explored the possibility 
of taking advantage of its pH-sensitivity as a drug delivery system in a reducing pH 
environment.  By emulsion polymerization, we successfully synthesized 
monodisperse pH-sensitive PDEAEMA-core/PAEMA-shell nanoparticles whose size 
was around 200 nm.  We further demonstrated that these core-shell nanoparticles 
were capable of efficient cytosolic delivery of membrane-impermeable molecules 
(such as calcein, OVA protein, Influenza A, or siRNA) to dendritic cells via the 
‘proton sponge effect’.  These nanoparticles showed significant improvement in 
cross presentation of Class I MHC molecules and T cell activation by delivering the 
antigen protein OVA to BMDCs, and promising knockdown of mRNA by delivering 
siRNA to epithelial cells for gene silencing.  These preliminary applications 
indicated that those nanoparticles may be of utility for delivery of membrane 
impermeable drug compounds or oligonucleotides to the cytosol of dendritic cells for 
immunotherapy, and other cell types for gene therapy.   
The pH-sensitivity of polymers for endosome escape has been widely used to 
design intracellular drug delivery system.  However, different from typical 
polymeric drug delivery systems which are formed by physical complexation of the 
polymer and drug molecules, our strategy is to use monodisperse crosslinked hydrogel 
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nanoparticles whose size, stability, and properties are predefined and under control.  
This modification demonstrated the highly improved efficiency for intracellular drug 
delivery in different cell types, as the hydrogel nanoparticles potentially improved the 
cellular uptake efficiency and the stability of the drug delivery system besides 
endolysosomal escape function.  
We further introduced core-shell structure to the nanoparticles.  By sequestering 
the slightly hydrophobic, pH-buffering component of the polymer particles within the 
core by a more hydrophilic shell composition, these nanoparticles effectively 
disrupted endolysosomes and delivered molecules to the cytosol of cells without overt 
cytotoxicity, which was often observed by polymeric drug delivery systems that could 
disrupt endolysosomes.  This design proved a method to reduce cytotoxicity by 
‘hiding’ toxic components from contacting cells.  This simple concept could 
potentially be applied widely to any drug delivery system suffering cytotoxicity.  In 
addition, the segregation of drug/cell binding function of the shell from the 
pH-sensitivity and endolysosomal escape function of the core provided flexibility to 
tune the surface charge and charge density to desirable drug molecules, and to 
chemically modify the shell structure with targeting functions.    
  The extension to biodegradable nanoparticles that quickly dissolve to nontoxic 
soluble components upon reaching the cytosol is under investigation.  The 
biodegradability could promote efficient unpacking of drugs carried to the cytosolic 
compartments, and lead to further in vivo test.  Different from hydrolysis or 
enzymatic degradation, we designed the degradability by using reducible crosslinker 
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which could be digested in the cytosolic environment.  Similar as PEGylation of a 
polymer, we applied PEGMA as a comonomer to the hydrogel, and demonstrated that 
the break-down polymer chains turned into nontoxic soluble components.  This idea 
may be of use in designing nontoxic polymeric materials for biological applications.  
 
7.2 Future Directions 
7.2.1 Shell Structures for Drug Loading and Targeting 
 In this thesis, we mostly focused on evaluating the delivery efficiency of the 
nanoparticles.  Our effort was to demonstrate the pH-sensitivity and endolysosomal 
escaping function of the core.  We have proved that the shell structure, which is a 
very important part of the design, decreased the cytotoxicity significantly.  Further 
studies of the shell structure need to be carried out.  We could investigate the shell 
formation and the surface charge density on the shells by exploring the emulsion 
polymerization process.  These characters of shell structure would help us 
understand drug binding and cell binding efficiency of the nanoparticles.  In addition, 
the segregation of core and shell according to their functions provides us opportunities 
to alternate the shell structure without affecting the endolysosomal disrupting function.  
Exploring the use of different polymers as the shell structure to provide different 
binding properties would be very interesting.  For instance, most studies have 
focused on using polycationic polymers to bind DNA or negatively charged proteins, 
but few systems have been reported for delivering a positively charged drug 
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molecules.  A shell with carboxyl group could be used for this function.  This 
investigation could potentially increase the application of our nanoparticles to a larger 
variety of drug types.   
 Another aspect that would be interesting to explore would be alternative methods 
for drug loading.  Currently, the drug molecules bind to the shell of nanoparticles 
electrostatically.  The binding efficiency could decrease by competitive binding of 
proteins in biological systems.  A method to protect the drug molecules from this 
effect would be very practical, as it could reduce the drug dosage and avoid repeating 
drug treatment if the drug could be carried and delivered efficiently.  A strategy to 
load the drug in the shell, between the shell and core, or in the core could be very 
useful and important to improve this system’s efficiency.   
 Furthermore, the capability of targeting specific cell types could be added to the 
shell structure of the nanoparticles.  An advantage to use polymeric materials for 
drug delivery system is their tunable chemistry.  Conjugating targeting ligands or 
peptide sequences is achievable with our shell structure.  Again, the core-shell 
structure makes this modification very flexible, without affecting the endolysosomal 
escaping function.  
 
7.2.2 Study on Biodegradability 
 Our preliminary study showed promising results on the biodegradability of the 
nanoparticles in vitro.  However, we have not proven the thoroughly degradation of 
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nanoparticles in cell cytosol by CLSM.  It has been reported that although GSH is 
present in all mammalian cells, the concentration of GSH varies in different cell 
types.120, 125  This fact could potentially limit the application of biodegradable 
nanoparticles since the degradation efficiency would be affected by the concentration 
of GSH in cells.  So far, 10 mM of GSH was used for our study to detect the 
degradation, and it would be worth to evaluate the cellular GSH level in the cell types 
we are interested in.  Other the other hand, the chemical compositions which could 
achieve more fast/efficient degradation in lower GSH concentrations (5 mM in 
general) could be a major task.  Further applications using biodegradable 
nanoparticles as an intracellular drug delivery system should be investigated.  
    
7.2.3 A Practical Intracellular Drug Delivery System  
Overall, we have designed and demonstrated the capability of the core-shell 
nanoparticles for a variety of intracellular delivery applications.  The final goal 
would be to test the biodegradable nanoparticles in vivo.  To perform the animal 
study, the first step is to investigate the toxicity of the nanoparticles and understand its 
biodistribution with different administrations.  The fluorescent or radioactive tracing 
and the histology samples of different organs could be used to identify the pathway 
and toxicity of nanoparticles and to prove their clearance or degradation.  
Combining the targeting and improved drug binding property, we believe this 
system may be of great utility as a practical delivery system in market in the near 
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future.  In addition, the concepts of pH-sensitivity for endolysosomal escaping, 
core-shell structure for non-toxicity and drug/cell binding, reducible crosslinker for 
biodegradablilty, and PEGylation to shield the toxic elements are significant 
contributions for designing intracellular drug delivery systems. 
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Appendix 3D Periodic Porous pH-Sensitive Hydrogels 
for Drug Delivery 
As we discussed in Chapter 2, pH-sensitive hydrogels could be used as a 
controlled drug release system responding to a change in the environmental pH.  A 
mechanism to load the drug molecules into the hydrogels and to release drug in a 
controlled manner is necessary.  Current strategies include encapsulation of drug 
molecules in the hydrogel130-133 or conjugation of drug molecules to the polymer chain 
constructing the hydrogels.72, 133  In these methods, the drug loading is very limited, 
and drug molecules are released slowly via diffusion through the mesh of the 
hydrogels or upon the hydrogel erosion/degradation.  In this Appendix, we present 
an alternative method of forming porous hydrogels that would help load 
macromolecule drugs such as DNA, siRNA, or protein into the porous structure of the 
hydrogels.  Those connective pores could potentially form the basis for the better 
storage and protection of drug molecules.  Drugs can be released in a controlled 
manner when the pore size changes corresponding to the environmental pH changes.   
 
A.1 Porous pH-Sensitive Hydrogels 
A.1.1 Porous Structure in a Hydrogel Matrix  
There are several methods to create porous structures in hydrogels.  
Microsyneresis is a phenomenon where a phase separation occurs during the 
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polymerization and a heterogeneous polymer network is formed consisting of 
domains of highly crosslinked microgels which are connected by loosely crosslinked 
chains.  It happens if the amount of water present in the monomer solution is greater 
than the water content corresponding to the equilibrium degree of swelling.134, 135  
The pores generated in this way are relatively large, and can used as microreservoirs.  
Porogen is a method to create pores by gas foaming136 or leaching solid crystal such 
as NaCl.137  To obtain high pore interconnectivity, a porosity of 95 v% needs to be 
introduced to the matrix.138-140  It therefore makes this method only suitable for stiff 
materials.  Crystalline arrays of monodispersed spherical colloids have been 
demonstrated or proposed for use in a wide variety of areas, such as templates to 
generate porous materials with highly ordered structures.  In this method (Figure 
A.1), the colloidal crystals are assembled to serve as templates, the voids of which are 
infiltrated by materials that solidify/polymerize there.  The original colloidal 
particles are subsequently removed, leaving behind a new material with pores that 
preserve the most valuable property of the colloidal crystals: the well-defined long 
ranged periodic structure.  The colloidal crystal template method has the advantage 
of being able to control the dimensions of the pores easily, by varying the size of the 
beads in the templates.  The close-packing porous structure results in a number of 
useful properties such as maximal packing density, high surface to volume ratio, 
tightly controlled thickness, and sufficiently large domain size.  This method 
originally has been used to gain the structure for optical diffraction and photonic band 
gaps for stiff materials such as inorganic oxides, carbons, and polyurethane.141  Our 
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lab has been able to synthesize the bioactive hydrogel of poly ethylene glycol (PEG) 
or gelatin with interconnecting macropores for tissue engineering.138, 140  This 
provides a good foundation for applying this method to our porous pH-sensitive 
hydrogel as a drug delivery system. 
 
Figure A.1 Schematic illustration of constructing colloidal crystal templating for 
porous hydrogels.  A) Patterning; B) Templated polymerization of hydrogel; C) 
Template removal. 
 
A.1.2 Porous pH-Sensitive Hydrogels as Drug Delivery System 
Discussed in Chapter 2, pH-sensitive hydrogels have been widely used for drug 
delivery.  They have the potential to provide drug molecules with hydrophilic 
surroundings.  The gels’ swelling/deswelling abilities according to environmental pH 
could be applied as a trigger to encapsulate or release the drug molecules.  In this 
Appendix, colloidal crystal templating is applied to create periodic porous structures 
in the pH-sensitive hydrogels.  Drug molecules are expected to move among these 
periodic pores via the connective windows to their nearest neighbors (Figure A.2).  
Importantly, the porous gels are expected to swell/deswell rapidly because of 
A B C
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extensive contact area to water.133, 134  We hypothesized that the pH-sensitivity of the 
hydrogel could potentially work as a ‘valve’ for drug release (in Figure A.2).  When 
environmental pH is above the pKb of the gel, (for the poly(DEAEMA-co-PEGMA 
chosen, the pKb is slightly lower than physiological pH 7.4), the gel is in a collapsed 
state, and the connective windows and pores are in their minimal sizes.  Thus drug 
molecules will be highly restricted in the porous structure.  When the environmental 
pH is below pKb of the gel, the gel is in the swelled state and the connective windows 
and pores will be enlarged, resulting in the drug’s rapid movement toward the surface 
of the gel, allowing it to escape.  In this manner, the hydrogel protects drugs in a 
hydrophilic environment from degradation, and releases them with its pH-sensitivity. 
 
Figure A.2 Schematic of pH-sensitive ‘valve’ for drug encapsulation and release in a 
porous pH-sensitive hydrogel.  
 
Drug release from bulk gels can be fundamentally very interesting besides its 
potential applications.  Through detailed characterization of the pH-sensitivity and 
the porous structure of hydrogels, we seek to gain a fundamental knowledge of the 
importance of these parameters as a general drug delivery system.  In contrast to 
pH 5-6 
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typical cationic polymer DNA/drug delivery systems (such as PEI), we hypothesize 
that porous gels would facilitate DNA/drug release rapidly responding to pH changes 
instead of entrapping DNA/drug tightly via electrostatic force on the positively 
charged polymer chains.  Although the monomer chains of gels will be positively 
charged in the swelled state at reduced pH, the counterions (in this case, Cl-) in water 
rather than the negatively charged drug molecules will be attracted to them.  Thus 
the porous structure eliminates the direct contact between DNA/drug molecules and 
the ionized groups comparing to other cationic polymeric drug delivery systems.   
 
A.2 Materials and Experiments 
A.2.1 Materials 
All reagents were used as received without further purification.  2-diethylamino 
ethyl methacrylate (DEAEMA), tetraethylene glycol dimethacrylate (TEGDMA), 
ammonium peroxodisulfate (APS), and micro particles based on poly methyl 
methacrylate (PMMA) (4 µm) were purchased from Sigma-Aldrich Chemical Co. 
Poly (ethylene glycol) monomethacrylate (PEGMA, MWPEO = 200 g/mol), and poly 
fluorTM 570 methacryloxyethyl thiocarbamoyl rhodamine B were purchased from 
Polysciences Inc.  Polydimethylsiloxane (PDMS) were made from Sylgard® 184 
Silicone Elastomer Kit, Dow Corning Corporation.  
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A.2.2 Colloidal Crystal Templating for 3D Porous pH-Sensitive 
Hydrogels  
Monodisperse PMMA microparticles (4 µm) solution (2.6 wt%) was centrifuged 
down at 15,000 xg for 10 min.  The particles were re-suspended in 70 wt% EtOH to 
make the final concentration of 20 wt%.  After 15 min sonicating to avoid the 
aggregation, 200 µL of condensed particle suspension was added to the PDMS ring 
holder (H = 5 mm, R = 2.5 mm, cut by revolving punch, Small Parts Inc.) adhered to 
the glass slide with plasma treatment.  The particles were then dried and 
close-packed on top of a reciprocating shaker (Lab Rotator 2314Q, Barnstead 
International) operated at 250 rpm for about 4 hours at room temperature.  
A hydrogel precursor solution was prepared as described in Section 2.1.2.  In a 
typical polymerization process, 103 µL DEAEMA (0.5 mM), 155 µL PEGMA 200 
(0.5 mM), and 1.5 µL TEGDMA (0.5% mol crosslinker/mol comonomers) were 
mixed in 269 µL 25 v% EtOH, giving a final solution containing 50 wt% 
comonomers.  For fluorescent labeling of gels, 10 µL poly fluorTM 570 
methacryloxyethyl thiocarbamoyl rhodamine B stock solution (50 mg/mL in 25% 
EtOH) was included in the precursor solution.  The initiator APS (20 µL of 
200 mg/mL APS in water, freshly made) was added, and 50 µL of the fluorescent 
labeled precursor solution was gently pipetted onto the colloidal crystal template 
formed by PMMA microspheres, and perfused by centrifugation (5 min, 2000 xg).  
After polymerizing at 45 °C (covered by glass slide to avoid solvent evaporation) 
for 20 min, the polymerized construct was taken out from the PDMS ring holder and 
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transferred to excessive acetone for three days in order to etch the microsphere and 
form the porous structure.  The templated gels were further cleaned by soaking in 
EtOH for one day to dilute all the acetone and remove the dissolved PMMA.  After 
swelling in water for another three days, the porous gels were stored in clean water for 
further characterization. 
   
A.2.3 Morphology of the Porous Hydrogels  
The porous gel discs were dehydrated serially in 25, 50, 75, 95 wt% EtOH for 
30 min each, and 100 wt% EtOH overnight.  The gel discs were air-dried for 
24 hours in the presence of desiccant.  After sputter coating (Desk II cold 
sputter/etch unit, Denton Vacuum LLC) of gold particles with 10 nm thickness, the 
porous gels were imaged using a JEOL 6060SEM (JEOL, Ltd., Japan) at 5kV. 
Fluorescent porous gels were observed using a confocal laser scanning 
microscope (CLSM, Zeiss LSM 510) with 40X or 100X Apochromat oil objectives 
with the presence of PBS. 
  
A.2.4 pH-sensitivity of the Porous Hydrogels 
Poly(DEAEMA-co-PEGMA) hydrogel discs were transferred to a 6-well plate, 
and immersed in phosphate buffers of varying pH (100 mM ionic strength, 3 mL) 
with mild agitation in a Jitterbug shaker (Boekel Scientific, Model 130000).  The 
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wet mass of each sample was measured for each condition to determine the mass 
swelling ratio (Q), defined as the mass of the gel in the swelled state divided by the 
mass of gel in the deswelled state at pH 9.  To assess equilibrium swelling, the gels 
were allowed to equilibrate for up to 24 hours.  The mass of the gels was assessed at 
different time points (swelling over 2, 4, 8, and 24 hours) to confirm that swelling had 
reached equilibrium.  The pore size under different pH conditions was examined by 
CLSM.  During the imaging process, porous gel discs were confined in a PDMS ring 
holder adhered to a glass slide after reaching equilibrium.  Buffers with different 
conditions were added in the PDMS holder to keep the gels in desired 
environment/pH.  
To assess swelling kinetics, the hydrogel discs were first equilibrated in a pH 7.48 
buffer.  For the swelling phase, gels were transferred to a pH 5.66 buffer, and the 
masses of the gels were measured every 10 min for the first hour, every 20 min for the 
second hour, and every 30 min until it reached equilibrium.  For the deswelling 
phase, gels were then transferred back to a fresh pH 7.48 buffer, and the masses of 
gels were measured every 10 min for 1 hour, and then measured at 8 hours. 
 
A.3 Results and Discussion 
A.3.1 Fabrication of Porous Hydrogels 
Colloidal crystal template was referred as the fabrication of three dimensional 
(3D) porous materials by employing monodisperse colloid spheres as the building 
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blocks.142-144  Choosing a type of colloidal sphere as the template and patterning the 
spheres in a close-packed manner is crucial to generate periodic pore structures with 
high interconnectivity.  
PMMA particles of 4 µm were used here as they are commercially available and 
relatively inexpensive, and most importantly, possess good monodispersity, which 
affects the patterning and therefore the porous structure in the hydrogel.  In addition, 
proper solvents were needed for etching the particle templates after polymerization to 
obtain the final porous structure.  It is necessary for the solvent to be able to dissolve 
the particle materials without destroying the polymer matrix.  It was also important 
that the solvent is miscible with water to facilitate solvent removal and exchange into 
aqueous solutions for future experiments.  Acetone, which was used for etching the 
PMMA particles template, satisfied these requests.  Therefore, choosing PMMA 
particles was suitable for both templating and etching processes.  
The template particle size dictates the pore size, interconnectivity, window size, 
void percentage for polymer loading, and therefore the mechanical properties of the 
gels and the affine deformation when the resulting gels respond to varying pH.  For 
these reasons, templates with particle sizes of 4 µm were formed to allow systematic 
studies of the effect of 3D porous structure on the soft hydrogel properties and the 
pH-sensitivity of the hydrogel as the potential control of the pore size changes. 
Monodisperse colloid spheres were self-assembled into an ordered 3-D pattern.  
There are a variety of approaches to help with self assembly, such as sonicate 
packing,145 patterned sedimentation,146 controlled evaporation,147 centrifugation, 
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pressing, filtration, or slit filling.144  In this Appendix, we used controlled 
evaporation to generate compact packing from the self-assembly of high 
monodisperse PMMA colloidal spheres.  To provide a defined macroscopic shape to 
templates, PDMS molds of disc shape were used to confine the template assembly on 
top of a glass substrate.  Parameters such as the particle concentration/density of 
colloidal spheres, the property of the suspending solution, and the evaporation rate 
(the concentration of the EtOH, the shaker speed etc.) were practiced to optimize 
close packing qualities, which are not discussed in detail here. 
It is very important to remove the deposition solvent from the template interstices, 
and make space for the polymer solution.  Failure to dry the template might cause 
the collapse of patterned particles, and the beads might re-suspend in monomer 
solution without patterning.  In addition, polymer precursor could only cover the 
voids partially if some of them were occupied by the solvent of colloidal crystal 
suspension.  Our template was dried at room temperature, as we found that high 
temperatures tended to change the self-assembled close-packing template, or even 
melt the PMMA particles.  It has been found that applying centrifugation facilitates 
the penetration of the gel precursor solution into the template. 
 
A.3.2 Morphology of Porous Hydrogels 
The morphology of the resulting porous hydrogels was characterized by optical, 
fluorescent and scanning electron microscopy extensively.  Shown in Figure A.3 are 
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some typical images from each approach. 
In SEM images of dehydrated gels (Figure A.3 A-D), a two-layer gel membranes 
were examined.  Shown in Figure A.3 A is the free surface of the hydrogel.  On the 
left half of the image, the pattern of well ordered hexagons was observed.  The 
diameter of these hexagons was about 3 µm, indicated the pores formed by etching 
the particles themselves.  The smaller size compared to the original 4 µm was caused 
by the dehydration of the hydrogel sample in the SEM sample preparation process.  
On the right half of the image, only unconnected pores of much smaller size (about 
1 µm) were observed.  Those pores were formed by the cotangent points between the 
particles and the contacting substrate, or the free surface of the gel where the polymer 
solution covering the top of the particles.  After etching, these smaller inter-pores 
were formed at the cotangent points where the polymer solution could not infiltrate. 
As reported, those inter-pores usually take the size of about 1/4 of the original 
packing colloidal particle size.140  In Figure A.3 B, by tilting the sample mount to 
20°, we observed the cross section of the porous gel, where, the two layers of 
patterned pores are seen clearly.  The free end was mainly sealed, but some of the 
inter-pores could be seen.  More inter-pores were shown in Figure A.3 C.  In this 
image, each pore formed by taking space of original colloidal particles was connected 
to the next layer with three smaller inter-pores, which indicates the FCC assembly 
pattern where the second layer of particles would fall on top of the void of three 
contacting particles on the first layer.  In a zoomed image (in Figure A.3 D), the 
inter-pore size was measured as 0.9 µm ± 0.2 µm, while the pore size was 3.3 µm ± 
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0.2 µm.   
Under optical microscope, usually two to ten layers of well-ordered pores could 
be clearly resolved.  A two-layered porous gel with its pores hexagonally 
closed-packed over a long range was shown in Figure A.3 E.  The white lines 
indicated the first layer in the focal plane, while the dark lines were the second layer 
underneath.  Since the particles self-assembled in a FCC pattern, the cotangent 
points between each particle on the lower layer were clearly observed in the center of 
the upper layer.  It was obvious that the pore size was slightly larger than the original 
particle size (4 µm) due to the slight swelling status of the hydrogels compared to its 
as-synthesized size.  In the up-right and down-left corners of the images, two patchy 
areas, where only one layer was observed, indicated that the inefficient close packing 
had occurred.  The infiltrated precursor solution occupied these areas, and formed a 
solid gel region instead of a porous structure. 
Using CLSM with serials scanning on the z-direction, we could potentially study 
the 3D porous structure in depth.  In Figure A.3 F, a swollen porous hydrogel at 
pH 4.79 buffer was examined.  Similar to the schematic shown in Figure A.1, the 
pore was connected with six other pores (as indicated by the arrows) at the same layer 
through inter-pores formed by blocking the infiltration of precursor solution and 
further polymerization by the cotangent points of the particles.  A porous gel with 
seven to eight layers was examined by CLSM with the intervals of 0.43 µm in the 
z-direction.  The x-y, y-z, x-z planes at random cross sections are shown in Figure 
A.3 G.  Each plane clearly showed the FCC pattern of the close packing.  By using 
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Volocity (Improvision Inc), the CLSM images were reconstructed to a 3D image of 
the porous hydrogel.  In Figure A.3 H, the inter-pores could be seen through clearly 
for several layers, demonstrating the high connectivity of these 3D porous hydrogels.  
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Figure A.3 Morphology of porous hydrogels.  (A-D) SEM image of the dehydrated 
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porous gels.  Porosity/inter-pores at the free surface of hydrogel (A, scale bar 10 µm); 
intersection showing at least two layers of patterned pores etched from PMMA 
spheres (B, scale bar 10 µm); a section of close-packed porous structure (C, scale bar 
5 µm); cross-sectional image of well ordered pores and inter-pores (D, scale bar 2 µm).  
(E) Brightfield optical image with 100X object lens showing two layers of ordered 
pores.  Scale bar 10 µm.  (F-H) CLSM images of fluorescence-labeled swelled 
hydrogels (in a pH 4.79 phosphate buffer).  Images of the 3D structure of the 
hydrogel lattice after etching (F, scale bar 10 µm); image of 3D structure of a 
well-patterned porous hydrogel examined in x-y, y-z, and x-z planes (G, scale bars 
20 µm); 3D reconstruction of CLSM images of a well-patterned porous hydrogel in 
the swelled state created using Volocity (H, scale bar 20 µm).  
 
In this Appendix, although we did not examine the mechanical properties of the 
hydrogels with high porosity, the swollen gels shown in Figure A.3 F-H would be 
able to support itself very well in any characterization process such as microscopy or 
weighing.  These swollen gels were with very high water content as the pore size 
were enlarged ~ 2-fold as their original size while the polymer content was less than 
25% of the total volume.  We did not observe any collapse of the hydrogel lattice in 
the swelled state.  At high pH of 9.5, the hydrogel shrank noticeably, and the pores 
in the gel lattice appeared to have slight deformation.  
Together these approaches guided us in how to obtain repeatable high quality 
patterning of 3D colloidal crystals template, and also proved that we successfully 
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fabricated periodic 3D porous hydrogel with self-assembled colloidal template.  
 
A.3.3 Effect of pH Sensitivity on Pore Size Changes 
The swelling capability of solid bulk hydrogels with different chemical 
compositions has been discussed extensively in Section 2.2.2.  Here, we evaluated 
the pH sensitivity of porous gels by comparing to the bulk gel formed with the same 
chemical composition.  As we described in Section A.2.2, the precursor solution 
only infiltrated into the voids between colloidal beads.  Thus, the swelling ability 
could be strongly affected, as the fraction of polymer in a porous hydrogel (less than 
25 v%) was much lower than that of a solid gel (100%) due to its high porosity.  To 
investigate this effect on pH sensitivity, we compared the equilibrium mass swelling 
ratio (Q) of porous gels and bulk gels at different pH.  Bulk gels and porous gels 
made in the same geometry in the PDMS ring holder were soaked in phosphate 
buffers at pH ranging from 4.8 to 9.0 to reach their equilibrated swelled state before 
being weighed.  As expected, the porous hydrogel still possessed the swelling 
property as a bulk hydrogel; however, the swelling capability was highly reduced due 
to its low content of polymer fraction in its total volume (Figure A.4 A).  The solid 
bulk hydrogel swelled reaching 18-fold mass/volume changes at pH 4.8, while porous 
gels could only swell by 8-fold.  Two kinds of gels had the similar transition point 
about pH 7.4 to perform their reversible swelling/deswelling.  This consistency 
proved that gel pKb decides the transition pH.  
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In addition, the effect of pH sensitivity on pore size and inter-pore size was 
evaluated by CLSM.  The pore size at different pH was plotted together with the 
mass swelling ratio Q (Figure A.4 B), and some of the CLSM images of porous 
hydrogels are shown in Figure A.4 C.  The pore size was enlarged to 7 µm at pH 4.9, 
while it collapsed to 3.7 µm at pH 9.0.  The pore size changes due to the pH change 
also induced the inter-pore size changes, which was reported as 1/4 of the pore.140  
This effect of the pore and inter-pore size enlargement at reduced pH could work as 
the ‘pH valve’ as we hypothesized in Figure A.2, and help release the drug molecules 
which loaded in the pores before swelling.  Interestingly, the change of pore size was 
approximately linear according to the pH change, instead of showing sharp transition 
at pKb.  The exact reason is still under investigation.  
 188
 
 
Figure A.4 pH sensitivity and pore size of porous hydrogel at 37 °C.  (A) Mass 
swelling ratio (Q) of both bulk (solid dots) and porous (empty dots) hydrogels 
(PEG200_50% with 0.5 mol% crosslinker) at different pH.  Shown are average ± 
S.D. of triplicate samples.  (B) Pore size (filled dots with solid line, y axis on the left) 
of porous hydrogels according to mass swelling ratio (open dots with dashed line, y 
axis on the right).  Error bars of pore size measurement showed standard deviation of 
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20 pores examined at each condition.  (C) CLSM images of porous structure of same 
gel sample at different pHs.  Shown are all x-y planes.  Scale bars 10 µm.  
  
A.3.4 Dynamic Swelling of pH-Sensitive Porous Hydrogels  
As discussed in Section 2.2.3, it is necessary to define and calculate the 
characteristic response time of gels, as this will be a significant parameter controlling 
drug loading and release profiles from gels used for drug delivery.  Different from 
bulk hydrogels, porous gels possessed periodic pores which provide extensive contact 
to water/solvent and ions.  Since the swelling kinetics are typically dominated by 
diffusion times for the ions in the solution,80 the pore size and porosity could 
significantly affect the response rate, due to the efficient transport of water and ions, 
and the ionic interactions in the porous structure.  
The dynamic swelling of solid bulk hydrogels has been shown in Figure 2.7.  
Here, we compared it with the porous hydrogels formed with the same chemical 
composition.  Similar to the bulk gel studies, changes in the mass swelling ratio as a 
function of time were measured following transfer of porous gels equilibrated at 
extracellular pH/ionic strength conditions to acidic pH conditions and vice versa.   
Porous hydrogels were able to respond to the environmental pH change 
immediately.  Within twenty minutes, the porous gels could reach their equilibrium 
swelling when located in pH 5.66 buffer (Figure A.5 A).  As expected, porous gels 
had much more contact with water, and reached equilibrium swelling much faster (in 
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20 min) than solid gels (in 60 min).  Swelling of the porous gels was also reversible, 
as hydrogels were able to shrink to the original size when put back in pH 7.48 buffer.  
As in Figure A.5 B, deswelling reached 95% of equilibrium within 60 min.  
Interestingly, the deswelling process happened in a similar pattern for both type of 
gels.  This similarity indicated that the driving force for removing the protons from 
the hydrogel was not affected by the porous structure significantly.  These 
comparisons between the two types of gels again indicated that the swelling and 
deswelling processes were controlled by a different mechanism.  This information 
could be instructive for the future design of a drug loading process and drug releasing 
profile using porous gels.  
In addition, both solid and porous hydrogels were able to shrink to their original 
size after a swelling cycle in pH 5.66 and in pH 7.48 buffer, which ensured that the 
hydrogels respond reversibly at different pHs. 
 
Figure A.5 Dynamic swelling of bulk and porous hydrogels at 37 °C.  Hydrogels 
(PEG200_50% with 0.5 mol% crosslinker) were equilibrated in pH 7.48.  (A) 
Swelling ratio in pH 5.66.  Hydrogels were transferred to pH 5.66 phosphate buffer 
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with 100 mM ionic strength, and weighed every 10 min for an hour, every 20 min for 
another hour, and every 30 min before reaching equilibrium.  (B) Deswelling of the 
same gels from (A) when transferred back to a buffer at pH 7.48.  Hydrogels were 
transferred to pH 7.48 phosphate buffer at 100 mM ionic strength, and weighed every 
10 min for the first hour, and then at eight hours.  The average ± S.D. of triplicate 
samples are shown. 
  
In conclusion, we have successfully fabricated pH-sensitive porous hydrogels 
which possess 3D periodic pores with controlled size and extensive inter-pores.  This 
porous structure together with pH-sensitivity of the hydrogels could be potentially 
used as drug delivery system, which can achieve desirable drug loading and drug 
protection in the pores, as well as a controlled release profile by pore/inter-pore size 
changes responding to the environmental pH.  The future work will focus on the 
design and understanding the drug loading process and release profile.  In addition, 
using a colloid crystal template to form porous hydrogels with different pore and 
inter-pore sizes could provide a feasible template working with drug molecules with 
different size, and provide a variety of different drug dosage and release profiles.  
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